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General introduCtion
Thrombosis is an everyday issue for cardiologists and is responsible for disabling 
and life-threatening conditions such as myocardial infarction and thrombo-embolic 
stroke. These conditions require the use of antithrombotic agents, both for its treat-
ment, as well as for preventive measures.
However, antithrombotic agents are also associated with safety issues and ad-
verse events, which increases the risk of non-compliance and undertreatment. For 
example, gastrointestinal side effects such as dyspepsia are associated with aspirin 
discontinuation, and the perceived risk of bleeding is one of the major determinants 
of underuse of oral anticoagulation in the elderly with atrial fibrillation.1-7 These 
examples demonstrate that efficacy of antithrombotic therapy may be hampered 
by associated safety issues. Improved insights into patients at risk of bleeding may 
facilitate daily decision making and could reduce the issue of undertreatment in the 
elderly.
On the other hand, efficacy of antithrombotic medication may be influenced 
by concomitant medication and comorbidities. For example, the concomitant use 
of proton pump inhibitors (PPIs) has been implicated to result in impaired efficacy 
of clopidogrel in patients with acute coronary syndromes through a CYP-mediated 
mechanism.8-12 In addition, patients with multiple co-existing diseases will use more 
drugs, increasing the risk of inhibiting or potentiating interactions. Apart from drug-
drug interactions, patients with more comorbidity are more fragile, with impaired 
adaption mechanisms. This is an additional reason why fragile patients may have a 
differential response in terms of efficacy and/or safety to oral anticoagulants. These 
issues are especially important in patients with atrial fibrillation, which is a disease 
of the elderly.
Finally, special interest is warranted for patients with recurrent events, despite 
antithrombotic treatment. For example, in specific cases of acute coronary syndrome 
(ACS), the benefit of a long-term combination of both antiplatelet and anticoagulant 
therapy may outweigh the associated increased risk of bleeding.13,14
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In this thesis, issues with regard to the efficacy and safety of oral antithrombotic 
therapy will be addressed, both in the treatment and prevention of arterial thrombo-
sis and thrombotic complications of atrial fibrillation.
In the general introduction, the formation of thrombi will be highlighted, as well 
as the antithrombotic options. In the outline of this thesis, the different research 
questions will be addressed into more detail.
Pathogenesis of thrombosis in acute coronary syndromes and atrial fibrillation
Thrombosis formation depends on the interaction of thrombocytes, coagulation 
factors, and also red blood cells. Numerous conditions are known to increase the 
risk of thrombosis. Over one and a half century ago, Rudolph Virchow postulated 
that all these conditions can be classified among three key mechanisms: endothelial 
dysfunction/damage, abnormal blood flow (e.g. stasis), and hypercoagulability.15
The pathogenesis of an acute coronary syndrome involves the rupture of an ath-
erosclerotic plaque of the coronary artery (endothelial damage). Due to this plaque 
rupture, the blood becomes exposed to the subendothelial layer containing various 
thrombo-active substrates, resulting in vasoconstriction of the blood vessel, platelet 
recruitment at the site of injury (primary hemostasis) as well as activation of the 
coagulation cascade (secondary hemostasis). Total occlusion of the coronary artery 
will result in an ST-elevation myocardial infarction indicating transmural ischemia, 
after which myocardial infarction will ensue. This demonstrates the importance of 
early reperfusion therapy in ST-elevation myocardial infarction. In contrast, if some 
perfusion is still present, this would result in a non-ST elevation acute coronary 
syndrome representing subendocardial myocardial ischemia, which not necessarily 
results in myocardial infarction.16
In atrial fibrillation, the development of a thrombus is multifactorial and involves 
all three aspects of Virchow’s triad.17 Due to functionally ineffective contractions of 
the atria, blood flow in the left atrium and left atrial appendage is altered. Moreover, 
structural defects in the atrial (appendage) walls have been documented, as well as 
increased levels of activated coagulation factors. These abnormalities observed in 
atrial fibrillation result in a prothrombotic state which can result in thrombo-embolic 
events such as ischemic stroke or a non-cerebral systemic embolism.
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Thrombus formation
The formation of thrombi involves the activation of two different mechanisms: 
platelet aggregation (i.e. thrombocytes) and activation of the coagulation cascade 
(Figure 1).18
Platelets
Under normal conditions, thrombocytes are in a nonreactive state and do not adhere 
to the endothelium or aggregate.19 In case the endothelium is disrupted, collagen 
and Von Willebrand factor become exposed. These substrates anchor platelets to 
the subendothelium by bonding to receptors present on platelets (collagen: GPVI, 
GPIa-IIa; Von Willebrand factor: GPIb-IX-V), triggering the adhesion of platelets to 
the damaged endothelium.20-22 The exposed matrix from the vessel wall, as well as 
thrombin generated from activation of the coagulation cascade, initiate the activa-
tion of the thrombocytes. The activation of platelets induces a shape change of the 
glycoprotein IIb/IIIa (GpIIb/IIIa) receptor distributed on the membrane of the plate-
let. The expression of the activated GpIIb/IIIa can serve as a receptor for adhesive 
ligands (e.g. Von Willebrand factor, fibrinogen) initiating platelet-platelet connection 
VII - Tissue factor
COAGULATION CASCADE
X Xa
II IIa
I Ia
PLATELETS
Collagen vWF
Platelet adhesion and secretion
TxA2 ADP
Platelet recruitment and activation
GP IIb/IIIa activation
Platelet aggregation
VKA
Aspirin
Rivaroxaban
Apixaban
Edoxaban
Dabigatran
Clopidogrel
Prasugrel
Ticagrelor
Thrombus
Figure 1. Coagulation and platelet cascade and target sites of oral antithrombotic agents
Abbreviations: vWF = von Willebrandfactor, TxA2 = thromboxane A2, ADP = adenosine 
diphosphate, GP = glycoprotein, VKA = vitamin-K antagonists.
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or platelet aggregation. Finally, platelet activation initiates the recruitment of other 
platelets by initiating an increased production of thromboxane, a platelet agonist, as 
well as the secretion of various granules present in the platelets. These granules con-
tain other platelet agonists such as adenosine diphosphate (ADP), platelet derived 
growth factor (involved in vessel repair) but also coagulation factors (factor I, V and 
XIII).
Coagulation cascade
The other mechanism involved in the formation of a thrombus involves the activation 
of the coagulation cascade.21,22 This results in the production of thrombin (factor IIa), 
which is the most potent platelet activator and is also responsible for the cleavage of 
fibrinogen to fibrin (factor I and Ia, respectively). Fibrin binds to the glycoprotein (Gp) 
IIb/IIIa receptor of activated platelets connecting platelets thereby reinforcing the 
platelet plug. Tissue factor (TF) is the main initiator of the coagulation cascade and 
expressed within the vessel wall. Following vascular injury, coagulation factor VII/
VIIa, present in the blood plasma, becomes exposed to tissue factor, which forms a 
complex initiating the coagulation cascade. The TF/FVIIa complex induces the forma-
tion of factor Xa which converts prothrombin into thrombin.
Mode of action of oral antithrombotics
In this thesis we mainly focus on efficacy and safety issues of oral antithrombotic 
agents. Hence, parenteral agents, such as fibrinolytics, glycoprotein IIb/IIIa receptor 
antagonists and (low-molecular weight) heparins, will be discussed only briefly in 
Chapter 4. Oral antithrombotics can be categorized in two groups: antiplatelet agents 
and anticoagulants.
Antiplatelet agents
Antiplatelet drugs inhibit the activation and/or aggregation of thrombocytes.23,24 
In the current field of cardiology, the most important oral antiplatelet agents are 
aspirin and thienopyridines such as clopidogrel, prasugrel and ticagrelor. Aspirin, or 
acetylsalicylic acid, irreversibly inhibits the formation of thromboxane by blocking 
the cyclooxygenase-1 (COX-1) pathway in circulating platelets.23 Consequently, upon 
13
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activation by different stimuli, platelets affected by aspirin are hampered in their 
ability to recruit other platelets. Thienopyridines inhibit both activation of platelets
(ADP-dependent) and subsequent aggregation by blocking or modifying the platelet 
P2Y12 receptor.24 Despite this inhibition, platelets can still be activated by other 
stimuli and excrete ADP from their granules, but the P2Y12 receptors of platelets are 
inhibited by thienopyridines and the occupied receptors will thus not be stimulated, 
preventing further activation through the ADP-dependent pathway.
Anticoagulants
The second group of antithrombotics involve oral anticoagulants which either reduce 
the production or inhibit the activity of clotting factors.25 Although novel oral antico-
agulants have emerged in the last decade, vitamin K antagonists (VKA) have tradition-
ally been the only form of oral anticoagulation therapy. The working mechanism of 
VKAs involves the inhibition of vitamin K epoxide reductase.26 Although patients on 
VKA anticoagulation continue to manufacture the vitamin-K dependent coagulation 
factors (pro-coagulant factors: II, VII, IX, and X; anticoagulant factors: protein C and S) 
their function is impaired, and they are referred to as ‘proteins induced by vitamin K 
absence/antagonism’ (PIVKA).27 As such, there is a shortage of effective coagulation 
factors in case of VKA treatment. Importantly, despite the anticoagulant effect of 
VKAs on the long-term, an increased coagulation status can be observed in the early 
phase due to the relative short half-life of protein C and S. To ensure optimal efficacy 
and safety, VKAs need careful monitoring using the International Normalized Ratio 
(INR).26
Recently, other forms of oral anticoagulants have entered the market. The work-
ing mechanism of these drugs does not involve vitamin-K and they are therefore 
referred to as non-VKA oral anticoagulants (NOAC). Instead, rather than targeting the 
production of coagulation factors these drugs directly inhibit the activity of factor Xa 
(apixaban, rivaroxaban and edoxaban) or thrombin (factor IIa; dabigatran).28
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Safety and efficacy of oral antithrombotic drugs
Although platelet activation and the coagulation cascade are intertwined, their 
treatment differs according to the disease. Although VKA monotherapy proved ef-
fective in acute coronary syndromes, aspirin is the cornerstone in treatment given 
its safety profile and logistics (no INR measurement).29 On the other hand, aspirin 
monotherapy, as well as in conjunction with clopidogrel, is inferior to oral anticoagu-
lation in atrial fibrillation.6,30-32 This results in a different approach of antithrombotic 
treatment for myocardial infarction when compared to atrial fibrillation.
Prevention of acute coronary syndromes
Given the central role of platelets in an acute coronary syndrome, antiplatelet therapy 
is the key player in prevention of recurrent events. The efficacy and safety of aspirin 
has been assessed in numerous randomized controlled trials. In a meta-analysis of 16 
long-term secondary prevention trials among over 17,000 patients with a previous 
vascular event, aspirin yielded an absolute risk reduction of coronary events from 
5.3% to 4.3% per year during a 2.5 year follow-up period, which is equivalent to a 
20% relative risk reduction.33
Lower risk of recurrent ischemic events:
• Aspirin: 20% risk reduction (Chapter 2)
+ Clopidogrel: 20% risk reduction (Chapter 3)
+ VKA: 27% risk reduction (Chapter 4)
• Aspirin plus clopidogrel
+ NOAC: 16% risk reduction (Chapter 4)
Benefits Risks
Side effects:
• Dyspepsia and non-compliance (Chapter 2)
• Drug-drug interactions (Chapter 3)
• Risk of bleeding (Chapter 4)
Acute coronary syndrome (ACS)
Atrial fibrillation (AF)
Lower risk of stroke / systemic embolism:
• VKA: 64% risk reduction (Chapter 7)
• NOAC: at least as effective as VKA with lower
risk of IC bleeding (Chapter 5)
Increased total / major bleeding:
• Fear of bleeding and undertreatment (Chapter 7)
• Poor identification of bleeding risk factors (Chapter 7)
• Some NOACs: increased risk of GI bleeding (Chapter 5)
Figure 2. Balance between risks and benefits of oral antithrombotic therapy for ACS and AF
Abbreviations: AF = atrial fibrillation, ACS = acute coronary syndrome, IC = intracranial, GI = gastrointestinal,
VKA = vitamin-K antagonist, NOAC = non-VKA oral anticoagulation therapy.
NOACs are a new alternative to VKA:
• Sound data in ‘general trial population’ (Chapter 6)
• Less drug-drug interactions than VKA (Chapter 6)
• Robust data in AF (Chapter 5)
• Trials in ACS/stable angina awaited (Chapter 5)
Inadvertent / liberal use of NOAC:
• Limited data in frail and elderly patients (Chapter 6)
• Limited data on drug-drug interactions (Chapter 6)
• Use in ACS with DAPT in AF dosing (Chapter 5)
• Use in ACS/stable angina without trial data (Chapter 5)
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In primary prevention, the relative risk reduction was comparable, but given the 
very low event rates (~0.20% per year for non-fatal myocardial infarction), absolute 
benefits are minimal.33 As for safety, in patients at high risk of atherothrombotic 
events, long-term treatment with aspirin approximately doubles the risk of major 
bleeding.23,33,34 The majority of this risk increase was due to gastrointestinal bleed-
ing complications. This well-known side-effect of aspirin is due to its inhibition 
of the COX enzyme, resulting not only in inhibition of the platelet agonist throm-
boxane, but also in impairment of the production of prostaglandin E2, which has 
protective properties of the stomach by producing a protective mucous layer.35 In 
addition to this systemic gastrotoxicity, aspirin also has a more local, direct harmful 
effect to the stomach due to its ability to easily transfer through the gastroprotec-
tive mucous layer and enter and damage the underlying epithelial cells.36-38 Hence, 
aspirin increases the risk of gastric ulcus formation and gastrointestinal bleeding, 
but also dyspepsia.33,39-42 Although the latter is not a direct life threatening condi-
tion, it increases the risk of non-compliance to aspirin treatment resulting in a loss 
of efficacy.43,44 This will be discussed in Chapter 2.
Thienopyridines are also important in the prevention of acute coronary syn-
dromes. Although the current guidelines recommend the newer and more potent 
prasugrel and ticagrelor following an ACS, clopidogrel is worldwide still commonly 
used in the setting of secondary prevention following a myocardial infarction.45,46 
Clopidogrel has been studied both as monotherapy (vs. aspirin) and as adjunctive 
to aspirin (vs. placebo). As for monotherapy in the secondary prevention of vascular 
events, clopidogrel was comparable with regard to both efficacy as well as safety 
outcomes when compared to aspirin.47 In the setting of dual antiplatelet therapy 
following an ACS, the addition of clopidogrel to aspirin reduced the rate of ischemic 
events from 11.4% to 9.3%, which represents a 20% relative risk reduction.48 As to 
be expected was the combination of aspirin with clopidogrel associated with an 
increased risk of major bleeding when compared to aspirin monotherapy (2.7% vs. 
3.7%), albeit that the trade-off (ischemic vs. bleeding) was in favor of double anti-
platelet therapy with clopidogrel. As such, guidelines recommend the use of dual 
antiplatelet therapy for 12 months following an ACS.45,46
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Notably, the addition of clopidogrel resulted in an increase in gastrointestinal 
bleeding complications (0.7% vs 1.3%), and the risk of those bleeding complications 
was dependent of the aspirin dose.48,49 Given this observation, current guidelines rec-
ommend to prophylactically add a proton pump inhibitor in case of dual antiplatelet 
therapy, which is known to provide a 66% relative risk reduction in gastrointestinal 
bleedings in patients with dual aspirin and clopidogrel.45,46,50 Notably, the Food and 
Drug Administration, as well as the European Medical Association issued warnings on 
a reduced efficacy of clopidogrel in case of PPI coadministration, which is the topic of 
Chapter 3.51-53 This efficacy issue can result in discontinuation of the PPI by physicians, 
or may lead to a switch to different antitrombotic agents, which may affect safety.
Unfortunately, recurrent ischemic events still occur in about 10% of patients 
in the first year following an acute coronary syndrome, despite dual antiplatelet 
therapy.48 Given the knowledge that VKA monotherapy was effective in reducing the 
risk of myocardial infarction, the addition of an anticoagulant to antiplatelet therapy 
in selected high risk patients could be of additional value. This will be addressed in 
Chapter 4.
Prevention of thrombo-embolic stroke in atrial fibrillation
Several trials studied the effects of aspirin in stroke prevention in AF and a meta-
analysis indicated a 22% relative risk reduction of stroke and systemic embolism for 
aspirin.28 Moreover, the addition of clopidogrel to aspirin further reduced the risk of 
stroke. However, every additional ischemic event prevented was at the cost of one 
major bleed.32 Notably, oral anticoagulants proved to be much more effective than 
antiplatelet therapy. A meta-analysis of six trials comprising nearly 3000 patients ran-
domized to either dose-adjusted warfarin or placebo/no treatment demonstrated 
a 64% relative risk reduction for stroke.28 Importantly, also in elderly patients, the 
number needed to treat versus the number needed to harm favoured treatment 
with oral anticoagulants over placebo.
Also in comparison to aspirin, treatment with warfarin had a better risk-benefit 
profile, as it was not associated with higher rates of bleeding, and more effective in 
a large trial concerning elderly patients.31 VKA therapy also proved more effective 
17
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when compared to aspirin used in combination with clopidogrel, without signs of 
safety concerns.54
In the last decade, an alternative to warfarin has become available. As of to date, 
four different NOACs have been approved for use in clinical practice: apixaban, 
dabigatran, edoxaban and rivaroxaban.55 Importantly, NOACs do not require regu-
lar INR monitoring making them an interesting alternative to VKA treatment. Four 
large randomized trials concerning over 70,000 patients have demonstrated that 
this new class of drugs results in efficacy outcomes that are at least similar to those 
realized with VKAs with superiority for apixaban and dabigatran 150mg bid (relative 
risk reductions 21% and 34% respectively). 55-59 Importantly, all NOACs reduce the 
rate of intracranial hemorrhage with about 50%, and rates of major bleeding were 
significantly lower for apixaban, dabigatran 110mg bid and edoxaban (relative risk 
reductions 31%, 20% and 20%, respectively).56-59 The flipside of the coin concerned 
an increased risk of gastrointestinal bleeding for dabigatran 150mg bid, edoxaban 
and rivaroxaban (relative risk increase 50%, 23% and 30%, respectively). Although 
this is a serious concern which requires attention, the reported rates in atrial fibrilla-
tion should be put in the context of the overall safety profile. This in contrast to the 
situation of ACS, in which the combination with dual antiplatelet therapy seemed 
associated with more harm than benefit (Chapter 5). Although current guidelines 
recommend to consider oral anticoagulation in patients with a CHA2DS2-VASc score 
of 1 or higher, appreciation of the associated number needed to treat and number 
needed to harm is warranted.60,61 Moreover, it is important to realize whether trial 
data can be inferred to the general population, which is less selected than a study 
population. In that context, and with a growing population of elderly patient with 
atrial fibrillation with extensive comorbidity and associated drugs, we should ques-
tion whether these patients could have a differential response to oral anticoagula-
tion therapy. This issue is addressed in Chapter 6. Finally, the prediction of bleeding 
requires optimization, not only in the population as a whole, but especially in the 
elderly. In the abovementioned context, it is very well possible that risk factors for 
bleeding in the elderly differ from those in the young. Therefore we sought to assess 
the performance of the classical risk models for bleeding in the elderly. Insights into 
these issues may provide the prescribing physician more information to make a bal-
18
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anced decision, and to potentially reduce the rate of undertreatment in the elderly. 
This issue will be discussed in Chapter 7.
Outline of the thesis
Aspirin is associated with gastrointestinal complaints affecting compliance and thus 
efficacy. In Chapter 2, we performed a large cohort study comparing the prevalence 
of gastrointestinal symptoms between patients using plain aspirin and effervescent 
calcium carbasalate.
Following the concerns of several medical agencies, Chapter 3 addresses the 
impact of concomitant therapy of a proton pump inhibitor on the antiplatelet ef-
fect of clopidogrel in terms of efficacy. In this systematic review, both the effects on 
laboratory (platelet reactivity) and clinical outcomes are assessed.
About 10% of patients suffer from a recurrent thrombotic event while on adequate 
antiplatelet therapy. In this context, Chapter 4 provides an overview of the treatment 
options with regard to anticoagulation therapy in patients with high platelet reactiv-
ity, i.e. patients in whom dual antiplatelet therapy has been proven ineffective. This 
chapter also touches upon the antithrombotic challenges with regard to efficacy and 
bleeding risk in case a patients suffers from both coronary artery disease and atrial 
fibrillation.
Chapter 5 concerns a commentary to a meta-analysis on the impact of treatment 
with a non-VKA oral anticoagulant on gastrointestinal bleeding. In this chapter, we 
provide a critical appraisal of the methodology and we address to the importance of 
balancing all risks and benefits of antithrombotic therapy.
Given that patients using more drugs are generally more fragile, these patients 
could have a differential response to anticoagulation therapy. In the post-hoc analysis 
of the ARISTOTLE trial depicted in Chapter 6 we studied whether the number of 
concomitant drugs used is associated with the extent of comorbidity and the risk 
of adverse outcome, both ischemic as well as bleeding events in patients with atrial 
fibrillation. Moreover, we assessed the impact of the number of concomitant drugs 
on the effects of apixaban therapy on efficacy and safety when compared to warfarin.
Given that undertreatment in the elderly is common due to a perceived risk of 
bleeding, Chapter 7 aims to provide insight in the discriminatory ability of three cur-
19
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rently used bleeding risk stratification models in the very elderly patients (≥80 years) 
using a vitamin K antagonist in the setting of stroke prevention in atrial fibrillation. 
In addition to assessing and comparing the bleeding risk models, we also focused 
on the identification of bleeding risk factors in this specific cohort of very elderly 
patients.
Chapter 8 summarized the main findings and conclusions of all studies presented 
in this thesis. This chapter is concluded by an epilogue in which the clinical implica-
tions of the main findings are discussed.
Chapter 9 provides a Dutch translation of the summary and epilogue.
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abstraCt
Background: Aspirin is associated with gastrointestinal side effects such as 
gastric ulcers, gastric bleeding and dyspepsia. High-dose effervescent calcium 
carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced 
gastric toxicity compared with plain aspirin in healthy volunteers, but at lower 
cardiovascular doses no beneficial effects were observed.
Aim: To compare the prevalence of self-reported gastrointestinal symptoms 
between low-dose plain aspirin and ECC.
Methods: A total of 51,869 questionnaires were sent to a representative sam-
ple of the Dutch adult general population in December 2008. Questions about 
demographics, gastrointestinal symptoms in general and specific symptoms, 
comorbidity, and medication use including bioequivalent doses of ECC (100 
mg) and plain aspirin (80 mg) were stated. We investigated the prevalence of 
self-reported gastrointestinal symptoms on ECC compared with plain aspirin 
using univariate and multivariate logistic regression analyses.
Results: A total of 16,715 questionnaires (32%) were returned and eligible for 
analysis. Of these, 911 (5%) respondents reported the use of plain aspirin, 633 
(4%) ECC and 15,171 reported using neither form of aspirin (no aspirin). The 
prevalence of self-reported gastrointestinal symptoms in general was higher 
in respondents using ECC (27.5%) compared with plain aspirin (26.3%), but 
did not differ significantly with either univariate (OR 1.06, 95%CI 0.84-1.33), 
or multivariate analysis (aOR 1.08, 95%CI 0.83-1.41). Also, none of the specific 
types of symptoms differed between the two aspirin formulations.
Conclusions: In this large cohort representative of the general Dutch popula-
tion, low-dose ECC is not associated with a reduction in self-reported gastro-
intestinal symptoms compared with plain aspirin.
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introduCtion
Optimal antithrombotic therapy has proven to be essential in secondary prevention in 
cardiovascular disease. In this, aspirin has a pivotal role and is associated with a rela-
tive reduction of approximately 25% in recurrent cardiovascular events.1 However, 
gastric toxicity is a well-known side effect of aspirin presenting as gastric or duodenal 
ulcers, bleeding and dyspepsia.1-7 Of these, dyspepsia is most often reported (in 20-
40% of chronic aspirin users)4,7,8 and is associated with reduced aspirin compliance 
(9,10), increased healthcare costs11 and reduced health-related quality of life.12
To reduce gastrointestinal damage, different formulations of aspirin have been 
developed. These formulations either delay the release of aspirin beyond the stom-
ach (enteric-coated aspirin), facilitate the transit of aspirin across the gastric mucous 
layer (PL2200), or increase solubility of aspirin supposedly resulting in lower irritating 
concentrations on the gastric mucosa (effervescent calcium carbasalate (ECC)). The 
gastric toxicity of different formulations was mainly studied in high dosages and 
showed clear benefit over plain aspirin with respect to gastric ulcer formation when 
studied in healthy volunteers.13-18 However, when investigating its clinical effect in 
patients on (low-dose) chronic antiplatelet therapy, no clear beneficial effect on 
gastrointestinal side effects was noticeable.19-22
In the Netherlands, a total of 1,290,000 patients use low-dose aspirin of which 
41% are prescribed ECC.23 No data have been published comparing the effects of ECC 
and plain aspirin on gastrointestinal symptoms. In this population-based cohort of 
respondents using low-dose aspirin we studied and compared the prevalence of gas-
trointestinal symptoms between those using ECC and plain aspirin. We also studied 
whether respondents using different formulations may present with different types 
of gastrointestinal symptoms.
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Methods
Study population
We sent 51,869 questionnaires by surface mail to a representative sample of the 
Dutch population in December 2008. Invited subjects were aged 18 years and above, 
and randomly selected from municipal databases of five different municipalities 
selected on their geographical location in the Netherlands, in order to gather a rep-
resentative sample of the Dutch population. We included returned questionnaires 
until 31 March 2009. We excluded returned questionnaires with missing elements 
that were part of the primary outcome measure. We also excluded returned ques-
tionnaires in which all baseline characteristics were missing or when the medication 
was unreadable or if the used aspirin formulation was not reported. The complete 
cohort has been described previously.24 The current sample size consisted of those 
respondents reporting the use of either low-dose plain aspirin or ECC.
The Medical Ethical Committee of the Radboud University Nijmegen assessed the 
research proposal of this study and concluded that it could be waived for ethical 
review, as questionnaires were returned and stored anonymously, and (non-)re-
sponders would not be contacted again. For this reason, we did not obtain written 
informed consent.
Questionnaire
The questionnaire has been used before and was specifically designed for collec-
tion of demographic information, gastrointestinal symptoms, and medication use 
(25,26). Participants were asked whether they suffer from gastrointestinal symptoms 
in general and about the presence of 26 gastrointestinal symptoms such as nausea, 
early satiety and bloating. Severity of gastrointestinal symptoms was assessed on a 
seven-point Likert scale (0 = absent, 1 = almost absent, 2 = mild, 3 = moderate, 4 = 
moderately severe, 5 = severe, 6 = very severe) over the preceding four weeks.27 A 
symptom was considered to be present if the participants scored ≥ 2 on the Likert 
scale.
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Outcomes
Our primary outcome was the presence of gastrointestinal symptoms, which was as-
sessed with the question: ‘Do you experience gastrointestinal complaints?’ and had 
to be answered with either ‘yes’ or ‘no’. Secondary outcomes were duration of the 
primary endpoint and the individual gastrointestinal symptoms among responders 
who reported the presence of gastrointestinal complaints. The primary and second-
ary outcomes were compared between respondents reporting the use of low-dose 
plain aspirin (80 mg) and those using ECC (100 mg).
Statistical analysis
Statistical analyses were performed with SPSS statistical software, version 16.0 (SPSS, 
Inc., Chicago, Illinois, USA). Frequency tables were provided describing respondents’ 
baseline characteristics. Pearson’s chi squared test was used to compare categori-
cal variables. Continuous variables were compared with the Student T-test or the 
Mann-Whitney U method whenever appropriate. Univariate and multivariate as-
sociations for gastrointestinal endpoints in respondents using plain aspirin or ECC 
were analysed using logistic regression. Two-sided p-values of <0.05 were considered 
statistically significant. Covariates were included in the multivariate analysis if they 
significantly differed between respondents using ECC versus plain aspirin. In addi-
tion, those covariates associated with gastrointestinal symptoms at a level of p<0.1 
in univariate analysis were included in multivariate analysis. Using forward selection, 
a covariate was allowed into the multivariate model if it influenced the model with a 
likelihood ratio significance level of p<0.05, and was removed again if its significance 
level exceeded p=0.1 during any of the following steps. The type of formulation used 
(ECC versus plain aspirin) was forced into the model.
With respect to the duration of symptoms and the analyses of the individual 
symptoms, only participants reporting the presence of the primary outcome were 
selected. The duration of symptoms was compared using the Mann-Whitney U 
method. The individual symptoms were divided into upper and lower gastrointestinal 
symptoms and figures were provided describing their frequencies. The sum of the 
individual symptoms present was categorised according to the number of symptoms 
present and frequencies were provided.
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results
A total of 18,317 (35%) questionnaires were returned, of which 742 unopened for 
various reasons (Fig. 1). After applying our predetermined exclusion criteria a total 
of 16,715 questionnaires were included in our analyses. In total, 911 persons (5.4%) 
reported plain aspirin use, 633 ECC (3.8%) and 15,171 reported not using any form of 
aspirin (90.8%). Nearly all baseline characteristics differed between participants with 
and without aspirin (Online Supplementary Table 1). When comparing plain aspirin 
and ECC, participants using ECC were older, reported more comorbidity and were 
using more concomitant medication (Table 1).
The self-reported prevalence of gastrointestinal symptoms of no aspirin, plain 
aspirin, and ECC were 25.6%, 26.3%, and 27.5%, respectively. We observed no dif-
ference between plain aspirin and ECC for self-reported gastrointestinal symptoms 
(ECC: OR 1.06, 95% CI 0.84-1.33). Also after adjustment with multivariate regression 
51,869 questionnaires sent (100%)
18,317 questionnaires returned (35%)
16,715 questionnaires analyzed (32%)
742 questionnaires returned unopened
360 no reason
298 moved
47 deceased
37 not interested
860 questionnaires excluded*
284 all baseline variable missing
308 primary outcome missing
413 gastrointestinal symptoms missing
111 medication unreadable
43 type of aspirin not specified
911 plain aspirin 633 ECC 15,171 no aspirin
Figure 1: Flow chart
* Some respondents fulfilled more than 1 exclusion criterion
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Table 1: Baseline characteristics
Plain aspirin
effervescent calcium 
carbasalate P-value
n = 911 n = 633
Mean age (±SD) (years) 59.7 (15.2) 64.7 (11.3) <0.01
Male (%) 494 (56) 377 (61) 0.09
Smoking (%) 160 (18) 116 (19) 0.74
BMI (±SD) (kg/m2) 26.3 (4.6) 27.0 (4.9) <0.01
Comorbidity (%)
Diabetes mellitus 108 (12) 106 (17) <0.01
Rheumatoid arthritis 53 (6) 54 (9) 0.04
Asthma / COPD 62 (7) 69 (11) <0.01
Coeliac disease 16 (2) 9 (1) 0.61
IBD 27 (3) 18 (3) 0.89
Medication use (%)
PPI 191 (21) 188 (30) <0.01
H2RA 24 (3) 14 (2) 0.60
Antacids 79 (9) 50 (8) 0.59
Paracetamol 474 (52) 276 (44) <0.01
NSAIDs 274 (30) 186 (29) 0.77
Clopidogrel 17 (2) 36 (6) <0.01
Dipyridamole 43 (5) 69 (11) <0.01
Beta blockers 351 (39) 301 (48) <0.01
ACE inhibitors 175 (19) 189 (30) <0.01
Angiotensin-receptor 
antagonist
103 (11) 83 (13) 0.28
Calcium antagonist 128 (14) 105 (17) 0.17
Diuretics 185 (20) 155 (25) 0.051
Statins 396 (44) 373 (59) <0.01
Systemic corticosteroids 15 (2) 11 (2) 0.89
Oral glucose lowering agents 85 (9) 70 (11) 0.27
Antidepressants 47 (5) 40 (6) 0.33
History (%)
Peptic ulcer disease 69 (8) 76 (12) <0.01
Peptic ulcer bleeding 26 (3) 15 (2) 0.56
SD = standard deviation, BMI = body mass index, kg/m2 = kilogram per square meter, COPD = 
chronic obstructive pulmonary disease, IBD = inflammatory bowel disease, PPI = proton pump 
inhibitor, H2RA = H2-receptor antagonist, NSAID = non-steroid anti-inflammatory drugs, ACE = 
angiotensin converting enzyme.
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for multiple possible confounders there was no significant difference between plain 
aspirin and ECC for the presence of gastrointestinal symptoms (ECC: aOR 1.08, 95% CI 
0.83-1.41, Table 2). Among those reporting gastrointestinal symptoms, respondents 
using ECC had a significantly longer history of symptoms (10 years, IQR 4-20) com-
pared with participants using plain aspirin (7 years, IQR 3-16, p=0.04).
In respondents reporting the presence of gastrointestinal symptoms and using either 
plain aspirin or ECC the presence of no more than one individual upper gastrointes-
tinal symptom was reported by 26.9% while five or more symptoms were reported 
present by 32.3%. The most frequently reported upper gastrointestinal symptoms 
were bloating (61%), belching (47%) and regurgitation (42%)(Fig. 2a). With respect 
to lower gastrointestinal symptoms, 23.0% reported no more than one symptom, 
while 39.0% experienced the presence of 5 or more symptoms. Flatulence (70%) 
and borborygmi (56%) were the most frequently reported lower gastrointestinal 
symptoms (Fig. 2b). No significant differences between plain aspirin and ECC were 
present for any of the upper or lower gastrointestinal symptoms.
Table 2: Multivariate logistic regression model for reporting gastrointestinal symptoms with 
effervescent calcium carbasalate entered into the model
aor 95% CI P-value
Age (per year increase) 0.98 0.97-0.99 <0.01
Male gender 0.71 0.55-0.92 0.01
Comorbidity
Asthma / COPD 1.54 1.01-2.36 0.046
IBD 2.01 1.00-4.04 0.050
Medication use
PPI 3.96 2.96-5.30 <0.01
H2RA 4.39 2.01-9.57 <0.01
Antacids 2.90 1.90-4.44 <0.01
Paracetamol 1.42 1.09-1.86 <0.01
effervescent calcium carbasalate 1.08 0.83-1.41 0.57
History
Peptic ulcer disease 2.39 1.60-3.58 <0.01
aOR = adjusted odds ratio, CI = confidence interval, COPD = chronic obstructive pulmonary 
disease, IBD = inflammatory bowel disease, PPI = proton pump inhibitor, H2RA = H2-receptor 
antagonist.
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disCussion
We aimed to compare the prevalence of self-reported gastrointestinal symptoms 
between respondents using plain aspirin and those who were prescribed ECC. We 
observed that in respondents using any form of low-dose aspirin the prevalence 
of gastrointestinal symptoms was 27%. The use of ECC is not associated with less 
gastrointestinal symptoms compared with plain aspirin. The most reported upper 
Figure 2: Type and prevalence of specific upper (a) and lower (b) gastrointestinal symptoms in 
patients experiencing gastrointestinal symptoms categorised by aspirin formulation
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gastrointestinal symptoms were bloating, belching, and regurgitation, whereas 
flatulence and borborygmi were reported most for lower gastrointestinal symptoms. 
No differences in the type of symptoms between users of ECC and plain aspirin were 
observed.
The prevalence of gastrointestinal symptoms in our study cohort is in line with 
previously reported data of aspirin users.4,7,8 Interestingly, the prevalence of gastroin-
testinal symptoms in our non-aspirin using population is comparable with those who 
use aspirin. The selection of our study population could have contributed to this find-
ing. Low-dose aspirin is generally a long-term treatment, i.e. for the remainder of the 
patients’ life span. For our study we selected all low-dose aspirin users from a large 
cohort of randomly selected participants returning the questionnaire. As a result of 
this study design the odds that aspirin treatment was recently initiated for our par-
ticipants are minimal. Those patients who suffered from gastrointestinal symptoms 
during (the initiation of) aspirin treatment were likely to receive co-treatment with a 
proton pump inhibitor, H2-receptor antagonist or antacid or were even switched to 
other antiplatelet agents. Consequently, our cohort may consist of a selected popula-
tion of respondents in whom aspirin is relatively well tolerated. This hypothesis is 
supported by the more frequent use of gastroprotective agents in low-dose aspirin 
users compared with our non-aspirin using population (e.g. proton pump inhibitor 
use: 25% vs 9%). Irrespectively, our data indicate that ECC is of no beneficial value for 
gastrointestinal symptoms among our population of long-term aspirin users.
So far, only two studies have been conducted to investigate endoscopically 
proven gastric mucosal damage in users of ECC and plain aspirin. In a randomised 
cross-over trial, ECC significantly reduced endoscopically observed gastric erosions 
and ulcers compared with the bioequivalent dose of plain aspirin.13 However, this 
study assessed healthy volunteers, investigated very high doses of aspirin (650 mg 
three times a day) and only studied the short-term effects. More recently, the effects 
of low-dose ECC and plain aspirin were compared in patients using long-term aspirin 
for cardiovascular prevention.19 In this large retrospective cohort study, the authors 
concluded that the incidence rates of endoscopically proven peptic ulcers were not 
significantly different between the two groups.
37
Gastrointestinal symptoms in low-dose aspirin users
2
This is the first study comparing the effects of ECC with plain aspirin for gastrointes-
tinal symptoms. Moreover, in order to obtain a representative sample, persons were 
randomly selected through databases of local authorities without stringent inclusion 
and exclusion criteria. We do acknowledge some limitations in our study. First, due to 
our study design, response bias could be a potential limitation. Due to concealment 
we were unable to contact non-responders and compare their characteristics with 
responders. To minimise the effect of response bias all participants were invited with 
a personalised invitational letter and were asked explicitly to participate irrespective 
of experiencing gastrointestinal symptoms. Seventy-five percent of all respondents 
indeed did not report the presence of gastrointestinal symptoms. Secondly, we did 
not study the duration of low-dose aspirin use or the effect of gastrointestinal symp-
toms on aspirin compliance. Finally, we observed important differences in baseline 
characteristics between the two aspirin formulations, all to the detriment of those 
participants using ECC. This could be an indication that physicians are more likely to 
prescribe plain aspirin to the relatively healthy subjects and preferentially prescribe 
ECC to the older and more fragile patients. In order to adjust for this possible bias we 
performed multivariate analysis. Nonetheless, this observation suggesting confound-
ing by indication should be noted and calls for a study with random allocation of 
aspirin formulation.
We observed that low-dose ECC is not associated with a reduction in gastroin-
testinal symptoms compared with plain aspirin. This absence of a beneficial effect of 
ECC over plain aspirin is in analogy to a previous study indicating that low-dose ECC 
is not associated with a reduction in the prevalence of gastric ulcer complications. 
Notably, the costs of ECC are significantly higher compared with plain aspirin (€1.55 
vs. €0.79/month in the Netherlands).28 With 530,000 ECC users in the Netherlands, 
these additive costs comprise nearly 5 million euro annually. In view of the lack of 
a beneficial clinical effect and the higher costs of ECC, we feel that plain aspirin is 
the first drug of choice. If gastrointestinal symptoms occur, we advise to prescribe a 
relatively cheap proton pump inhibitor with proven beneficial effects.29-31 Only if this 
does not reduce the symptoms, might one consider ECC as an alternative to plain 
aspirin.
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In conclusion, the prevalence of gastrointestinal symptoms among aspirin users 
in the Dutch community is 27% with no difference between effervescent calcium 
carbasalate and plain aspirin in overall prevalence and type of symptoms reported.
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suMMary
Background Clopidogrel as adjunct to aspirin has improved outcomes after 
acute coronary syndromes (ACS), but laboratory studies suggest a reduced 
antiplatelet effect when proton pump inhibitors (PPIs) are co-administered. 
Despite corroborating data from retrospective studies, new clinical data fuel 
the controversy on this issue.
Purpose Systematic review on the impact of the addition of PPIs to clopidogrel 
both on platelet function and cardiovascular outcome.
data sources PubMed, Web-of-Science, Cochrane Database, and reference 
lists of related articles.
Study selection Published articles on controlled studies addressing the addi-
tion of PPIs to clopidogrel. Platelet function studies describe patients as well 
as healthy volunteers. Clinical studies concern patients using clopidogrel for 
ACS or due to stent implantation for stable coronary disease.
data extraction Two investigators independently reviewed the identified 
articles for eligibility, one author extracted the data.
data synthesis In 70% (7/10) of the laboratory studies examining healthy vol-
unteers on clopidogrel, addition of PPIs resulted in a significant reduction in 
platelet inhibition. For patients this was observed in 11/18 (61%) studies. The 
33 clinical studies showed significant heterogeneity in observed outcomes, 
with risk ratios for major adverse cardiovascular events varying from 0.64 to 
4.58 in case of PPI use, which was randomly allocated in only two studies. 
Consequently, imbalances between prognosticators at baseline and PPI pre-
scription bias markedly contributed to the variability in results.
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Conclusions Despite indications of reduced antiplatelet activity ex vivo in case 
of PPI administration in clopidogrel users, data on the clinical consequences 
are controversial. With the accumulating evidence from better designed, 
prospective clinical studies an adverse impact of PPI use on clinical outcome 
in patients on clopidogrel cannot be substantiated. The present review 
challenges the validity of conclusions based upon quantitative analyses of 
predominantly non-randomized data.
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introduCtion
Optimal antithrombotic therapy has proven to be essential in secondary prevention 
after an acute coronary syndrome (ACS).1 Aspirin is associated with a relative reduc-
tion of 25% on recurrent events.1 Addition of clopidogrel has resulted in a further 20% 
reduction and the combination is therefore widely implemented.2 In patients who 
use antiplatelet agents gastrointestinal complications are well-known side effects, 
which are reduced by proton pump inhibitors (PPIs).3 Therefore, current guidelines 
advise to prescribe a PPI in high risk patients.4
However, the FDA and EMA published warnings for co-therapy of clopidogrel with 
PPIs which, initially, were primarily based on laboratory and retrospective cohort 
studies.5-7 The former reported reduced ex vivo inhibition of platelet aggregation, 
indicative of a pharmacological interaction between (certain) PPIs and clopidogrel.8-10 
Retrospective studies that reported adverse clinical outcome in case of co-therapy 
seemed to corroborate the laboratory findings.11,12
From a pharmacological point of view, interference with clopidogrel metabolism 
seems plausible and could affect clinical efficacy. Transformation of clopidogrel into 
its active metabolite requires the liver’s enzyme cytochrome P450 2C19 (CYP2C19).13 
PPIs also act through this enzyme, thereby reducing the enzymes’ bio-availability.14
With regard to clopidogrel metabolism in healthy individuals, carriers of a 
reduced-function allele of CYP2C19 had 30% lower levels of the active clopidogrel 
metabolite and a 25% relative reduction in platelet inhibition ex vivo.15 This suggests 
that CYP2C19 could affect pharmacodynamics of clopidogrel in patients as well.
A clinical effect of CYP2C19 polymorphisms has been shown among patients us-
ing clopidogrel: carriers with a loss of function CYP2C19 allele had a 53% increased 
risk for myocardial infarction, stroke, or cardiovascular death as compared with 
non-carriers.15 Notably, these results were not adjusted for the patients’ baseline 
cardiovascular risk profile and their demographic characteristics. In view of the 
above, addition of a PPI might have adverse impact on clinical outcome in patients 
using clopidogrel.16
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In follow-up on the first retrospective clinical studies, several new prospective 
studies have been published that questioned the potentially reduced clinical efficacy 
of clopidogrel in case of PPI co-administration.17,18
Clopidogrel is most commonly prescribed in case of coronary heart disease, i.e. in 
the clinical setting of an acute coronary syndrome or after a percutaneous coronary 
intervention for stable angina. For these indications this review describes the pres-
ently available laboratory and clinical data on this controversial issue.
Methods
The methodology and report of the present review is based on the recommenda-
tions described in the PRISMA statement.19
Study selection
Eligible studies were identified by searching the following electronic databases: 
PubMed, Web-of-Science, Cochrane Database. In these databases we combined 
the search terms “clopidogrel” and “proton pump inhibitors”. The last search was 
performed on June 12th 2012. In addition we scrutinized the reference lists of the 
eligible articles, and the reviews, letters, or editorials on this subject.
After removing duplicates, we excluded scientific meeting abstracts. Second, 
articles reporting no original study data (e.g. reviews) were excluded. We only in-
cluded studies written in European language. There were no restrictions with respect 
to publication date or with regard to the type of PPI studied. Third, studies were 
excluded if there was no control group that consisted of clopidogrel users without 
adjunctive use of a PPI. Fourth, studies without data on platelet function test results 
and/or cardiovascular clinical outcomes were excluded.
Platelet function studies
Patients as well as healthy volunteers were considered. Cross-over trials were ac-
cepted only for studies investigating healthy volunteers and only when a wash-out 
period of at least 10 days was used. In patient studies, we only included studies 
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when clopidogrel was administered in the setting of ACS (with or without coronary 
intervention) or after stent implantation for stable coronary disease. A cross-over 
design was not accepted given the effect of time on platelet function after ACS and/
or stent implantation. We excluded studies that only reported relative reductions 
between groups. In case of reported relative reductions, at least in one of the groups 
an absolute measure of platelet function should be reported. No selection in type of 
platelet function test used was made.
Clinical outcome studies
Patients using clopidogrel in the setting of ACS (with or without coronary interven-
tion) or after stent implantation for stable coronary disease were considered, studies 
with other indications for clopidogrel were excluded. We excluded studies that only 
reported relative reductions between groups. In case of reported relative reductions, 
at least in one of the groups absolute numbers/proportions should be available.
Endpoints
For the laboratory studies we reviewed the results of reported platelet function tests. 
The endpoints for the clinical studies consisted of all-cause mortality, myocardial 
infarction (MI) and major adverse cardiac events (MACE) as defined by the authors 
of the original articles, which are outlined in the online supplementary materials. 
We reported the outcome measures (i.e. relative risk, odds ratio, hazard ratio) as 
reported by the author.
Quality assessment and data collection
We assessed the methodological validity of each included study using criteria for 
minimization of bias. In detail, we determined the investigated populations, the 
possibility of exclusion bias, measurement of exposure, definition and measurement 
of the outcome, blinding, length of follow-up, loss to follow-up and control for con-
founders. In addition, for case-control studies we assessed matching and the defini-
tion of cases and controls. No scales that numerically summarized the components 
were used.
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Two investigators (JJF and MGHvO) independently performed the study selection. 
One investigator (JJF) then extracted study characteristics and data from the included 
studies using a prespecified data collection form and assessed the study quality. 
These data were validated by a second author (MGHvO). In case of discrepancies, a 
third independent adjudicator (GEC) was asked. Reviewers were not blinded to the 
author, institution or journal.
Statistics
With regard to the comparison of the laboratory studies, outcome parameters can-
not be pooled, given the wide variety of laboratory parameters that were used as 
endpoints. Therefore, we decided to review and describe the changes in platelet 
inhibition observed and not to perform summarized quantitative comparisons.
For the clinical trials, we assessed the risk of publication bias across studies by vi-
sually evaluating a funnel plot. Notably, there were only two randomized trials among 
the clinical studies and outcome data showed marked between-study heterogeneity: 
all-cause death I2 83%, p<0.001; myocardial infarction I2 96%, p<0.001; MACE I2 83%, 
p<0.001 (RevMan version 5.0 Copenhagen, 2008). As the terms and conditions for a 
sound meta-analysis were not met, an approach of systematic review was adopted. 
Finally we performed separate analyses for certain individual PPIs for the endpoint 
MACE.
results
We identified a total of 838 hits with the search terms “clopidogrel” and “proton 
pump inhibitors”.
After adjustment for duplicates 577 unique records remained. After applying the 
exclusion criteria 59 records remained (figure 1). Of these records one reported data 
both on laboratory and clinical endpoints,20 and one record addressed data both for 
healthy volunteers and for patients.21
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Laboratory studies
The study characteristi cs are outlined in the online supplementary materials both for 
studies on healthy volunteers (online supplementary table 1) and pati ents (online 
supplementary table 2). Of the studies investi gati ng healthy volunteers, 90% (9/10) 
were randomized studies.10,21-28 With regard to the 18 studies investi gati ng pati ents, 
61% (11/18) were of observati onal design.8,29-38 Only 28% (5/18) had random alloca-
ti on of a PPI.9,21,39-41
PubMed: 369 records
Web-of-Science: 448 records
Cochrane Database: 19 records
Other sources*: 2
577 records after removing duplicates
59 records included‡
27 laboratory studies§ 33 clinical studies
Excluded (n=518)
Meeting abstracts: 58
No original study data: 338
No active and control group†: 74
No laboratory or clinical endpoint: 25
Not fulfilling prespecified population criteria: 8
Other prespecified reasons: 15
Figure 1. Flowchart of the study selecti on process.
*Records derived by scruti nizing the reference lists of the eligible arti cles, and reviews, lett ers, 
or editorials on this subject.
†Acti ve group is defi ned as clopidogrel with PPI, control group is defi ned as clopidogrel with-
out PPI.
‡One record reported both laboratory and clinical endpoints.
§One laboratory study reported data regarding both healthy volunteers and pati ents.
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Clinical studies
The study characteristi cs are outlined in online supplementary table 3. Of the in 
total 33 clinical studies, in only two studies the use of a PPI was randomized.42,43 
Seven studies were prospecti ve registries.44-50 There were three post-hoc analyses on 
clinical data prospecti vely collected in the setti  ng of a trial that randomized for stent 
treatment or for anti thromboti c therapy.20,51,52 Nineteen were retrospecti ve cohort 
studies,12,53-70 and two were case-control studies.11,71
Outcomes
Laboratory studies
With regard to the studies investi gati ng healthy volunteers, the main results are 
summarized in table 1 (more detailed descripti on in online supplementary table 4). 
In 70% (7/10) of the studies, additi on of PPIs to clopidogrel resulted in a signifi cantly 
reduced platelet inhibiti on in at least one platelet functi on test.10,21,22,24,25,27,72
The results of the 18 pati ent studies show that 11 (61%) reported a signifi cantly 
reduced inhibiti on of platelet aggregati on in at least one platelet functi on test when 
PPIs were co-administered.8,9,20,30-32,34,36,37,40,73 Considering the fi ve studies with ran-
dom allocati on of a PPI only two reported a signifi cant diff erence (table 1 and more 
detailed descripti on in online supplementary table 5).9,40
Table 1 Summary of the Results of the Laboratory Studies
Populati on design number of 
studies
Total subjects 
(analyzed)
Adverse impact of PPIs 
on at least one platelet 
functi on test
Healthy 
volunteers
Randomized controlled 
trial
Prospecti ve study
Total
9
1
10
473 (441)
21 (21)
494 (462)
6/9 (67%)
1/1 (100%)
7/10 (70%)
Pati ents Randomized controlled 
trial
Post-hoc analyses
Observati onal
Total
5
2
11
18
505 (489)
131 (131)
4815(4815)
5451 (5435)
2/5 (40%)
2/2 (100%)
7/11 (64%)
11/18 (61%)
PPI, proton pump inhibitor.
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Clinical studies
With regard to the baseline characteristics, it should be appreciated that there is 
a higher incidence of established prognosticators for adverse short- and long-term 
outcome among patients using PPIs, most prominent in the retrospective studies 
(online supplementary table 6).
The main results of the clinical studies are presented in table 2 (summarized 
description in online supplementary table 7). Mortality was reported in 23 stud-
ies. In total, 17 (74%) articles reported no risk difference for patients on PPIs
.11,12,42,43,45-51,53,54,58,62,63,68 In the other 6 studies the effect ranged from a reduced risk 
in one study (adjusted hazard ratio 0.68, 95% confidence interval (CI) 0.47-0.96),20 
to an increased risk in five studies, with a relative risk of up to 2.63 (95% CI 1.17-
5.94).44,52,57,61,70 The endpoint MI was reported in 25 studies of which 11 (44%) reported 
a significantly increased risk ratio for PPI users from 1.19 up to 4.58.11,12,51,55,58-61,63,67,71 
The other 14 reported no difference in outcome.20,42,45,46,48,50,52,54,57,65,66,68-70 Of the 25 
studies reporting MACE, twelve (48%) showed a significantly increased risk when 
PPIs were combined with clopidogrel,12,44,51-53,58,59,61,63,65,67,70 with an effect that ranged 
from hazard ratios of 1.20 to 4.58. The other 13 studies showed no impact on out-
come.20,42,45-50,54,56,62,64,68
When examining esomeprazole/omeprazole as specific PPIs of interest, the re-
ported effect between studies showed marked heterogeneity for the endpoint MACE 
as well: (es)omeprazole I2 70%, p<0.01. Regarding (es)omeprazole, an increased risk 
was present in 2/7 (29%) studies.44,65 The other 5 studies reported no significant risk 
difference.42,45,47-49 Of the four studies reporting data for pantoprazole (no significant 
heterogeneity; I2 0%, p=0.69), one study (25%) reported an increased risk,59 while the 
other three studies reported no significant difference.44,47,49
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disCussion
The findings of the present review are that the majority of laboratory studies sug-
gests that the addition of certain PPIs reduces platelet inhibition ex vivo in clopido-
grel users. The studies on clinical outcome are often not well designed, with signs 
of prescription bias and apparent imbalances in baseline characteristics that mainly 
account for the large variability in the observed outcomes. It is only by acknowl-
edgement of these aspects that reports suggesting harm from PPIs with relative risk 
increases up to 50-150% can be understood. Considering the firmly and thoroughly 
established relative benefit of about 20% with addition of clopidogrel to aspirin,2 we 
feel that the reported magnitudes of increased risk cannot (solely) be attributed to 
the use of PPIs in many of these studies. Notably, nearly all prospective registries, 
and, most importantly, the only two trials with random allocation of a PPI reported 
no detrimental clinical effect of PPIs among clopidogrel users.
Indisputably, in the (predominantly) randomized trials on healthy individuals 
using clopidogrel monotherapy, addition of certain PPIs has proven to reduce the 
inhibition of platelet aggregation as measured by multiple platelet function tests. 
This supports a pharmacological interaction ex vivo under physiological conditions.
In contrast, acute coronary disease differs from physiological conditions, and 
patients use both aspirin and clopidogrel. Patients with stable coronary disease who 
underwent revascularization and stenting use dual therapy as well. Although about 
60% (11/18) of laboratory studies suggest reduced platelet inhibition in case of co-
therapy with a PPI, these results should be interpreted with caution. Importantly, 
only 5 of the 18 studies on patients had random allocation of PPIs, two of which 
demonstrated impaired platelet inhibition. Notably, it has been suggested that PPIs 
may also adversely affect the platelet response to aspirin. This may form an addi-
tional reason for the observed reduced inhibition of platelet aggregation.74 Finally, 
some methodological issues characteristic for laboratory studies remain.
First, it is uncertain to what extent reproducibility contributes to the observed 
results, despite observed relative differences in laboratory outcome parameters of 
about 10 to 30%. A difference in lab results may be numerically statistically significant, 
but it depends on the coefficient of variation of the respective test whether there is 
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a true difference between values. Second, issues with regard to the pharmacology 
of antiplatelet therapy have not been accounted for. It should be appreciated that 
the timing of the laboratory assessment in relation to the intake of the antiplatelet 
therapy is often not systematically reported.
Although it is tempting to assume that a pharmacological interaction under physi-
ological conditions will also be present in the setting of an acute coronary syndrome, 
the laboratory findings in patients are less uniform, which also holds true for the 
quality of the studies. The warnings issued for the combined use of certain PPIs and 
clopidogrel by the FDA were predominantly based upon laboratory studies showing 
reduced platelet inhibition, and the hypothesis that this surrogate endpoint might 
result in adverse outcome. Although data from retrospective studies seemed to 
support these recommendations, emerging evidence from prospective controlled 
studies fuelled the controversy on this issue.
It should be appreciated that there is uncertainty with regard to the question 
whether, and if so, to what extent adverse laboratory findings translate into clini-
cal outcome. Even if the platelet function test results for patients on PPIs would be 
correlated with prognosis, these laboratory parameters may merely be a marker 
of poor outcome, and not indicate causality. In analogy, the GRAVITAS trial studied 
the impact of a more intense antithrombotic therapy when platelet function tests 
indicated inadequate reduction of platelet activity, a strategy that did not result in 
better clinical outcomes.75 To date, it is uncertain which, if any, test is (most) reliable 
in the prediction of incident events, and how large the laboratory effect should be to 
result in a meaningful clinical difference.
With regard to clinical outcomes, accumulating data from recently published 
clinical studies fuelled the controversy on the potential adverse impact of PPIs in 
clopidogrel users. Cardiovascular outcomes of the different studies show marked 
heterogeneity (statistically significant), in our opinion precluding a reliable meta-
analysis. Moreover, in only two of the 33 controlled studies the PPI was randomly 
allocated. Consequently, in most studies imbalances were present with regard to 
well-established baseline predictors of adverse outcome, which were more frequent 
in PPI users. For example, in the study by Ho et al. the odds ratio for all-cause mortal-
ity was 1.24 (95% CI 1.10-1.40), but after adjustment it changed to an odds ratio of 
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0.91 (95% CI 0.80-1.05), indicating the importance of confounders in the observed 
results.12
Another explanation for the observed differences in outcome is indication/pre-
scription bias. According to the latest guidelines, patients on dual antiplatelet therapy 
(i.e. aspirin and clopidogrel) are -by definition- at an increased gastrointestinal risk and 
should consequently receive gastroprotective therapy in the form of PPIs.4 Interest-
ingly, only 30 to 40% of patients were using PPIs. This low incidence of PPI prescription 
could be due to a delay in guidelines applied to practice.76 It is plausible that physi-
cians are more likely to withhold PPIs from the relatively healthy patients, and more 
preferentially prescribe them to patients with more comorbidity. Post-hoc analyses 
of the PLATO trial corroborate with this hypothesis and stated that PPI use should be 
interpreted more as a marker of, than as a cause of higher cardiovascular event rates.52
To minimize the impact of the abovementioned factors, randomized PPI alloca-
tion is of the utmost importance. In case of controlled studies without random al-
location other aspects of the study design are of importance. During our process of 
testing the criteria to perform meta-analysis, exploratory analyses showed that the 
heterogeneity was primarily caused by the retrospective studies (data not shown). 
Figure 2 provides insight into the distribution of point estimates of the prospective 
studies; there is no significant heterogeneity. If pooled estimates for the relative risk 
Figure 2. Forest plot of odds ratios of the prospective clinical studies of the endpoint MACE 
for patients using proton pump inhibitors (PPI) vs. those without concomitant PPI therapy. 
The squares represent risk ratios for the individual studies and the lines represent the 95% 
confidence intervals (CI). The pooled 95% confidence interval is visualized by a black diamond.
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of PPIs were to be calculated, the prospective studies would result in an OR of 1.13 
(95% CI 0.98-1.30), mutually exclusive from the 95% CI of the retrospective studies 
(OR 1.63, 95% CI 1.45-1.83).
The largest of the two studies with random allocation of a PPI, the COGENT 
trial, included 3873 patients, with a median follow-up of 106 days, and reported no 
significant difference in cardiovascular outcome for adjunctive use of omeprazole in 
clopidogrel users.42 This result is especially interesting since omeprazole has most 
often been implicated with regard to warnings based upon laboratory findings and 
observational data on clinical outcome. Notably, if pooled estimates for (es)omepra-
zole and pantoprazole were to be calculated (online supplementary figure 1a and 1b, 
respectively), an adverse effect of PPIs on outcome would have been present only 
for pantoprazole (OR 1.54, 95% CI 1.13-2.09). This is one more indication that other 
factors are of more importance to the observed adverse clinical outcome than the 
observed pharmacological effect of the individual PPIs in the laboratory.
In summary, 40-50% of the studied records suggested adverse outcome in case of 
co-administration of PPIs for the endpoints MI and MACE, whereas for mortality this 
percentage was 22%. In view of the above mentioned methodological aspects, we 
feel that the many reports suggesting risk increases that are ‘out of proportion’ - i.e. 
more than the relative benefit of 20% that can be achieved with clopidogrel treat-
ment 2,77,78 - should be interpreted with caution.
In view of the above, only well-designed, randomized trials powered to assess the 
impact on cardiac events can address the potential adverse impact of adjunctive PPI 
use in patients on clopidogrel. Until then, methodological flaws in laboratory studies, 
the fact that there is no one-to-one translation of impaired ex vivo platelet inhibition 
into adverse clinical outcome, and the marked heterogeneity observed in the clinical 
studies preclude a definite conclusion. Emerging evidence from the recent prospec-
tive studies strongly does not support the statement that the addition of PPIs in 
patients who use clopidogrel should be considered harmful. The suggestion that the 
potential adverse impact may not hold true for pantoprazole and should especially 
be considered in the event omeprazole is prescribed, is based upon pharmacologi-
cal assumptions and laboratory measurements, but is contradicted by the available 
clinical evidence.
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Limitations
As clopidogrel is predominantly prescribed in the setting of ACS or after coronary 
stent implantation for stable coronary disease, we defined our population accord-
ingly. As a consequence, clopidogrel administration for other indications like stroke 
prevention were not included in our analyses. Notably, for these less frequent indica-
tions the lack of well-designed studies on the impact of PPIs holds true as well. With 
regard to the selection process of the reviewed studies, data presented in the form 
of an abstract only were not considered. However, the funnel plot did not indicate 
publication bias. It can be considered a limitation that we do not provide a sum-
marized quantitative effect of the reported studies. As outlined before, we feel there 
are several arguments not to support the strategy of meta-analysis. In view of this, 
we addressed the question whether there are potential differences in effect between 
the various PPIs (pantoprazole vs. (es)omeprazole) only in the form of data review.
Conclusions and implications
In summary, there is clear ex vivo evidence of a pharmacological interaction between 
clopidogrel and PPIs in healthy individuals. In contrast, data for patients - who use 
both clopidogrel and aspirin - are less uniform.
As of to date, the available clinical evidence does not support the statement that 
PPI co-administration will adversely affect clinical outcome in patients treated with 
clopidogrel. These findings once again fuel the discussion with regard to the use of 
ex vivo data as a surrogate endpoint for clinical outcome. Moreover, it should be 
realized that summarized quantitative overviews on this subject are mainly driven 
by non-randomized, retrospective studies, with apparent differences in baseline 
characteristics and prescription bias.
These observations fuel the debate on this controversial issue and call for recom-
mendations based upon well designed clinical trials.
Chapter 3
58
aCknowledGeMents
We thank G.E. Cramer (GEC) for critically reviewing this paper and for serving as 
an independent adjudicator in the selection of the included studies. We gratefully 
acknowledge J.L. Bonnes for critically revising the manuscript.
FundInG
The authors or institutions received no funding with regard to this manuscript.
59
Concomitant Use of Clopidogrel and Proton Pump Inhibitors
3
ReFeRenCeS
 1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised tri-
als of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in 
high risk patients. BMJ 2002;324(7329):71-86.
 2. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute 
coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
 3. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomepra-
zole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: 
a randomised, controlled trial (OBERON). Heart 2011;97(10):797-802.
 4. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus docu-
ment on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a 
report of the American College of Cardiology Foundation Task Force on Clinical Expert 
Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-1517.
 5. FDA. Early communication about an ongoing safety review of clopidogrel bisulfate 
(marketed as Plavix). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyIn-
formationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/
ucm079520.htm.
 6. FDA. Follow-Up to the January 26, 2009, Early Communication about an Ongoing Safety 
Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as 
Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-
SafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfes-
sionals/ucm190784.htm.
 7. EMEA. Public statement on possible interaction between clopidogrel and proton pump 
inhibitors. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.
pdf.
 8. Gilard M, Arnaud B, Le GG, et al. Influence of omeprazol on the antiplatelet action of 
clopidogrel associated to aspirin. J Thromb Haemost 2006;4(11):2508-2509.
 9. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action 
of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omepra-
zole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51(3):256-260.
 10. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole 
on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin 
Pharmacol 2008;48(4):475-484.
 11. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction 
between proton pump inhibitors and clopidogrel. CMAJ 2009;180(7):713-718.
 12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomi-
tant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. 
JAMA 2009;301(9):937-944.
 13. Kurihara A, Hagihara, K, Kazui, M, et al. In vitro metabolism of antiplatelet agent clopi-
dogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the 
active metabolite formation. Drug Metab Rev 2005;37(Suppl 2):99.
 14. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton 
pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and 
rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32(8):821-
827.
Chapter 3
60
 15. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to 
clopidogrel. N Engl J Med 2009;360(4):354-362.
 16. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump 
inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13 Suppl 327-336.
 17. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus 
document on the concomitant use of proton pump inhibitors and thienopyridines: a 
focused update of the ACCF/ACG/AHA 2008 expert consensus document on reduc-
ing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 
2010;56(24):2051-2066.
 18. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients 
according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor 
coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56(2):134-143.
 19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic 
reviews and meta-analyses of studies that evaluate health care interventions: explana-
tion and elaboration. Ann Intern Med 2009;151(4):W65-W94.
 20. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clini-
cal efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an 
analysis of two randomised trials. Lancet 2009;374(9694):989-997.
 21. Zhang R, Ran HH, Zhu HL, et al. Differential effects of esomeprazole on the antiplatelet 
activity of clopidogrel in healthy individuals and patients after coronary stent implanta-
tion. J Int Med Res 2010;38(5):1617-1625.
 22. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of 
clopidogrel. Int Heart J 2010;51(1):13-16.
 23. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the 
anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharma-
col 2010;70(3):383-392.
 24. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pan-
toprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy 
subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharma-
col Ther 2011;89(1):65-74.
 25. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant ver-
sus staggered clopidogrel and omeprazole intake: results of a prospective randomized 
crossover study. Circ Cardiovasc Interv 2010;3(5):436-441.
 26. Ferreiro JL, Ueno M, Tomasello SD, et al. Pharmacodynamic evaluation of pantoprazole 
therapy on clopidogrel effects: results of a prospective, randomized, crossover study. 
Circ Cardiovasc Interv 2011;4(3):273-279.
 27. Frelinger AL, III, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study 
to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole 
on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy 
volunteers. J Am Coll Cardiol 2012;59(14):1304-1311.
 28. Uotani T, Sugimoto M, Nishino M, et al. Ability of Rabeprazole to Prevent Gastric 
Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 
Genotype. Clin Gastroenterol Hepatol 2012;10:879-885.
 29. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on 
platelet inhibition by clopidogrel. Am Heart J 2009;157(1):148-155.
61
Concomitant Use of Clopidogrel and Proton Pump Inhibitors
3
 30. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplate-
let effects of clopidogrel. Thromb Haemost 2009;101(4):714-719.
 31. Zuern CS, Geisler T, Lutilsky N, et al. Effect of comedication with proton pump inhibitors 
(PPIs) on post-interventional residual platelet aggregation in patients undergoing coro-
nary stenting treated by dual antiplatelet therapy. Thromb Res 2010;125(2):e51-e54.
 32. Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite 
dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
Am J Cardiol 2009;103(10):1339-1343.
 33. Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the 
antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary 
stenting. J Cardiovasc Pharmacol 2010;56(1):91-97.
 34. Amoah V, Worrall AP, Smallwood A, et al. Clopidogrel and proton pump inhibitors: can 
near patient testing help in the tailoring of dual antiplatelet prescription? J Thromb 
Haemost 2010;8(6):1422-1424.
 35. Gremmel T, Steiner S, Seidinger D, et al. The influence of proton pump inhibitors on 
the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. 
J Cardiovasc Pharmacol 2010;56(5):532-539.
 36. Harmsze AM, van Werkum JW, Taubert D, et al. Esomeprazole but not pantoprazole is 
associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann 
Pharmacother 2011;45(4):542-543.
 37. Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump 
inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactiv-
ity and on the occurrence of atherothrombotic events after percutaneous coronary 
intervention. J Thromb Haemost 2011;9(10):1892-1901.
 38. Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet 
therapy in stable angina pectoris patients after percutaneous coronary intervention. 
Pharmacol Rep 2012;64(2):360-368.
 39. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopidogrel efficacy but not ischemic 
events in patients with acute coronary syndrome undergoing elective percutaneous 
coronary intervention. Chin Med J (Engl ) 2011;124(6):856-861.
 40. Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-
controlled crossover study to determine the effects of esomeprazole on inhibition of 
platelet function by clopidogrel. J Thromb Haemost 2011;9(8):1582-1589.
 41. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versus famotidine on platelet 
inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J 2011;162(5):870-
874.
 42. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coro-
nary artery disease. N Engl J Med 2010;363(20):1909-1917.
 43. Wu H, Jing Q, Wang J, et al. Pantoprazole for the prevention of gastrointestinal bleeding 
in high-risk patients with acute coronary syndromes. J Crit Care 2011;26(4):434-436.
 44. Gaglia MA, Jr., Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after 
percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 
2010;105(6):833-838.
 45. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole 
on the effectiveness of clopidogrel drug therapy during the first year after successful 
coronary stenting. Can J Cardiol 2010;26(2):e54-e57.
Chapter 3
62
 46. Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment with proton pump 
inhibitors and clopidogrel on clinical outcome in patients after coronary stent implanta-
tion. Thromb Haemost 2010;104(6):1211-1218.
 47. Rossini R, Capodanno D, Musumeci G, et al. Safety of clopidogrel and proton pump 
inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis 
2011;22(3):199-205.
 48. Harjai KJ, Shenoy C, Orshaw P, et al. Clinical outcomes in patients with the concomitant 
use of clopidogrel and proton pump inhibitors after percutaneous coronary interven-
tion: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. Circ 
Cardiovasc Interv 2011;4(2):162-170.
 49. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibi-
tor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide 
cohort of acute myocardial infarction: results from the French Registry of Acute ST-
Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 
2011;123(5):474-482.
 50. Chitose T, Hokimoto S, Oshima S, et al. Clinical outcomes following coronary stenting in 
Japanese patients treated with and without proton pump inhibitor. Circ J 2012;76(1):71-
78.
 51. Burkard T, Kaiser CA, Brunner-La RH, et al. Combined clopidogrel and proton pump in-
hibitor therapy is associated with higher cardiovascular event rates after percutaneous 
coronary intervention: a report from the BASKET trial. J Intern Med 2012;271(3):257-
263.
 52. Goodman SG, Clare R, Pieper KS, et al. Association of Proton Pump Inhibitor Use on 
Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet 
Inhibition and Patient Outcomes Trial. Circulation 2012;125(8):978-986.
 53. Gupta E, Bansal D, Sotos J, et al. Risk of adverse clinical outcomes with concomitant use 
of clopidogrel and proton pump inhibitors following percutaneous coronary interven-
tion. Dig Dis Sci 2010;55(7):1964-1968.
 54. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in 
patients using clopidogrel with proton pump inhibitors after percutaneous coronary 
intervention or acute coronary syndrome. Circulation 2009;120(23):2322-2329.
 55. Sheng-Wen WS, Tsai SS, Hsu PC, et al. Concomitant use of clopidogrel and proton pump 
inhibitors or cimetidine after acute myocardial infarction would increase the risk of 
re-infarction. Am J Gastroenterol 2009;104(12):3116-3117.
 56. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and 
proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152(6):337-345.
 57. Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent thrombosis in patients 
receiving proton pump inhibitors. Thromb Haemost 2010;104(3):626-632.
 58. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effective-
ness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes 
study. Pharmacotherapy 2010;30(8):787-796.
 59. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopido-
grel with a proton pump inhibitor. Arch Intern Med 2010;170(8):704-710.
 60. Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in 
patients discharged on clopidogrel and a proton pump inhibitor after stent placement 
for acute myocardial infarction. Clin Cardiol 2010;33(3):168-171.
63
Concomitant Use of Clopidogrel and Proton Pump Inhibitors
3
 61. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with 
increased cardiovascular risk independent of clopidogrel use: a nationwide cohort 
study. Ann Intern Med 2010;153(6):378-386.
 62. Gaspar A, Ribeiro S, Nabais S, et al. Proton pump inhibitors in patients treated with aspi-
rin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010;29(10):1511-
1520.
 63. Ortolani P, Marino M, Marzocchi A, et al. One-year clinical outcome in patients with 
acute coronary syndrome treated with concomitant use of clopidogrel and proton 
pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown) 
2012;13(12):783-789.
 64. Yasu T, Ikee R, Miyasaka Y, et al. [Efficacy and safety of concomitant use of rabeprazole 
during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent 
implantation: a retrospective cohort study]. Yakugaku Zasshi 2010;130(12):1743-1750.
 65. Hudzik B, Szkodzinski J, Danikiewicz A, et al. Effect of omeprazole on the concentra-
tion of interleukin-6 and transforming growth factor-beta1 in patients receiving dual 
antiplatelet therapy after percutaneous coronary intervention. Eur Cytokine Netw 
2010;21(4):257-263.
 66. Hsiao FY, Mullins CD, Wen YW, et al. Relationship between cardiovascular outcomes 
and proton pump inhibitor use in patients receiving dual antiplatelet therapy after 
acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011;20(10):1043-1049.
 67. Ulhaq I, Sood R, Hegade V, et al. Response to clopidogrel with proton pump inhibitors: 
safe or not? Clin Cardiol 2011;34(11):721.
 68. Aihara H, Sato A, Takeyasu N, et al. Effect of individual proton pump inhibitors on 
cardiovascular events in patients treated with clopidogrel following coronary stenting:: 
Results From the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv 
2012;80(4)556-563.
 69. Lin CF, Shen LJ, Wu FL, et al. Cardiovascular Outcomes Associated with Concomitant Use 
of Clopidogrel and Proton Pump Inhibitors in Patients of Acute Coronary Syndrome in 
Taiwan. Br J Clin Pharmacol 2012;74(5)824-834.
 70. Ching GG, Li D, Baker WL, et al. Major adverse cardiac events among postpercutaneous 
coronary intervention patients on clopidogrel and proton pump inhibitors. Conn Med 
2012;76(4):205-211.
 71. Valkhoff VE, ‘t Jong GW, Van Soest EM, et al. Risk of recurrent myocardial infarction with 
the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol 
Ther 2011;33(1):77-88.
 72. Hulot JS, Wuerzner G, Bachelot-Loza C, et al. Effect of an increased clopidogrel mainte-
nance dose or lansoprazole co-administration on the antiplatelet response to clopido-
grel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 2010;8(3):610-613.
 73. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with 
clopidogrel on platelet function in patients with acute coronary syndromes: the 
PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 
2010;56(18):1456-1462.
 74. Wurtz M, Grove EL, Kristensen SD, et al. The antiplatelet effect of aspirin is reduced by 
proton pump inhibitors in patients with coronary artery disease. Heart 2010;96(5):368-
371.
Chapter 3
64
 75. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on 
platelet function testing after percutaneous coronary intervention: the GRAVITAS 
randomized trial. JAMA 2011;305(11):1097-1105.
 76. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial 
infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287(10):1269-
1276.
 77. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-1339.
 78. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 pa-
tients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 
2005;366(9497):1607-1621.
4
High platelet reactivity – the challenge of 
prolonged anticoagulation therapy after ACS
Thrombosis and Haemostasis 2013;109:799-807
Marc A. Brouwer  
Jeroen Jaspers Focks 
Freek W.A. Verheugt
 
Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands
Chapter 4
66
suMMary
Despite dual antiplatelet therapy (DAPT), 1-year event rates after ACS vary 
from 9-12%. The development of novel oral anticoagulants (NOAC) without a 
need for monitoring has initiated renewed interest for prolonged adjunctive 
anticoagulation. Importantly, the cornerstone of treatment after ACS consists 
of long-term DAPT.
In that context, the NOACs have only been tested as adjunctive therapy. 
Of all new agents, only rivaroxaban –in a substantially lower dose than used 
for atrial fibrillation– has been demonstrated to improve outcome, albeit at 
the cost of bleeding. In selected cases, adjunctive therapy with dose-adjusted 
vitamin-K antagonists (INR 2.0-3.0) can be considered as well. These two 
strategies of prolonged anticoagulation can be considered in case of ‘high 
platelet reactivity’, i.e. in patients at high risk of recurrent thrombotic events 
despite DAPT.
Both during admission and after discharge for ACS, the use of NOACs in 
doses indicated for atrial fibrillation is strictly contra-indicated in patients on 
DAPT. In case of post-discharge anticoagulation therapy for atrial fibrillation, 
patients should preferably receive vitamin-K antagonists (INR 2.0-3.0), with 
discontinuation of one antiplatelet agent as soon as clinically justifiable.
Importantly, the impact of prolonged anticoagulation (low-dose rivar-
oxaban, vitamin-K antagonists) as adjunctive to DAPT after ACS has not been 
addressed with the most potent antiplatelet agents (prasugrel, ticagrelor) and 
merits further study.
Despite the potential indication of prolonged oral anticoagulation as 
adjunctive treatment, it remains to be established whether anticoagulation 
therapy could also be an alternative for either aspirin or thienopyridine treat-
ment in selected ACS patients on DAPT.
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introduCtion
With new antiplatelet agents as adjunctive to long-term aspirin treatment, outcome 
after acute coronary syndromes has improved over the years.1,2 As of to date, for the 
majority of patients aspirin and clopidogrel form the standard regimen, but more 
potent agents such as ticagrelor and prasugrel have been introduced as more effica-
cious alternatives for clopidogrel, especially in case of coronary interventions.3-5
Despite the use of long-term dual antiplatelet therapy after myocardial infarc-
tion6,7, there is still a considerable rate of death, myocardial infarction and stroke of 
about 9-12% of patients at one year.2-4 Moreover, the strategy of revascularization 
has changed over the years, in that the proportion of patients treated with a percuta-
neous coronary intervention (PCI) has increased. Stent thrombosis is an infrequent, 
but ominent complication, with mortality rates of up to 45%.8-10 These findings call 
for further optimization of antithrombotic regimens, both during hospital admission, 
but also after discharge.
High platelet reactivity has been proposed as an indicator for adverse cardiac 
events, which could guide the choice of a more aggressive antithrombotic approach. 
So far, this approach cannot be substantiated by randomized evidence on clinical 
endpoints, and we feel that this strategy cannot be supported as regular clinical ap-
proach.11-13
In daily clinical practice, we are frequently faced with patients who experience 
recurrent thrombotic events despite dual antiplatelet therapy. In particular, this is 
a group of patients that merits further attention with regard to a more aggressive 
antithrombotic regimen.
In the formation of arterial thrombosis there is a strong interaction between the 
clotting cascade and circulating platelets.14 In the acute phase of acute coronary 
syndromes, the impact of anticoagulation therapy has been extensively studied, and 
several new agents have been developed that have affected outcome.15-21 Research 
with long-term treatment of anticoagulation has so far been primarily dominated 
by vitamin K antagonists. With the introduction of newer agents without need for 
monitoring, anticoagulation after discharge has become a more feasible option.
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Given the need for more refined antithrombotic strategies in patients with throm-
botic events despite dual antiplatelet therapy, we will shortly summarize the patho-
physiology of clot formation and the clinical evidence of (long-term) anticoagulation 
therapy. In the context of the available data, we will address both the risks and 
benefits of potential treatment options that can be considered in patients in whom 
dual antiplatelet therapy has been proven clinically ineffective.
PathoPhysioloGiCal rationale
The vast majority of acute coronary syndromes are caused by (sub) acute thrombosis 
in a coronary artery, resulting in a subtotal (non ST elevation acute coronary syn-
drome) or total (ST elevation acute coronary syndrome) occlusion. The precipitating 
pathophysiological event is often rupture of a plaque, with exposure of subendothe-
lial matrix. In response, platelets adhere to the damaged vessel wall (adhesion) and 
secrete chemoattractive substances, involved in the process of platelet aggregation 
and the stimulation of the coagulation cascade.
Three key players in the process of coagulation are the tissue factor-factor VIIa 
complex, factor Xa and factor IIa (Figure 1). Thrombin (factor IIa) promotes the for-
mation of a fibrin rich blood clot, but it is also a potent activator of platelet aggrega-
tion.22 This demonstrates that coagulation and platelet aggregation are interrelated 
processes in the formation of a (sub)total occlusion.
Angiographic studies have confirmed this hypothesis, suggesting that anticoagu-
lation therapy affects the risk of (re)occlusion on both the short- and the long-term. 
23-26
Therefore, several studies have been conducted based upon the rationale that 
anticoagulants such as (in)direct thrombin inhibitors, or Xa inhibitors could improve 
clinical outcome in acute coronary syndromes (ACS).
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AnTICOAGuLATIOn THeRAPY In ACS : CLInICAL eVIdenCe
Indirect thrombin inhibition. The first randomized studies on the impact of anticoagu-
lation therapy demonstrated that unfractionated heparin resulted in a ~ 30% risk re-
duction in myocardial infarction in patients treated with aspirin for unstable angina.15 
Subsequently, low molecular weight heparins (LWMH) were developed, which seem 
slightly more efficacious than unfractionated heparin (UFH).16 They have a better 
bioavailability and more predictable effect, which obviates the need for monitoring.
Xa
VaCa++
Fibrinogen Fibrin
VIIIa
IIaII
X
IX IXa
Xa inhibitors:
•Fondaparinux
•Rivaroxaban
•Apixaban
Direct thrombin inhibitors:
•Bivalirudin/hirudin
•Ximelagatran
•Dabigatran
Indirect thrombin inhibition:
•UFH
•LMWH
VKA:
•Warfarin
•Acenocoumarol
•Phenprocoumon
VIIa +      TF
Figure 1
Figure 1: The coagulation cascade and the pharmacological interventions.
In response to plaque rupture or erosion, tissue factor (TF), forms a complex with coagulation 
factor VIIa. This complex initiates the formation of factor Xa.
Factor Xa is part of the prothrombinase-complex (Xa-Va-Ca++ complex), converting prothrom-
bin (II) into thrombin (IIa). Thrombin on its turn converts fibrinogen into fibrin, the endproduct 
in the coagulation cascade.
The dotted arrows represent pharmacological interventions. Vitamin-K antagonists (VKA) in-
hibit the formation of factors II, VII, IX and X. Factor Xa can be inhibited directly (rivaroxaban, 
apixaban) or by potentiating the natural inhibitor antithrombin III (UFH, LMWH, fondaparinux). 
Factor IIa can also be inhibited directly (bivalirudin/hirudin, ximelagatran, dabigatran) or indi-
rectly (UFH, LMWH).
UFH, unfractionated heparin; LMWH, low-molecular weight heparin.
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For patients with ST elevation myocardial infarction (STEMI) treated with fibrino-
lysis similar observations hold true,17 and it is suggested that reocclusion rates are 
lower with the use of LMWH.27 The ease of longer administration (subcutaneous) 
and its more stable effect may both account for these observations.
After primary PCI the evidence for the routine use of heparin after the procedure 
is not very well established. It is often stated that thrombin inhibition can be discon-
tinued after the procedure, with a few exceptions.28 Still, routine periprocedural use 
of fondaparinux seemed less efficacious than unfractionated heparin in the setting of 
primary PCI, indirect evidence that routine anti-thrombin therapy seems indicated. 19
Direct thrombin inhibition. Whereas UFH and LMWH both act on factors IIa and Xa, 
direct thrombin inhibitors only act on factor IIa, and are also able to inhibit clot-bound 
thrombin.22 In patients with non ST elevation ACS, bivalirudin results in lower bleeding 
complications when compared to heparin alone, or the combination of UFH/LMWH 
with glycoprotein IIb/IIIa receptor blockers. This was observed without significant 
difference in efficacy. However, in the subgroup of patients without pretreatment 
with a thienopyridine bivalirudin seemed less efficacious, indirect evidence that this 
new drug may have a less intense antithrombotic effect.20
In patients treated with fibrinolytic therapy, bivalirudin resulted in a significant 
reduction in the combined endpoint of mortality and reinfarction at 30-days when 
compared to UFH.29 For patients undergoing primary PCI again bleeding complica-
tions were markedly lower with the use of direct thrombin inhibition, mortality was 
lower and the composite of ischemic events was similar to the control arm of indirect 
thrombin inhibition with/without use of a GPIIb/IIIa receptor blocker.21
Xa-inhibition. Based on the hypothesis that interference in the earlier stages of 
coagulation, i.e. “higher in the coagulation cascade” (Figure 1), would require less 
potent drugs with potentially less bleeding complications factor Xa inhibitors have 
been developed. Fondaparinux is a synthetic pentasaccharide that selectively binds 
antithrombin and inhibits factor Xa.
In non ST elevation ACS it has improved 30-day outcome compared to enoxapa-
rin, and the achieved clinical benefit was primarily realized through a reduction in 
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mortality. Notably, at hospital discharge (i.e. at the end of treatment), there was no 
difference in efficacy between fondaparinux and enoxaparin. The reduction in 30-day 
mortality was associated with a lower bleeding rate on fondaparinux as compared to 
enoxaparin.18 These observations demonstrate that the choice of in-hospital antico-
agulation, can affect outcome after discharge.
The fact that guiding cathether thrombosis was more often observed with this 
agent indirectly underscores its modest antithrombotic efficacy,18,19 and shows that 
despite of this reduced antithrombotic potency outcome improved. Based on these 
cathlab observations, intravenous administration of an indirect or direct thrombin 
inhibitor is the preferred agent of choice in case of early PCI for non STEMI, and for 
similar reasons, Xa-inhibitors should not be given as anticoagulant shortly before/
during primary PCI.
As adjunctive agent to fibrinolysis, the efficacy and safety of fondaparinux has 
unequivocally been demonstrated with use of streptokinase. In case of fibrin-specific 
agents, which require adjunctive thrombin inhibition, no randomized controlled 
evidence is available with Xa-inhibitors.
Oral Xa inhibitors have been the topic of interest for many years, providing the 
opportunity of a feasible form of extended anticoagulantion after discharge. Ximela-
gatran was the first drug that showed the potential of such a strategy, but due to an 
unacceptable incidence of liver toxicity this drug has not undergone further develop-
ment. Notably, in this study patients used aspirin monotherapy (30). Recently, new 
oral Xa-inhibitors have been developed, and tested successfully in the field of atrial 
fibrillation: rivaroxaban and apixaban.31,32
Of these agents, rivaroxaban is the only agent that has also been proven effica-
cious in ACS in a phase III trial.33,34 In contrast to the study with ximelagatran, the 
vast majority of patients was on dual antiplatelet therapy in the trials with the new 
agents.33-35 It should be appreciated that the dose administered was markedly lower 
than the dose tested in atrial fibrillation (5 or 10 mg per day vs. 20 mg per day) and 
that the risk of bleeding was markedly increased.33 Yet, these data show again that 
new adjunctive anticoagulation therapies have been developed that are efficacious 
in ACS (table 1).
Chapter 4
72
Vitamin K antagonists. In contrast to all abovementioned agents which exert their 
action through inhibition of activated coagul ation factors, the oral vitamin K an-
tagonists interfere with the production of factors II, VII, IX and X. For optimal efficacy 
in patients with a prothrombotic state (pulmonary embolism, venous thrombosis, 
ACS), vitamin K antagonists should be initiated in combination with another form of 
anticoagulation therapy to counteract the potential procoagulant effect early after 
initiation. The adjunctive form of anticoagulation can be discontinued when two 
subsequent INRs are in the target range.22
Importantly, vitamin K antagonists have been proven to be efficacious in ACS as 
monotherapy, with outcomes similar to those achieved on patients managed with 
aspirin. Most of the clinical experience and randomized trials on the impact of pro-
longed anticoagulation therapy after discharge as adjunct to aspirin is with vitamin K 
antagonists. There are robust data to demonstrate that the long-term combination 
of anticoagulation therapy and antiplatelet therapy results in better clinical outcome 
than aspirin alone, be it at the cost of more bleeding (table 1).22,36 This especially 
holds true for patients after non ST ACS and STEMI patients not undergoing primary 
PCI.
Now that primary PCI has become the preferred reperfusion strategy, and man-
agement of non ST ACS has become more aggressively, dual platelet therapy has 
become the standard. Notably, even in the more modern era of revascularization 
with stenting, a strategy of aspirin and oral anticoagulation has been proven more 
efficacious than aspirin alone.37 Yet, only indirect comparisons between aspirin and 
clopidogrel versus aspirin and vitamin K antagonists are available (38). Treatment 
with vitamin K antagonists is cumbersome, and the effect of therapy largely depends 
on an infrastructure to guarantee dose-adjusted, frequently monitored and indi-
vidually tailored therapy. It should be appreciated that during the first 8 weeks after 
initiation of anticoagulation therapy, patients are less often in the therapeutic range 
than during long-term follow-up.39 Moreover, intervention studies with aspirin and 
ticlopidine showed better outcome than an antithrombotic regimen of aspirin with 
long-term anticoagulation therapy.40
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These aspects have largely contributed to the preference of dual antiplatelet 
therapy after ACS. Despite the proven efficacy, it should be appreciated that bleeding 
on dual antiplatelet therapy has also been related to mortality.41
AnTICOAGuLATIOn THeRAPY And BLeedInG: THe FLIP SIde
With the appreciation that bleeding is related to short- and long-term mortality 
(18,41), intensifying antithrombotic therapy may not necessarily result in better clini-
cal outcome.
Even more complicating, the clinical factors that predict ischemic events are also 
associated with an increased risk of bleeding.42,43 Therefore, the choice of adjunctive 
anticoagulation therapy to improve the net clinical benefit in patients with events 
while on dual antiplatelet therapy forms a clinical challenge.
Both patient factors (age, sex, prior history of bleeding, renal function etc),44 
concomitant medication and the choice of reperfusion strategy affect the options for 
adjunctive anticoagulation.
Renal function. In patients with poor creatinin clearance UFH is the drug of choice. 
Although labour-intensive, unfractionated heparin has the advantage that it can 
be discontinued and that protamine can be administered to counteract its effects. 
Fondaparinux has been tested in patients with a creatinin of up to 265 µmol and is a 
rather safe alternative, but no antidote exists.6,7
Concomitant medication. When glycoprotein IIb/IIIa blockers are administered, UFH 
dosing should be adjusted to reduce bleeding complications. In case of fibrinolysis, 
enoxaparin should be reduced to once daily dosing in case of a clearance < 30 ml/
min.6,7 Dosing of the newer agents like fondaparinux and bivalirudin is irrespective 
of patient characteristics and concomitant medication, which is likely to result in less 
administration errors. In case of non ST ACS or STEMI without reperfusion therapy, 
anticoagulation with fondaparinux is an attractive option given its excellent safety, 
and the reduced mortality compared to enoxaparin demonstrated in OASIS-5.18,19
75
High platelet reactivity
4
Bivalirudin resulted in similar ischemic events but lower bleeding rates in non ST 
ACS when compared to indirect thrombin inhibition (ACUITY).20
Reperfusion therapy. In patients treated with fibrinolysis for STEMI, bivalirudin 
reduces ischemic events, but increases bleeding as compared to UFH.29 Yet, in the 
setting of primary PCI bivalirudin is associated with lower bleeding rates and similar 
ischemic events as compared to UFH/LMWH with/without the use of glycoprotein 
IIb/IIIa receptor blockers.21 Fondaparinux can be used with non-fibrin specific fibrino-
lysis, but is not recommended as pretreatment in the setting of a primary PCI.
These are only a series of examples of clinical decision making that affect efficacy 
and safety of the chosen antithrombotic regimen. As to the mechanism how bleeding 
results in worse outcome, various explanations have been proposed, varying from 
discontinuation of antithrombotic medication and subsequent events to the adverse 
impact of administration of blood transfusions and the statement that bleeding is 
merely a marker of a vulnerable patient.44
OPTIOnS FOR PROLOnGed ORAL AnTICOAGuLATIOn THeRAPY 
in aCs
With the appreciation of the robust data on long-term adjunctive oral anticoagu-
lation in patients using aspirin, and the recent ATLAS-2 trial,34,36 it is clear that the 
mechanism behind recurrent events after discharge is not merely a process of 
platelet activity (table 1). This is underscored by the fact that coagulation activity is 
increased up to 6 months after the index event, which is correlated with the risk of 
recurrent events.22
Despite these correlations, evidence for causality is not present: there is no ran-
domized evidence that a strategy of intensified antithrombotic therapy in patients 
with high platelet/coagulation activity improves outcome.11,13,45 As of to date, selec-
tion of patients at high risk for recurrent events in whom antithrombotic should be 
optimized should primarily be based on clinical risk models.46 Irrespective of these 
models, few clinicians will disagree that patients who experience a thrombotic event 
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despite dual antiplatelet therapy form a group of patients in whom antithrombotic 
therapy should be optimized .
During admission for ACS, recurrent events tend to cluster after cessation of anti-
coagulation therapy, often referred to as ‘rebound phenomenon’.47 In addition, about 
half of recurrent events occurs after discharge, despite (dual) antiplatelet therapy.25
Prolonged anticoagulation with vitamin K antagonists. Despite the disadvantages 
with regard to the rather complicated logistics to achieve dose-adjusted, frequently 
monitored, individually tailored anticoagulation, the risk-benefit ratio of this strategy 
merits appreciation. At the cost of 1 major bleeding, 3 myocardial infarctions can be 
prevented in patients on aspirin monotherapy (table 1).36 These data compare fairly 
well with adjunctive therapy with clopidogrel in aspirin users, although direct com-
parisons are lacking.48 Importantly, randomized trials on the impact of triple therapy 
(aspirin, clopidogrel, vitamin K antagonist) are lacking as well.
Yet, the observed risk-benefit ratio suggests that there might be room for im-
provement in case a thienopyridine is added to aspirin and a vitamin K antagonist, 
provided that dose-adjusted (INR 2.0-3.0) adjunctive treatment with vitamin K 
antagonists is optimally organized and monitored. Whether triple therapy confers a 
benefit in patients without an established indication for oral anticoagulation therapy, 
has never been addressed in a trial. Safety data on triple therapy after PCI and 
stenting in patients with an established indication for oral anticoagulation therapy 
suggests that the bleeding risk with this approach is considerably increased.49
Prolonged anticoagulation with NOACs. Various new agents have been tested in 
phase II trials (table 2).30,35,50-52 Despite the successful data in atrial fibrillation studies, 
no phase III trials in ACS were initiated with oral thrombin inhibitors (dabigatran, 
ximelagatran). Of all NOACs, rivaroxaban is the only agent that has been proven effec-
tive in a phase III trial.34 Importantly, in this study almost all patients (93%) used dual 
antiplatelet therapy, and the risk-benefit ratio of this strategy should be interpreted 
in this context. Dosing of the oral Xa-inhibitor seems crucial, and it should be realized 
that the doses used for atrial fibrillation are associated with unacceptable bleeding 
rates and a lack of efficacy in the setting of ACS.33,50,51 In the case of rivaroxaban, 2.5 
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mg twice daily seems the strategy with the best trade off (table 1), which has recently 
been confirmed in the subgroup of STEMI patients on dual antiplatelet therapy.53 In 
contrast to the evidence with oral vitamin K antagonists, the data on rivaroxaban 
reflects only one trial, with little information on how patients were managed with 
regard to revascularizations (PCI, CABG), bleeding and peri-operative care for non-
cardiac indications.
Optimizing antiplatelet therapy. For both strategies of adjunctive oral anticoagulation 
it should be stressed that the available data reflect patients on aspirin monotherapy 
or dual antiplatelet therapy with clopidogrel. Information with the more potent 
agents such as prasugrel and ticagrelor is not available. We are of the opinion that 
in patients presenting with ACS while on dual therapy with aspirin and clopidogrel, 
optimization of antiplatelet therapy (prasugrel, ticagrelor) forms the cornerstone 
of treatment, especially if a coronary intervention is performed (3-5). Prasugrel de-
serves attention with regard to the risk of ICH and should be avoided in patients with 
a prior CVA and those > 75 years and < 60 kg.7 If the clinician decides to treat a STEMI 
patient with fibrinolysis we strongly advise against addition of these new antiplatelet 
agents during fibrinolysis.
How to initiate oral anticoagulation therapy (figure 2). In patients with a high throm-
botic risk on DAPT, without an established indication for oral anticoagulation therapy, 
vitamin K antagonists can be considered as adjunctive therapy. When vitamin K an-
tagonists are initiated in a prothrombotic milieu (pulmonary embolism, deep venous 
thrombosis, myocardial infarction) concomitant anticoagulation is initially required22 
to counteract the potential procoagulant effect of vitamin K antagonists after the first 
few doses. This procoagulant effect can be minimized with use of a less aggressive 
dosing scheme. For example, in case of coumadin, initation of oral anticoagulation 
with a 3-day schedule of 4-4-2 mg (or 4-2-2) is to be preferred over 6-4-2 mg.
Given the fact that nowadays most patients are on dual antiplatelet therapy, 
extra attention is required with regard to the prevention of bleeding complications. 
Traditionally, UFH infusion or LWMH twice daily in therapeutic dose are the agents of 
choice. However, fondaparinux seems a very interesting alternative, not only given 
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the lower bleeding rate and superior efficacy as compared to these agents.18,19 In 
contrast to most other anticoagulants, prolonged administration has been extensive-
ly studied (8 days/up to discharge). In addition, its dosing is irrespective of patient 
characteristics, and administration is only once daily.
Another strategy to reduce bleeding complications could be a dose-adjusted 
strategy of enoxaparin until the target INR has been reached twice. For example, 
patients with a creatinin clearance < 30 mL/min could be treated with once daily 
doses (1 mg/kg) and patients > 75 years with twice daily a reduced dose (0.75 mg/
kg). It should be noted that this strategy is not evidence based, and has only been 
tested in case of fibrinolysis.7
However, in lack of sufficient studies addressing the issue of dual antiplatelet 
therapy with adjunctive anticoagulation, choices can only be made to the best of 
the phycian’s knowledge. Prevention of bleeding and improving efficacy will more 
and more become a matter of individualized antithrombotic therapy, using adjusted 
doses or dosing intervals, based upon characteristics of the particular patient and 
without firm evidence from clinical trials.
With regard to the initiation of rivaroxaban, little information is available as to the 
initiation in the early phase after ACS. It seems rational to start these agents about 
3-4 days after admission, at the time that the anticoagulants that were initiated in 
the acute phase have been discontinued. In ATLAS-2 rivaroxaban was started at a 
median of 4.7 days after the index event.34
Atrial fibrillation and ACS. The most challenging group of patients is formed by those 
with a strict indication for oral anticoagulation therapy. Although the introduction of 
new oral anticoagulants seems a major step forward in the treatment of atrial fibril-
lation, these agents are insufficiently tested in the acute setting of ACS, or in case 
of urgent or primary PCI. Moreover, data on how to manage patients in the setting 
of an elective PCI are scarce as well. We therefore recommend that in patients with 
atrial fibrillation who develop ACS these new agents are discontinued during hospital 
admission. As mentioned before, the doses used in the prevention of systemic em-
bolism are high, and have been proven unsafe in combination with dual antiplatelet 
therapy for ACS.33,35,50,51
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Importantly, the anticoagulant regimens used for ACS (UFH, LWMH, fondaparinux) 
are also effective in the treatment of deep venous thrombosis. Therefore, vitamin K 
antagonists and the new oral anticoagulants can be safely discontinued when pa-
tients are admitted for ACS.
With regard to the most safe strategy to recontinue oral anticoagulation while on 
dual antiplatelet therapy, fondaparinux followed by a vitamin K antagonist seems the 
preffered strategy. As stated, post-discharge dual antiplatelet therapy in combina-
tion with new oral anticoagulants in a dose to prevent systemic embolism should be 
avoided at any time. The impact of dual antiplatelet therapy with low dose rivaroxa-
ban as antithrombotic strategy to prevent systemic embolism in patients with atrial 
fibrillation is uncertain.
Triple therapy after ACS (aspirin, thienopyridine, vitamin K antagonist) is associ-
ated with considerable bleeding rates, but the evidence is limited to observational 
data.54-56 The first randomized trial on the adjunctive use of vitamin K antagonists in 
patients with dual antiplatelet therapy showed a markedly increased bleeding risk 
when compared to patients on vitamin K antagonists and clopidogrel.49 Importantly, 
this trial was not powered for efficacy endpoints, and included only a minority of pa-
tients with ACS.57 All patients had an established indication for oral anticoagulation.
Given the increased risk of bleeding on triple therapy, the guidelines recommend 
to discontinue aspirin as soon as possible, dependent on the type of stent placed 
after intervention.58 If, for specific reasons, a novel oral anticoagulant for the preven-
tion of systemic embolism is the agent of choice, this should not be combined with 
dual antiplatelet therapy, given the unacceptable bleeding risks demonstrated in the 
various phase II trials (table 2). It should be appreciated that little information is 
available with regard to the efficacy and safety of combined treatment with a NOAC 
and a single antiplatelet agent after ACS. In patients with atrial fibrillation, we there-
fore recommend prolonged anticoagulation with vitamin K antagonists in the first 
year after ACS. Then, based upon the patients clinical condition and the evidence 
available at that time, a renewed evaluation can be made.
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ConClusions and iMPliCations
The collective data on prolonged adjunctive anticoagulation suggests that interfer-
ence with the coagulation system can improve outcome after ACS. The development 
of new oral anticoagulants without a need for monitoring has initiated a renewed 
interest for this strategy. Importantly, the cornerstone of antithrombotic treatment 
after ACS consists of optimal long-term dual antiplatelet therapy.
As of to date, the new oral anticoagulants have only been tested as adjunctive 
therapy. Of all the new agents, only rivaroxaban – in a substantially lower dose than 
used for atrial fibrillation – has been proven to improve outcome after ACS, albeit 
with an increased risk of bleeding. In selected cases, adjunctive therapy with dose-
adjusted vitamin K antagonists can be considered as well. These two strategies of 
prolonged anticoagulation can be considered in patients with ‘high platelet reactiv-
ity’, i.e. patients at high risk of recurrent thrombotic events despite dual antiplatelet 
therapy (figure 2).
During admission for ACS, the higher doses of novel oral anticoagulants as 
indicated for atrial fibrillation should be avoided, given the unacceptably high bleed-
ing rates. After discharge, patients on DAPT with atrial fibrillation should receive 
vitamin K antagonists (INR 2.0-3.0). After careful evaluation of the expected risks 
and benefits, one of the two antiplatelet agents should be discontinued as soon as 
clinically justifiable. Whereas monitoring and dose-adjustment have previously been 
considered drawbacks of oral vitamin K antagonist therapy to treat large groups of 
patients, it may be of value in selected patients who need careful monitoring of 
the risks and benefits of a rather aggressive antithrombotic regimen. Moreover, an 
antidote is available and clinical experience has been obtained in many thousands of 
patients, also in case of CABG, PCI and peri-procedural management of non-cardiac 
surgery and intervention.
In case of post-discharge use of a novel oral anticoagulant for atrial fibrillation, 
dual antiplatelet therapy is strictly contra-indicated in patients after ACS.
Notably, the accumulating evidence suggesting a role for prolonged adjunctive 
anticoagulation after ACS (low dose rivaroxaban, vitamin K antagonists) should be 
interpreted in the context that this strategy has not been addressed with the most 
potent antiplatelet agents (prasugrel, ticagrelor) and merits further study.
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Despite the potential indication of prolonged oral anticoagulation as adjunctive 
treatment, it remains to be established whether anticoagulation therapy could serve 
as an alternative for either aspirin or thienopyridine treatment in selected cases and 
how the risk-benefit ratio of this regimen compares to dual antiplatelet therapy or 
triple therapy.
Fondaparinux
Enoxaparin
Day 3-4 DischargeAdmission
Acute anticoagulant
management of ACS
Rivaroxaban 2.5mg bid
VKA (INR 2-3)
Aspirin + thienopyridine
Figure 2: Potential options for prolonged adjunctive OAC
The initial antithrombotic management after admission for acute coronary syndromes de-
pends on many factors, such as patient characteristics, concomitant medication and the choice 
of the revascularization/reperfusion strategy.
The cornerstone of antithrombotic treatment after ACS consists of long-term optimal dual an-
tiplatelet therapy. In patients with a high thrombotic risk, or “high platelet activity”, prolonged 
anticoagulation therapy can be considered. As initial strategy for anticoagulation unfraction-
ated heparin, bivalirudin, enoxaparin or fondaparinux can be started.
Following the acute phase, potential options for prolonged OAC are vitamin K antagonists 
(VKA) and low dose rivaroxaban. Both bivalirudin and unfractionated heparin are less attrac-
tive agents for long-term in-hospital treatment. Given the potential procoagulant effect of 
VKAs when initiated in patients in a prothrombotic state, concomitant anticoagulation therapy 
(see figure) should be given until two subsequent INRs are within therapeutic range (22). No 
overlapping treatment is required for rivaroxaban (34).
Note that the dose of rivaroxaban is considerably lower (5 mg per day) than for the indication 
atrial fibrillation (15-20 mg per day). New oral anticoagulants with a dosing scheme as in atrial 
fibrillation should not be combined with dual antiplatelet therapy.
If VKAs are chosen, the expected benefit should be carefully weighed against the potential risk. 
In this context, dual antiplatelet therapy with a reduced target INR (2.0-2.5) can be considered, 
as alternative to a target INR of 2-3 (59).
ACS, acute coronary syndrome; bid, bis in die (twice daily); INR, international normalized ratio; 
OAC, oral anticoagulation; VKA, vitamin K antagonist.
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dear sir,
We read with interest the article on the increased risk of gastrointestinal bleeding 
(GIB), associated with the use of the novel oral anticoagulants (NOAC).1 We compli-
ment the authors on their efforts to provide an up-to-date review on a very important 
issue. Despite the mortality rate (about 10%) associated with GIB, we sympathize 
with the authors’ call for a better documentation of this safety endpoint: for the 
present analysis, only in 19 of 43 trials data on GIB were available.
Notably, the authors describe that non-major clinically relevant GIB was often not 
reported, and that, therefore, their observed increased risk for bleeding may even 
have been underestimated. Given the potential consequences for the perception of 
these new drugs in daily clinical practice, we call for a more cautious interpretation 
of the reported risk as outlined in this systematic review.
The inclusion of data from trials on acute coronary syndromes, reporting evidently 
increased bleeding rates, is questionable. As an adjunct to dual antiplatelet therapy, 
NOACs have been tested, but the doses represented in the present meta-analysis are 
not endorsed for use in daily clinical practice.2 The only trial with data of an approved 
dose was not included in the meta-analysis as GIB was not reported in this study.3 
With regard to data from trials on atrial fibrillation, a substantial amount of available 
data on dabigatran is not incorporated in the analysis. Based upon data from RELY,4 
an 18,113 patients’ randomized controlled trial (dabigatran 150 bid/dabigatran 110 
bid/warfarin), dabigatran 110 mg has been approved in Europe, but not in the United 
States.5 In analogy to apixaban, this lower dose of dabigatran did not result in an 
increased rate of GI bleeds: 1.12 %/year versus 1.02 %/year on warfarin (RR 1.10 
95%CI 0.86-1.41).
Thus, not reporting data of an approved dose in Europe of a drug without an 
increased risk of GIB, and incorporating data for acute coronary syndromes on high 
doses that are not approved are two major points of concern.
We concur with the authors that it is important to assess numbers needed to 
harm, but we are more supportive of a careful evaluation of both the risk and the 
benefit, especially in the case of atrial fibrillation. Of note, with regard to efficacy, all 
NOACs for atrial fibrillation have proven to be non-inferior to vitamin K antagonists 
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for stroke prevention.6 With regard to bleeding, all agents have similar or significantly 
lower overall bleeding rates.
An appealing advantage is that intracranial bleeding is significantly reduced by 
all the new drugs.6 For example, when comparing dabigatran 150 mg bid with war-
farin,4 the reported absolute increase in GIB is 0.49%/year. However, the absolute 
reduction in intracranial hemorrhage is 0.44%/year. Given the much higher mortality 
rate (~60%) of intracranial hemorrhage,7 this increase in GIB deserves to be put into 
perspective. This overall safety profile of dabigatran 150 mg bid compares favorably 
to the use of vitamin K antagonists, which is additional to the significant reduction in 
efficacy (trombo-embolic events).4
These calculations demonstrate that warnings on individual safety endpoints of 
drugs should always be put in the context of overall safety, and in relation to efficacy.
In summary, the reported increased risk of GIB with the use of NOACs deserves 
further study, be it restricted to the doses and indications that the drugs have been 
approved for. In line with this, we acknowledge the authors’ statement that in future 
trials GIB events should be better reported. Finally, additional risk-benefit stratifica-
tion for the individual patient is warranted and calls for meta-analyses with individual 
patient data, an intention for which the authors should be commended. In an era 
of research and efforts to stimulate personalized medicine, already available data 
constitute an invaluable source of information, which we should share to improve 
individual patient care.
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abstraCt
Objective: In various clinical settings, polypharmacy has been associated 
with frailty and adverse outcome. Compared with warfarin, apixaban has a 
superior efficacy and safety profile in atrial fibrillation. However, patients with 
polypharmacy may have a differential response to anticoagulation therapy, 
due to extensive comorbidity and/or drug-drug interactions.
design, Participants, Interventions, Main Outcome Measures: Patients in 
the ARISTOTLE trial (n=18,201) were divided into tertiles according to the 
number of medications used at baseline. We compared clinical outcomes and 
the treatment effects of apixaban versus warfarin (adjusted for age, sex, and 
country).
Results: Patients used a median of 6 drugs (interquartile range 5 to 9); 
polypharmacy (≥5 drugs) was seen in 76%. Greater numbers of concomitant 
medications were used in older patients and in women, and in patients in the 
United States. Number of comorbidities increased across tertiles of increasing 
number of medications (0-5; 6-8; ≥9 drugs), as did the proportions of patients 
with drugs that interact with warfarin or apixaban. Mortality significantly 
increased as number of medications increased. Across tertiles of increasing 
numbers of drugs, rates of stroke/systemic embolism (1.29; 1.48; 1.57 per 
100 patient-years, respectively) and major bleeding (1.91; 2.46; 3.88 per 100 
patient-years, respectively) increased. The relative risk reductions of stroke or 
systemic embolism for apixaban versus warfarin were consistent, regardless of 
the number of concomitant medications (interaction p-value=0.8). With regard 
to major bleeding, there was less reduction seen with apixaban versus warfarin 
with greater numbers of concomitant drugs (interaction p-value 0.017). Pa-
tients with interacting (potentiating) drugs for warfarin or apixaban had similar 
outcomes and consistent treatment effects of apixaban versus warfarin.
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Conclusions: In ARISTOTLE, three quarters of patients have polypharmacy, 
and they constitute a population with a greater comorbidity, more interacting 
drugs, increased mortality, and higher rates of thrombo-embolic and bleeding 
complications. In terms of a potential differential response to anticoagulation 
therapy in patients with AF and polypharmacy, apixaban was more effective 
than warfarin and at least as safe.
Trial Registration: ClinicalTrials.gov (NCT00412984).
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introduCtion
In an era of increasing life expectancy, and with a growing population of survivors 
with various comorbidities, clinical decision making with regard to antithrombotic 
therapy for atrial fibrillation (AF) has become an even greater clinical challenge.1 
Despite the often well appreciated risk of stroke, oral anticoagulation is often not 
prescribed in the elderly, and undertreatment has been associated with adverse 
outcome.2,3 However, physicians increasingly acknowledge that treatment decisions 
should probably be based on biological rather than chronological age.4
In a variety of populations, polypharmacy has been associated with multiple 
comorbidities and frailty.5-10 Moreover, the risk of drug-drug interactions increases 
with the number of concomitant drugs. In addition, polypharmacy has been related 
to a higher risk of death and bleeding complications, also in patients with AF.6-17 In 
this context, patients with polypharmacy may have a differential response to antico-
agulation therapy.
With the introduction of apixaban, a safer alternative to warfarin has become 
available which has also proven to be of value in patients considered unsuitable for 
warfarin.18,19 In a previous report we demonstrated that the benefits of apixaban 
versus warfarin were irrespective of age (<65 yrs vs 65-74 yrs vs ≥75 yrs). However, 
among the elderly there are patients with hardly any comorbidity, whereas there are 
also younger patients with significant comorbidity. On average, patients with AF use 
about four to six different medications,.10,11,20 Given that polypharmacy is generally 
defined as the use of five or more concomitant medications, and thus represents an 
everyday issue, additional information on the impact of oral anticoagulation drugs 
in this specific subset of patients is of clinical importance.21 Especially in the case of 
apixaban, information on the impact of potentiating drugs is limited, an issue that is 
specifically of interest in patients with many concomitant drugs.
In this context, we performed a post-hoc analysis of the ARISTOTLE trial (Apixaban 
for Reduction of Stroke and Other Thromboembolic Events in Atrial Fibrillation) to as-
sess the association between the number of drugs used and the extent of comorbid-
ity and adverse outcome.19 In addition, we addressed the relative treatment effect 
of apixaban versus warfarin in relation to the number of concomitant medications.
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Methods
Patients
The study design and the main outcomes of the ARISTOTLE trial have been reported 
previously.19,22 In brief, ARISTOTLE was a multicenter double-blind, double-dummy 
trial comparing apixaban with warfarin performed from 2006-2011. Patients with 
documented AF or atrial flutter were eligible for inclusion if one or more of the follow-
ing risk factors for thromboembolism were present: symptomatic heart failure within 
3 months prior to inclusion or left ventricular function ≤40%; hypertension requir-
ing pharmacological treatment; age ≥75 years; diabetes mellitus; and prior stroke, 
transient ischemic attack (TIA), or systemic embolus. Exclusion criteria included 
clinically significant mitral stenosis, conditions other than AF requiring anticoagula-
tion, required aspirin treatment in a dose >165 mg/day or used in combination with 
a thienopyridine, recent ischemic stroke, AF due to reversible causes, an increased 
bleeding risk considered to be a contraindication for oral anticoagulation, and severe 
renal insufficiency (i.e., serum creatinine >2.5 mg/dL or a calculated creatinine clear-
ance <25 mL/min).
Patients were randomized to either apixaban 5 mg twice daily (n=9120) or  a 
dose-adjusted regimen of warfarin (n=9081). The target international normalized 
ratio (INR) range was 2.0 to 3.0, using a blinded encrypted point of care device. In 
cases where two or more of the following three criteria were present at baseline, 
patients received apixaban in a dose of 2.5 mg twice daily or matching placebo: age 
≥80 years, body weight ≤60 kilograms, serum creatinine ≥1.5 mg/dL. The study was 
approved by appropriate ethical committees at all sites and all patients provided 
written informed consent
Concomitant medications and comorbidity
To investigate the association between the number of concomitant medications and 
the extent of comorbidity, we assessed the number of drugs used for each patient. 
The study drug (apixaban or warfarin) and the matching placebo were counted as 
one drug. All medications were categorized according to the Anatomical Therapeutic 
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Chemical classification system.23 Polypharmacy was defined as the use of five or 
more concomitant drugs.21
The use of drugs known to interact with apixaban or warfarin was assessed for 
each patient. For apixaban, we studied drugs known to inhibit both the cytochrome 
P450 3A4 (CYP3A4) enzyme as well as the P-glycoprotein (P-gp) as depicted by the 
Food and Drug Administration (FDA).24 For warfarin, we studied the use of drugs 
known to inhibit or potentiate its anticoagulant effect with a high probability accord-
ing to the American College of Chest Physicians guideline.25
All analyses performed were based upon the baseline medication burden; only 
for the anticoagulant we also studied premature permanent study drug discontinua-
tion and for patients assigned to warfarin we calculated the time in therapeutic range 
(TTR) according to the Rosendaal method.26
Per protocol, the use of any concomitant medications during the trial was left to 
the discretion of the treating physician. The following concomitant medications were 
prohibited in combination with the study medication: potent inhibitors of CYP3A4 
(e.g., azole antifungals, macrolide antibiotics, protease inhibitors, and nefazadone), 
aspirin in a daily dose >165 mg, other anticoagulant agents (e.g., unfractionated hepa-
rin, low molecular weight heparin, direct thrombin inhibitors, pentasaccharides), and 
glycoprotein IIb/IIIa inhibitors. If these agents were used during trial participation, 
study medication was to be (temporarily) interrupted and restarted as soon as the 
prohibited medication was discontinued. In addition, during the trial it was advised 
to cautiously use aspirin in combination with a thienopyridine, chronic daily use of 
a non-steroid anti-inflammatory agent, and cytotoxic or myelosuppressive therapy.
Clinical outcomes
We assessed outcomes in relation to the number of concomitant medications used 
at the time of randomization, during a median follow-up of 1.8 years (25th, 75th per-
centiles: 1.3, 2.3 years). The primary efficacy outcome was stroke (i.e., abrupt onset 
of focal neurological symptoms lasting at least 24 hours), or a systemic embolism 
(i.e., symptoms suggestive of an acute loss of blood flow to a non-cerebral artery, 
supported by evidence of embolism from surgical specimens, autopsy, angiography, 
or other objective testing).
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Key secondary efficacy outcomes included assessment of the type of stroke (isch-
emic, hemorrhagic, unspecified) and all-cause death.
The primary safety endpoint was major bleeding according to the criteria set by 
the International Society on Thrombosis and Haemostasis (ISTH), which includes any 
clinically overt bleeding event accompanied by one or more of the following: a hemo-
globin drop of 2 g/dL or more over a 24-hour period, a transfusion of 2 or more units 
of packed red blood cells, bleeding at a critical site (i.e., intracranial, intra-spinal, in-
traocular, intra-articular, pericardial, intramuscular with compartment syndrome, or 
retroperitoneal), or fatal bleeding.27 Moreover, clinically relevant non-major bleeding 
events were monitored and were defined as all clinically overt bleeding not meeting 
the criteria of major bleeding though leading to either hospital admission, physician-
guided medical or surgical treatment, or a change in antithrombotic therapy.
The combined endpoint of ‘net benefit’ was defined as the combination of death, 
stroke, systemic embolism, and major bleeding.
Statistical analysis
Based on the tertiles of the distribution of the number of concomitant medications 
used at baseline, patients were classified in three groups. Comorbidities, organized 
by organ system, were summarized for the three groups, as well as other baseline 
characteristics. A similar approach was followed for the different drug classes. Data 
were depicted as means and standard deviations for continuous variables and fre-
quencies and percentages for categorical variables. One-way ANOVA and chi-square 
tests were used to compare groups. Efficacy, safety, and net benefit endpoints were 
compared among the three groups using rates per 100 patient-years of follow-up 
and adjusted hazard ratios with 95% confidence intervals. Adjusted hazard ratios 
were derived using Cox regression models adjusting for sex and age and country 
of randomization. In these models, age was considered non-linear and included 
as a restricted cubic spline. The randomized treatment effect was assessed within 
each group (0–5, 6–8, ≥9 medications) using a Cox regression model to estimate 
hazard ratios for apixaban versus warfarin along with 95% confidence intervals. The 
homogeneity of the randomized treatment effect across groups was tested by adding 
interaction terms to the Cox regression model.
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The proportional hazard assumption was evaluated using scaled Schoenfeld residu-
als and no clinically relevant departure from the assumption was observed. All the 
analyses performed with SAS version 9.4 (SAS Institute, Inc., Cary, NC).
Patient involvement
No patients were involved in designing the study, in assessing the burden of the 
intervention on patients, or in explicitly setting outcome measures; however, out-
comes were chosen to reflect daily practice described in earlier studies.28 Final study 
results of the ARISTOTLE trial were disseminated to study participants through their 
treating physicians.
results
Baseline characteristics and comorbidity
Table 1 depicts baseline characteristics of the study population, categorized in tertiles 
by the number of drugs. The randomized treatment was well balanced across tertiles 
and no relevant differences between apixaban and warfarin was observed for any of 
the drug categories across the tertiles (Online Supplementary Table 1).
Patients using more medications were older, more often female, and less often 
warfarin-naïve at study entry (Table 1). The CHADS2 and HAS-BLED scores increased 
across tertiles of increasing number of concomitant medications. With increasing 
number of medications the associated comorbidity increased significantly (Table 1).
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Table 1. Baseline Characteristics by number of Medications used
number of Medications
Characteristic
0-5
(n=6943)
6-8
(n=6502)
9 or more
(n=4756) p-value
Age, mean (SD), yrs 68 (10) 69 (10) 71 (9) <.0001
Male, no, (%) 4687 (67.5%) 4107 (63.2%) 2991 (62.9%) <.0001
Weight, mean (SD), kg 81 (19) 84 (21) 89 (23) <.0001
Body mass index, mean (SD), kg/m2 28.2 (5.4) 29.5 (6.0) 30.7 (6.5) <.0001
Prior use of Vitamin K antagonists for 
>30 days, no (%)
3555 (51.2%) 3656 (56.2%) 3190 (67.1%) <.0001
Creatinine, mean (SD) 1.02 (0.24) 1.06 (0.28) 1.12 (0.32) <.0001
Region of enrollment, no. (%) <.0001
North America 736 (10.6%) 1353 (20.8%) 2385 (50.1%)
Latin America 1809 (26.1%) 1306 (20.1%) 353 (7.4%)
Europe 3128 (45.1%) 2811 (43.2%) 1404 (29.5%)
Asia 1270 (18.3%) 1032 (15.9%) 614 (12.9%)
HAS-BLED score, mean (SD) 1.45 (0.96) 1.77 (1.02) 2.25 (1.05) <.0001
CHADS2 score, mean (SD) 1.87 (1.02) 2.15 (1.08) 2.44 (1.17) <.0001
CHADS2 score, no (%)
≤1 3093 (44.5%) 2057 (31.6%) 1033 (21.7%) <.0001
2 2309 (33.3%) 2400 (36.9%) 1807 (38.0%)
≥3 1541 (22.2%) 2045 (31.5%) 1916 (40.3%)
Randomized group, no. (%) 0.1
Apixaban 3424 (49.3%) 3320 (51.1%) 2376 (50.0%)
Warfarin 3519 (50.7%) 3182 (48.9%) 2380 (50.0%)
Low dose apixaban/placebo (2.5 mg 
bid) received
253 (3.6%) 288 (4.4%) 290 (6.1%) <.0001
Comorbidities organized by organ 
system, no. (%)
Cardiovascular
CAD 1795 (25.9%) 2184 (33.6%) 2063 (43.4%) <.0001
Prior MI 564 (8.1%) 985 (15.2%) 1036 (21.8%) <.0001
History of PCI/CABG 369 (5.3%) 815 (12.5%) 1292 (27.2%) <.0001
Congestive Heart Failure within 3 
Months
1931 (27.8%) 2194 (33.7%) 1416 (29.8%) <.0001
At Least Moderate Valvular Heart 
Disease
926 (13.4%) 1192 (18.3%) 1116 (23.5%) <.0001
Syncope in Last 5 years 258 (3.7%) 279 (4.3%) 322 (6.8%) <.0001
Hypertension with Pharmacological 
Treatment
5844 (84.2%) 5762 (88.6%) 4310 (90.6%) <.0001
PAD 193 (2.8%) 290 (4.5%) 401 (8.5%) <.0001
Aortic Aneurysm 46 (0.7%) 84 (1.3%) 139 (3.0%) <.0001
neurological/Cerebrovascular
Carotid Stenosis 54 (0.8%) 93 (1.4%) 190 (4.0%) <.0001
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Table 1. Baseline Characteristics by number of Medications used (continued)
number of Medications
Characteristic
0-5
(n=6943)
6-8
(n=6502)
9 or more
(n=4756) p-value
TIA 302 (4.4%) 315 (4.8%) 337 (7.1%) <.0001
Stroke 808 (11.6%) 750 (11.5%) 569 (12.0%) 0.8
Dementia 22 (0.4%) 29 (0.5%) 45 (1.0%) <.0001
Epilepsy 22 (0.4%) 49 (0.8%) 41 (0.9%) 0.0006
Pulmonary
COPD 435 (6.3%) 626 (9.7%) 889 (18.7%) <.0001
Asthma 157 (2.3%) 250 (3.9%) 462 (9.7%) <.0001
Sleep Apnea 145 (2.1%) 262 (4.0%) 606 (12.8%) <.0001
Gastrointestinal
Dyspepsia 374 (5.4%) 445 (6.9%) 556 (11.7%) <.0001
GE Reflux Disease 315 (4.5%) 527 (8.1%) 1074 (22.6%) <.0001
Peptic Ulcer Disease 383 (5.5%) 417 (6.4%) 406 (8.5%) <.0001
GI Surgery 509 (7.3%) 606 (9.3%) 575 (12.1%) <.0001
Chronic Liver Disease 190 (2.7%) 193 (3.0%) 121 (2.5%) 0.4
endocrine
Hypo/Hyperthyrodism 429 (6.2%) 733 (11.3%) 878 (18.5%) <.0001
Diabetes 806 (11.6%) 1603 (24.7%) 2138 (45.0%) <.0001
End organ Damage due to DM 75 (1.1%) 219 (3.4%) 459 (9.7%) <.0001
Musculoskeletal
Falls within 1 year 140 (2.3%) 215 (3.6%) 398 (8.8%) <.0001
Previous Non-Traumatic Fracture 299 (4.3%) 339 (5.2%) 436 (9.2%) <.0001
Osteoporosis 151 (2.2%) 298 (4.6%) 521 (11.0%) <.0001
renal
Chronic Kidney Disease 434 (6.3%) 520 (8.0%) 553 (11.6%) <.0001
Creatine Clearance < 50 mL/min 927 (13.4%) 1112 (17.2%) 970 (20.5%) <.0001
Hematological
History of Anemia 210 (3.0%) 359 (5.5%) 676 (14.2%) <.0001
Thrombocytopenia (platelet at 
baseline < 150)
510 (7.6%) 467 (7.4%) 332 (7.2%) 0.8
Bleeding History 779 (11.2%) 1029 (15.8%) 1232 (25.9%) <.0001
number of organ systems affected 
(median, 25th-75th)
2, 1-3 2, 2-3 3, 2-4 <.0001
Subcategorization of all baseline characteristics per treatment allocation is presented in Online 
Supplementary Table 1.
Abbreviations: n = number of patients, sd = standard deviation, yrs = years, no = number, kg = 
kilogram, m = meter, CAD = coronary artery disease, MI = myocardial infarction, PCI = percuta-
neous coronary intervention, CABG = coronary artery bypass grafting, PAD = peripheral artery 
disease, TIA = transient ischemic attack, COPD = chronic obstructive pulmonary disease, GE = 
gastroesophageal, GI = gastrointestinal, DM = diabetes mellitus, mL = milliliter, min = minute.
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Concomitant drugs - classification according to organ or system
The median number of medications used was 6 (25th, 75th percentiles: 5, 9) and 
polypharmacy was present in 13,932 (76.5%) patients (Online Supplementary Figure 
1). There were marked regional differences in the number of medications used, with 
53% (2385/4474) of patients enrolled in North America using 9 or more medications 
(United States 1980/3417 (58%); Canada 405/1057 (38%)), compared with 10–21% 
for the other regions (Table 1). Although 4 or more organ systems with comorbidity 
was higher in the U.S. (43.3% in the U.S. versus 20.5% in non-U.S. countries), the 
greater number of medications in the U.S. was observed regardless of the number 
of comorbidities.
Across tertiles of polypharmacy, the median number of represented drug classes 
increased from 2 (2, 3) for patients using 0–5 medications to 5 (4, 5) for patients using 
9 or more medications.
Across the three studygroups, there were no relevant differences between apixa-
ban and warfarin regarding the proportion of patients in each of the defined drug 
classes. For each of the respective drug classes the proportion of patients increased 
statistically significantly from the group with 0-5 drugs to the group with ≥9 concomi-
tant drugs.
Across groups of increasing concomitant medication, the proportion of patients 
in the respective drug classes was higher in the U.S. than in the non-U.S. population 
(Online Supplementary Table 2 A, B). Despite this difference in prescription pattern, 
there was a clear association between the number of concomitant drugs at baseline 
and the number of comorbidities, both for the U.S. and the non-U.S. populations.
CLInICAL OuTCOMeS ACCORdInG TO THe nuMBeR OF 
ConCoMitant MediCations
Efficacy outcomes
With regard to the primary efficacy endpoint (stroke and systemic embolism), patients 
using more concomitant medications were at higher risk, with an increase in event 
rates from 1.29 for patients using 0–5 medications to 1.57 per 100 patient-years for 
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patients using 9 or more medications (p<0.001; Table 3). For the secondary efficacy 
outcomes there was also a significant association with the number of concomitant 
medications, with a two-fold increased risk for all-cause death, when the highest 
tertile (≥9 medications) was compared with the lowest (0–5 medications) (p<0.001).
Safety outcomes
The risk of major bleeding for patients using 6–8 and 9 or more medications was 
significantly higher when compared with those using 0–5 medications (6–8 medica-
tions: adjusted HR 1.24, 95% CI 1.04 to 1.49; 9 or more drugs: adjusted HR 1.72, 
95% CI 1.41 to 2.10; Table 3). When subdividing major bleeding according to the 
location, no significant difference across tertiles was observed for intracranial bleed-
ing (p=0.73), while the event rate for gastrointestinal bleeding significantly increased 
with a higher number of concomitant medications.
Net benefit outcome
With regard to the combined endpoint stroke, systemic embolism, major bleeding, 
and all-cause death, event rates increased across tertiles (5.24, 6.59, and 8.92 per 
100 patient-years for 0–5, 6–8, and 9 or more medications, respectively, p<0.001). 
This was associated with an adjusted hazard ratio of 1.84 (95% CI 1.631 to 2.071) for 
patients using 9 or more medications when compared with those using 0–5.
Other outcomes
With increasing numbers of medications, the risk of permanent study drug discon-
tinuation increased significantly (discontinuation rates 14.3, 15.0, and 17.4 per 100 
patient-years at risk for 0–5, 6–8 and 9 or more drugs, respectively, p<0.001) (Table 
3). Poor INR control during follow-up (i.e., TTR below 66%) was highest in the patients 
using 0–5 concomitant medications and decreased across tertiles (53.2%, 50.2%, and 
44.9% for 0–5, 6–8, and 9 or more respectively, p<0.001) (Table 3).
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TReATMenT eFFeCT
Figures 1 and 2 outline the treatment effect of apixaban when compared with warfarin 
for the different outcomes categorized by the number of medications used at baseline.
For the primary efficacy outcome, risk reductions of apixaban versus warfarin 
were consistent, irrespective of the number of medications used (p interaction=0.8), 
with lower event rates on apixaban for all tertiles. Also for the secondary efficacy 
outcomes, no significant interactions were observed.
With regard to major bleeding, relative risk reductions for apixaban versus warfa-
rin decreased with increasing number of drugs (p interaction=0.017), corresponding 
with absolute reductions per 100 patient-years of 1.28 to 0.82 to 0.66 for the three 
respective categories (0–5, 6–8, and 9 or more drugs). For intracranial bleeding, the 
absolute benefit on apixaban showed a numeric increase across tertiles; this, in con-
trast to the numeric differences in major gastrointestinal bleeding observed between 
treatment groups. With regard to the combined outcome of stroke, systemic em-
bolism, major bleeding and all-cause death, we observed no significant interaction 
between treatment groups (p=0.1) Rates of permanent study drug discontinuation 
were lower for apixaban in all tertiles (p interaction=0.4).
interaCtinG druGs
The proportion of patients using an interacting drug increased across tertiles, both 
for CYP3A4/P-gp inhibiting as warfarin potentiating drugs. At least one combined 
inhibitor of both the CYP3A4 enzyme and P-gp was used by 20.9% (1903/9120) of the 
apixaban users and 21.1% (1913/9081) of patients on warfarin used VKA potentiating 
drugs. As for the concomitant use of aspirin, NSAID and/or prednisone, proportions 
were 13.8%, 31.7%, and 49.7%, respectively (p<0.001).
Rates of major bleeding did not significantly differ between patients with or 
without combined CYP3A4 and P-gp inhibitors (2.59 vs 2.61 per 100 patient-years, 
respectively). Moreover, no significant interaction with the treatment allocation 
was observed (p=0.4). With regard to drugs known to potentiate warfarin, we also 
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observed no difference in event rate of major bleeding (2.60 vs 2.61 per 100 patient-
year for users and non-users, respectively).
disCussion
In this post-hoc analysis of the ARISTOTLE trial, we observed that polypharmacy was 
present in three quarters of patients and that the number of concomitant medica-
tions is associated with increased comorbidity. Prescription patterns differed across 
regions, with approximately twice the number of concomitant medications in the 
U.S. vs non-U.S. populations. Adverse clinical outcome occurred more frequently in 
patients treated with a higher number of concomitant medications. The benefits of 
apixaban in reducing stroke were preserved, regardless of the number of medica-
tions taken. In terms of safety, while the rates of major bleeding were consistently 
lower with apixaban, the magnitude of benefit with apixaban decreased with the 
number of concomitant medications.
PolyPharMaCy and adverse outCoMes
AF is a disease of the elderly, who have a varying extent of comorbidity, and associ-
ated concomitant medication.29 Previous studies have reported rates of polyphar-
Table 4: Major bleeding with apixaban or warfarin according to the use of interacting drugs
use of potentiating 
drug
no use of potentiating 
drug
Interacting drugs
Apixaban
Rate (n)
Warfarin
Rate (n)
Apixaban
Rate (n)
Warfarin
Rate (n)
P 
interaction
≥ 1 combined P-gp and weak/
moderate/strong CYP3A4 inhibitor
2.27 (72) 2.91 (93) 2.10 (255) 3.14 (369) 0.4
≥ 1 Highly probable VKA 
potentiating drug
2.03 (62) 3.16 (96) 2.16 (265) 3.07 (366) 0.6
Abbreviations: n = number of patients, P-gp = P-glycoprotein, CYP = Cytochrome P450, VKA = 
vitamin K antagonist.
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macy in 40 to 64% of AF patients, with varying prescription patterns and inclusion 
and exclusion criteria.9,10
Various reports have demonstrated, for different clinical conditions, that poly-
pharmacy is associated with increased comorbidity.5-10 In addition, studies focusing 
on elderly populations have linked polypharmacy to adverse drug reactions, falls, 
disability, and frailty.6-8 In this context, patients with polypharmacy may constitute a 
population with a differential response to oral anticoagulation.
Although differences in prescription thresholds may affect the classification of pa-
tients in individual cases, several reports have repeatedly demonstrated on a group 
level that polypharmacy is associated with comorbidity and adverse outcome, also in 
AF populations.6-17 Our findings of higher risks of bleeding, stroke and all-cause mor-
tality with increasing numbers of drugs are in line with these previous observations.
Notably, this higher risk of adverse outcomes should be placed in the context of 
the association between the number of medications and comorbidities present at 
baseline, indicating a more frail status of patients with polypharmacy. If we were to 
adjust for these baseline differences, it is likely that the risk of adverse outcomes re-
lated to the number of medications would diminish. However, it is not our objective 
to study the association between polypharmacy and adverse outcomes independent 
of the baseline difference. On the contrary, we studied the number of concomitant 
medications as a marker of comorbidity/frailty and adverse outcome.
As such, we performed adjustments limited to age, sex, and country of random-
ization. The latter is of special importance given the differences in prescription pat-
terns between countries, independent of differences in comorbidity. It is striking that 
in the U.S., there is more use of polypharmacy, not explained by more comorbidity.
POLYPHARMACY And TReATMenT eFFeCT
Considering that patients with polypharmacy have a higher risk of adverse outcomes 
and multiple coexisting impairments, it is of special interest to study whether the 
main trial results of the ARISTOTLE study are consistent among patients using numer-
ous concomitant medications. As far as the primary endpoint of stroke and systemic 
Chapter 6
116
embolism is concerned, there was an absolute risk reduction from 1.60% per year 
with warfarin to 1.27% per year with apixaban (21% relative risk reduction in the 
complete population that was consistent irrespective of the number of medications 
used).19
Overall, the use of apixaban was associated with an absolute risk reduction in 
major bleeding from 3.09% to 2.13% per year when compared with warfarin (rela-
tive risk reduction 31%).19 However, we observed a statistically significant treatment 
interaction with relative risk reductions of apixaban varying from 50% (0–5 medica-
tions) to 28% (6–8 medications) and 16% (≥9 medications), respectively. Importantly, 
the risk reduction of intracranial bleeding did not diminish with an increasing number 
of concomitant medications. Therefore, the fact that the relative benefit of apixaban 
over warfarin appears to diminish across tertiles is due to other types of major 
bleeds. For example, with increasing numbers of medications, the numeric difference 
in gastrointestinal bleedings shifts from a benefit for apixaban (0–5 medications) to 
no apparent difference (≥9 medications) between both oral anticoagulants.
In the ROCKET AF trial, with overall similar rates of major bleeding for rivaroxaban 
and warfarin, there was also a treatment interaction for major bleeding, in that the 
hazard ratio for major bleeding in patients using fewer medications (0–4) was lower 
(adjusted HR 0.69, 95% CI 0.51 to 0.94) than observed in the entire study population 
(HR 1.04, 95% CI 0.90 to 1.20).10 As for mortality, there was no difference in treatment 
effect of rivaroxaban in patients with polypharmacy. In ARISTOTLE, apixaban reduced 
the risk of mortality from 3.94% to 3.52% per year when compared with warfarin in 
the main study, a relative risk reduction of 11% that was consistent regardless of the 
number of concomitant medications.19
In ARISTOTLE as well as in ROCKET AF, patients with polypharmacy were older.10 
Nonetheless, the relative reduction of both apixaban and rivaroxaban on major 
bleeding proved to be consistent across the different age groups in previously re-
ported post-hoc analyses.30,31 Importantly, this implies that our findings cannot be 
inferred to the ‘elderly patient’ in general. In fact, our findings are irrespective of age 
and sex, and refer to the group of patients, both younger and older, with multiple 
comorbidities and medications.
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Possible explanations for the attenuation of the observed safety benefit of 
apixaban with increasing concomitant drugs include effects of comorbidity and drug-
drug interactions, or the play of chance. We demonstrated that various co-existing 
diseases (COPD, gastrointestinal disease, renal impairment) were more frequent 
with increasing numbers of concomitant drugs. Of interest, given the consistent risk 
reduction of apixaban for intracranial bleeding, the treatment interaction for major 
bleeding is related to other major bleeding. Risk factors for gastrointestinal bleed-
ing complications (e.g., previous gastric ulcer, gastrointestinal surgery, dyspepsia, 
aspirin/prednisone/NSAID use) were more prevalent among patients with polyphar-
macy. In addition, other non-gastrointestinal risk factors for bleeding were also more 
often common in patients with more concomitant medications (e.g., older age, renal 
impairment, anemia, diabetes, and previous bleeding).32
Other aspects that may account for the decrease in benefit of apixaban in patients 
in the highest tertile are the higher rates of permanent study drug discontinuation 
and lower proportion of patients who were VKA-naïve.33 The lower rates of patients 
on study medication may blunt the observed risk reduction of apixaban in this tertile. 
In addition, bleeding rates on warfarin are usually lower in patients with prior VKA 
experience. Finally, the better INR control in patients with ≥9 medications may have 
diminished bleeding rates on warfarin in this subgroup.34,35
As for drug-drug interactions, we specifically studied the impact of warfarin 
potentiating drugs and the combination of CYP3A4 and P-gp inhibitors, given the 
possibility of higher apixaban plasma concentrations with these agents. However, 
there was no evidence of differential treatment effect between apixaban and warfa-
rin across tertiles of the number of concomitant drugs when accounting for warfarin 
potentiating or for apixaban potentiating drugs.
The abovementioned effects of non-vitamin K antagonist oral anticoagulants in 
patients with polypharmacy have also been studied in a pooled analysis of data in 
the setting of secondary prevention after a venous thromboembolism.15 For major 
bleeding, there was no treatment interaction, when the safety of dabigatran versus 
warfarin was compared in patients with ≤3 or >3 concomitant medications. However, 
these patients are much younger and less fragile when compared to patients with AF.
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Interestingly, also in the field of symptomatic venous thromboembolism the issue 
of a potential differential response to oral anticoagulation therapy in ‘fragile’ patients 
has been studied into more detail.36 Of note, in this study, patients were considered 
to be ‘fragile’ if they were >75 years, had a low body weight (<50 kg), or had impaired 
renal function (creatinine clearance <50 mL/min). Although this certainly identifies 
patients at risk, incorporation of multiple comorbidities would allow for a more 
refined identification of frail patients within these specific subsets of patients.37
In summary, polypharmacy may be a marker of multi-morbidity and a predictor of 
adverse outcomes, and it may provide a first, general impression of a patients’ frailty 
status. Future research on a differential response with oral anticoagulation therapy 
in patients with multi-morbidity may focus on incorporation of the key frailty criteria, 
for example the Fried criteria, which may help to identify a group of higher-risk 
patients that is often underrepresented in clinical trials.38 This may be a group that 
deserves additional attention, as far as the generalizability of trial data is concerned, 
not only in the field of anticoagulation therapy, but also for other therapies.39
liMitations
There are several limitations of this study. First, this is a post-hoc analysis, though 
there was a prospective detailed analysis plan. Second, the analyses are based on 
baseline medication burden, without information on drug changes, reason and/or 
appropriateness of drug prescription. However, with polypharmacy that is often 
driven by chronic medical conditions, dramatic reductions in the number of drugs 
are not very likely. Third, although the number of drugs may not only be driven by 
the extent of comorbidity, but also by prescription patterns, we acknowledge that 
this may have affected classification on an individual level. However, on a group level 
the use of polypharmacy has repeatedly demonstrated to be a marker of the extent 
of comorbidity and associated with adverse outcome. The cut-off value of 5 or more 
drugs may be somewhat arbitrary, but has been used in many previous reports. Ap-
preciating that three quarters of patients would qualify for polypharmacy according 
to this definition, our statistical approach was not arbitrary, but based on a common 
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approach of dividing our data into tertiles to allow exploration of polypharmacy 
across categories that are sufficiently large to avoid the hazard of small subgroups. 
With regard to generalizability, our findings may not apply to an unselected popula-
tion with AF, given the selection that occurs when enrolling patients in clinical trials.
ConClusions
In this population with atrial fibrillation on oral anticoagulation therapy, polyphar-
macy (≥5 drugs) is observed in three quarters of patients. The extent of comorbidity 
increased with greater numbers of concomitant drugs, which was irrespective of 
regional prescription patterns. Mortality, stroke and major bleeding were also more 
frequent with increasing numbers of drugs. As for a potential differential response to 
anticoagulation therapy in this context, we observed that apixaban was superior to 
warfarin in terms of efficacy, regardless of the number of medications taken, whereas 
its magnitude of benefit on major bleeding decreased with higher numbers of con-
comitant medications. There were important differences in the comorbidity profile 
that could account for this, and it did not appear that warfarin or apixaban potentiat-
ing drugs (CYP3A4, P-gp inhibitors) explained this observed treatment interaction. In 
summary, apixaban is more effective than and at least as safe as warfarin in patients 
with AF, regardless of polypharmacy.
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abstraCt
Background Anticipated bleeding complications contribute to underuse of 
oral anticoagulants, especially in elderly patients with atrial fibrillation (AF). 
Bleeding risk models could provide guidance, however, these were developed 
in the general AF-population.
Objective To study and compare the performance of the HAS-BLED, ATRIA and 
HEMORR2HAGES for major bleeding in very elderly AF-patients.
Methods Random sample (N=1,157) of VKA-anticoagulated AF-patients ≥80 
years with prospective clinical follow-up from 2011-2014. Primary outcome 
was major bleeding (ISTH criteria).
Results Patients aged 84 years (median; 25th-75th 82-87) were classified as low 
risk in 25.2% (HAS-BLED), 59.6% (ATRIA) and 23.3% (HEMORR2HAGES). Three 
year rates of major, clinically relevant and any bleeding were 6.7%, 28.3% and 
42.3%, respectively. We observed a statistically significant association for all 
models with major bleeding, but discriminatory abilities were rather poor 
(C-statistics <0.60) without clear superiority for either of the three. Only two 
(anemia, antiplatelet therapy) of the various classical risk factors were associ-
ated with bleeding. An estimated risk-benefit profile indicated a favorable 
trade-off for oral anticoagulation in this specific cohort (NNT=22, NNH=91).
Conclusions In this large prospective cohort of very elderly AF patients, the 
currently used bleeding risk scores were all associated with major bleeding, 
but with poor predictive abilities. Guidance by use of the ATRIA model may 
inadvertently result in less attention for modifiable risk factors in this particu-
lar population. Appreciating the issues of undertreatment and the suggested 
favorable risk-benefit profile, future models with incorporation of elderly-
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specific risk factors may provide more guidance in this growing population of 
AF patients.
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introduCtion
Stroke prevention among the elderly with atrial fibrillation (AF) remains a clinical 
challenge, as both the risk of stroke and bleeding increase with older age.1 Despite 
randomized evidence of beneficial effects of oral anticoagulation (OAC), also demon-
strated in patients aged 75 years or above, many physicians remain concerned about 
the bleeding risk; in the very elderly (≥80 years) undertreatment has been reported 
in up to 70% of patients.2-4
Appreciating the increasing life expectancy, risk stratification of bleeding in the 
specific subgroup of the very elderly has become a topic of increasing importance.5 
To assess the risk of major bleeding in the AF population as a whole, numerous risk 
stratification models have been introduced.6 The HAS-BLED score has currently re-
ceived most attention and has been implemented in the AF guidelines.7-9 The ATRIA 
and HEMORR2HAGES are two other models that have been studied extensively.
10,11 
Although the respective bleeding scores have been associated with the risk of major 
bleeding, discriminatory ability of all the models is -at most- modest and differs 
across studies.12-19
All three models have been derived from the general AF population.7,10,11 In 
these cohorts age was an acknowledged risk factor for bleeding, albeit with different 
cut-off values (>65 years HAS-BLED; ≥75 years ATRIA and HEMORR2HAGES). In the 
very elderly the performance of the models is unknown and will depend on other 
variables than age, as all patients will be attributed the maximum score for age. In-
terestingly, the ATRIA and HEMORR2HAGES scores have been derived in populations 
with a higher mean age, and might therefore better apply to the very elderly than 
the HAS-BLED score.7,10,11
In the abovementioned context, we sought to assess and compare the discrimi-
natory ability of the three risk schemes on major bleeding in patients aged ≥80 years. 
We addressed this issue with data derived from the Nijmegen area Anticoagulation 
Registry (NAR), which was an initiative to prospectively collect data on VKA-users in 
the outpatient clinic to monitor treatment quality and patient outcomes.
127
Low performance of bleeding risk models
7
Methods
Study population
The anticoagulation clinic in the region Arnhem/Nijmegen, the Netherlands, pro-
vides services for about 18,000 patients using a VKA for various indications. In May 
2011, a random sample of 5,000 VKA-users for AF was contacted by questionnaire to 
ask for participation in a quality control cohort with prospective data collection. The 
registry consists of the 3,162 patients (63%) who returned the questionnaire with 
written informed consent. Non-consenting patients were older (median age 77 vs 
75 years) and more often female (55% vs 44%). For the current analysis we studied 
patients ≥80 years with non-valvular AF (no mechanical heart valve and/or clinically 
significant mitral valve stenosis).
Patient characteristics and bleeding risk scores
Demographic and clinical characteristics were collected from the patients’ medical 
charts, the central database of the outpatient anticoagulation clinic as well as the 
data reported in the questionnaires. For each patient, the HAS-BLED, ATRIA and HEM-
ORR2HAGES risk scores were calculated according to the definitions as reported by 
each of the models, respectively (Online Supplementary Table 1).7,10,11 For example, 
HAS-BLED uses a creatinine of >200 µmol/L (2.26 mg/dL) or chronic dialysis for ab-
normal renal function, HEMORR2HAGES uses end-stage renal disease or a creatinine 
>221 µmol/L (2.5mg/dL) and ATRIA scores an estimated glomerular filtration rate of 
<30 ml/min or chronic dialysis.
To define subjects with a labile INR, the time in therapeutic range (TTR) was as-
sessed.20 In the Netherlands, the target INR range is usually set between 2.0-3.5. In 
general, we used the INR values of the 3 months prior to the study (Feb 2011–Apr 
2011) to calculate the TTR. For patients who initiated VKA therapy within the last 6 
months prior to study inclusion, we used INR values of the 4th until the 6th month 
after VKA initiation; this, because the first three months after initiation with VKA 
therapy is associated with suboptimal INR control. Genetic factors included in the 
HEMORR2HAGES score were not available. Laboratory analyses (e.g. renal or liver 
function) were derived from the medical charts which were performed as part of 
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routine clinical practice. Due to our inclusion criteria, the risk factor ´ age´ was present 
for all patients. Consequently, the minimum HAS-BLED and HEMORR2HAGES scores 
were 1, and the minimum ATRIA score was 2.
Follow-up and bleeding definitions
For all patients, clinical follow-up started at May 1st 2011 and ended at May 1st 2014.
The primary endpoint was major bleeding. Secondary outcome measures were 
non-major clinically relevant bleeding, any bleeding and stroke. Follow-up for major 
bleeding was performed until the earliest of: death; permanent VKA discontinuation; 
moving outside the region of outpatient anticoagulation clinic Arnhem/Nijmegen; or 
the end of the study period.
At each visit to the outpatient anticoagulation clinic, patients were interviewed by 
specialized nurses. Bleeding and/or ischemic events were reported in the electronic 
patient file. Follow-up information was obtained from the outpatient anticoagula-
tion clinic as well as the hospital medical records. All reported bleeding events were 
reviewed by a physician, with predefined categorization of its severity.
Major bleeding was defined according to the 2005 International Society on 
Thrombosis and Haemostasis criteria: fatal bleeding; and/or symptomatic bleed-
ing in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, 
intra-articular, pericardial, or intramuscular with compartment syndrome); and/or 
bleeding causing a fall in hemoglobin level of ≥20 g/L (1.24 mmol/L), or leading to 
transfusion of ≥2 units of whole blood or red cells.21
A clinically relevant non-major bleeding was defined as a bleeding event not 
meeting the major bleeding criteria, and associated with medical intervention, 
unscheduled contact with a physician, or (temporary) change in anticoagulation 
therapy. Clinically relevant bleeding was defined as a major and/or a clinically rel-
evant non-major bleed. All other bleeding events were classified as minor.
Statistical analyses
Every patient was appointed a bleeding risk score (Online Supplementary Table 
1). Rates of major bleeding were reported for each of the risk scores of the three 
models. In addition, they were divided into previously reported risk categories (low, 
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intermediate, high).12,16 Cohen’s kappa was calculated to measure the agreement of 
this categorization between the respective three bleeding models.
To assess and compare the performance of the models, univariate associations 
between the patients’ bleeding risk scores and the first occurrence of major bleed-
ing were analyzed using Cox proportional hazard regression analysis for HAS-BLED, 
ATRIA and HEMORR2HAGES, respectively. In addition to a continuous score, we also 
dichotomized the bleeding risk scores in analogy to previous publications.16 To assess 
the calibration of the models we used the Hosmer-Lemeshow goodness-of-fit statis-
tical method. The discriminatory ability of risk models was evaluated by constructing 
Receiver Operating Characteristics (ROC) curves and the C-statistic was calculated for 
the different bleeding scores. To compare the performance of the different bleeding 
risk models, the net reclassification improvement (NRI) was calculated.22 The NRI can 
be used to quantify how well one model reclassifies patients into low or high risk 
groups (either appropriately, or inappropriately) when compared to another model.
In order to identify risk factors for major bleeding we adopted the following 
approach. First, we performed multivariate Cox regression analyses, for each of 
the respective bleeding models separately, starting with the full set of items that 
comprise the HAS-BLED, ATRIA or HEMORR2HAGES models, respectively. Indepen-
dent risk factors were identified by a backward stepwise selection algorithm based 
on likelihood-ratio tests (p-out=0.10; p-in=0.05). The variables that remained in the 
multivariate model were considered as potentially valuable items for estimation of 
bleeding risk in the elderly. In addition to these, we chose to include gender, dia-
betes, polypharmacy and the use of selective serotonin reuptake inhibitors (SSRIs) 
given their reported impact in (some or more) publications on bleeding risk in the 
elderly.24-26,29
Statistical analyses were performed with PASW Statistical software, version 18 
(PASW, Inc., Chicago, Illinois, USA).
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results
Cohort description and clinical follow-up
The present study population consists of 1,157 out of the total of 3,162 patients in 
the registry (excluded: <80 years, mechanical heart valves, clinically significant mitral 
valve stenosis).
Median age was 84 years (IQR 82-87) with the eldest patient being 101 years. 
Patients were predominantly female, the mean BMI was 25.6 kg/m2 and the most 
frequently prescribed VKA was acenocoumarol (90%). Polypharmacy was present in 
79.3% of patients, and SSRIs were used in 3.4%.
Table 1 shows baseline characteristics, categorized by the occurrence of major 
bleeding. Most patients were categorized as low risk by the ATRIA risk model (59.6%) 
and as intermediate risk by the HAS-BLED (38.9%) and HEMORR2HAGES (51.9%). The 
agreement between the categories of the three models was low to moderate (Co-
hen’s kappa coefficient for all <0.50). A total of 210 patients (18.2%) were categorized 
as low risk by all three of the models, and 124 patients (10.7%) were categorized as 
high risk. This was associated with major bleeding in 4.3% and 6.5% of the patients, 
respectively. Figure 1 presents the percentage of patients with one or more major 
bleeding categorized for the different risk scores and categories (low, intermediate, 
high).
Table 1. Baseline characteristics organized by major bleeding
all
(n=1157)
no major bleed
(n=1080)
Major bleed
(n=77)
Demographics
Median age, years (IQR) 84 (82-87) 84 (82-87) 84 (82-87)
Age 80-84 years 610 (52.7%) 569 (52.7%) 41 (53.2%)
Age 85-89 years 415 (35.9%) 387 (35.8%) 28 (36.4%)
Age ≥90 years 132 (11.4%) 124 (11.5%) 8 (10.4%)
Male gender 493 (42.6%) 455 (42.1%) 38 (49.4%)
Median months on VKA (IQR) 37 (13-80) 37 (13-81) 35 (13-75)
Alcohol abuse# 157 (13.6%) 146 (13.5%) 11 (14.3%)
Medical history
Hypertension 761 (65.8%) 712 (65.9%) 49 (63.6%)
Hypertension (uncontrolled) 161 (13.9%) 153 (14.2%) 8 (10.4%)
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Table 1. Baseline characteristics organized by major bleeding (continued)
all
(n=1157)
no major bleed
(n=1080)
Major bleed
(n=77)
Previous stroke or TIA 256 (22.1%) 236 (21.9%) 20 (26.0%)
Left ventricular ejection fraction <40% 113 (9.8%) 106 (9.8%) 7 (9.1%)
Coronary artery disease 308 (26.6%) 286 (26.5%) 22 (28.6%)
Diabetes mellitus 297 (25.7%) 281 (26.0%) 16 (20.8%)
Previous bleeding* 252 (21.8%) 233 (21.6%) 19 (24.7%)
Recent or active malignancy 61 (5.3%) 56 (5.2%) 5 (6.5%)
History of falls 195 (16.9%) 182 (16.9%) 13 (16.9%)
Laboratory analyses
Anemia† 308 (26.6%) 278 (25.7%) 30 (39.0%)
Renal dysfunction‡ 100 (8.6%) 91 (8.4%) 9 (11.7%)
Liver dysfunction§ 2 (0.2%) 2 (0.2%) 0 (0.0%)
Thrombocytopenia¶ 102 (8.8%) 92 (8.5%) 10 (13.0%)
Time in therapeutic range < 60% 234 (20.2%) 218 (20.2%) 16 (20.8%)
Concomitant medication
Antiplatelet agent 48 (4.1%) 41 (3.8%) 7 (9.1%)
NSAID 24 (2.1%) 22 (2.0%) 2 (2.6%)
Risk models
Median CHADS2 score (IQR) 2 (2-3) 2 (2-3) 3 (2-3)
Median CHA2DS2-VASc score (IQR) 4 (4-5) 4 (4-5) 4 (4-6)
HAS-BLED score
Mean ± sd 2.23±0.99 2.22±0.98 2.48±1.03
Median (IQR) 2 (1-3) 2 (1-3) 2 (2-3)
ATRIA score
Mean ± sd 3.93±1.79 3.90±1.77 4.40±1.98
Median (IQR) 3 (3-5) 3 (3-5) 4 (3-6)
HEMORR2HAGES score
Mean ± sd 2.63±1.36 2.61±1.36 2.96±1.46
Median (IQR) 2 (2-3) 2 (2-3) 3 (2-4)
Results are presented as median (interquartile range) or mean±standard deviation for 
continuous data and as number of patients (%) for non-continuous data. #Defined as ≥8 
units of per week; *defined as previous clinically relevant bleeding; †defined as hemoglobin 
< 8.1 mmol/L (males) or <7.5 mmol/L (females); ‡defined as estimated glomerular filtration 
rate <30ml/min or dialysis dependent; §defined as chronic hepatic disease or biochemical 
evidence of significant hepatic derangement (i.e. bilirubin>2ULN in association with ALAT/
ASAT/ALP/GGT >3ULN); ¶defined as a trombocyte count of <150x109/L. Abbreviations: n= 
number of patients at risk; VKA = vitamin-K antagonist; TIA = transient ischemic attack; NSAID 
= non-steroid anti-inflammatory drug; IQR = interquartile range; sd = standard deviation.
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Follow-up
Mean follow-up was 30±10 months. A total of 735 (63.5%) completed the three 
year follow-up period, 367 patients (31.7%) deceased and 55 patients (4.8%) moved 
outside of the region or discontinued VKA treatment (e.g. perceived high bleeding 
risk; switch to NOAC).
After three years, major, clinically relevant and any bleeding occurred in 6.7%, 
28.3% and 42.3% of patients, respectively. Overall, 80 major bleeds occurred in 77 
patients, 448 clinically relevant bleeds were registered in 328 patients and any bleed-
ing event was observed 807 times in 489 patients. Major bleeding events occurred 
Figure 1: Major bleeding rates during the 3-year follow-up period in relation to the respec-
tive bleeding risk scores, and stratified by risk category.
Legend Figure 1: White bars represent low risk categories, grey bars represent intermediate 
risk categories, black bars represent high risk categories for the respective models. Categoriza-
tion was performed as previously described.12,16
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most often in the gastrointestinal tract (23/80 events), followed by intracranial 
bleeding (22/80) (Online Supplementary Table 2).
The median time with an INR in therapeutic range was 81% (IQR 74-87%).
Performance of the bleeding models
The continuous scores of all three models were significantly associated with major 
bleeding; for the dichotomized categories, there was no association between HAS-
BLED and major bleeding (Table 2). For clinically relevant bleeding, there only was a 
significant association with the HEMORR2HAGES score. Any bleeding was associated 
with both the ATRIA and HEMORR2HAGES models.
The calibration of the bleeding risk models was adequate for all three bleeding 
endpoints (Hosmer-Lemeshow Goodness-of-Fit significance level >0.05). The dis-
criminatory ability, measured by the receiver operating characteristic (ROC) analyses, 
was weak for all risk models for major bleeding (C-statistics <0.60) (Table 3). For 
clinically relevant and any bleeding, the performance of all models was also weak 
(C-statistic <0.55).
With use of NRI analyses, there were no significant differences between models 
in the classification of major bleeding (Table 4, Online Supplementary Tables 3-5). 
The same was observed for clinically relevant bleeding. For any bleeding, the predic-
tive ability of ATRIA was significantly higher when compared to the HAS-BLED model 
(NRI 8.51%, p=0.009).
Table 2. univariate analyses of the association of the risk models with bleeding
Major bleeding CR bleeding Any bleeding
HR (95% CI) HR (95% CI) HR (95% CI)
HAS-BLED cont 1.30 (1.05-1.61) 1.03 (0.93-1.15) 1.03 (0.94-1.12)
HAS-BLED dich 1.32 (0.84-2.08) 0.94 (0.74-1.18) 0.98 (0.82-1.18)
ATRIA cont 1.19 (1.06-1.33) 1.05 (0.99-1.12) 1.07 (1.02-1.12)
ATRIA dich 1.76 (1.13-2.75) 1.22 (0.98-1.52) 1.37 (1.14-1.63)
HEMORR2HAGES cont 1.22 (1.05-1.42) 1.11 (1.03-1.20) 1.09 (1.02-1.16)
HEMORR2HAGES dich 2.02 (1.07-3.83) 1.26 (0.97-1.65) 1.19 (0.96-1.47)
For the continuous models, hazard ratios were calculated per 1 unit of increase. For the di-
chotomous models, the low risk was used as the comparator and risk groups were defined as: 
HAS-BLED: low 0-2; high ≥3 points; ATRIA: low 0-3; high ≥4 points; HEMORR2HAGES: low 0-1; 
high ≥2 points.
Abbreviations: HR = hazard ratio; CI = confidence interval; CR = clinically relevant; cont = con-
tinuous; dich = dichotomous.
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Identification of risk factors for bleeding
Multivariate Cox regression analysis was performed on HAS-BLED, ATRIA and HEM-
ORR2HAGES separately, and resulted in the following variables that remained in the 
model after a backward stepwise approach: 1) Of the items in the HAS-BLED model 
we identified “bleeding predisposition” (=history of major bleeding and/or anemia) 
and “drugs” (=NSAIDs and/or antiplatelet therapy) 2) Of the variables in the ATRIA 
model “anemia” was the only identified variable 3) Of the various elements in HEM-
ORR2HAGES “anemia” and “reduced platelet count/function” (=thrombocytopenia 
and/or antiplatelet therapy) were identified.
Additional analyses showed that “anemia” and “drugs” were the variables of 
choice, after which we combined these with predefined potential new risk factors 
for the elderly (gender, diabetes, polypharmacy, use of SSRIs). Starting with this 
full model, applying a backward stepwise approach, neither of the new variables 
remained in the model.
Table 3. ROC analyses of the risk models with bleeding
Major bleeding CR bleeding Any bleeding
C-statistic 95% CI C-statistic 95% CI C-statistic 95% CI
HAS-BLED 0.57 0.50-0.63 0.50 0.47-0.54 0.51 0.47-0.54
ATRIA 0.58 0.51-0.64 0.52 0.49-0.56 0.53 0.50-0.57
HEMORR2HAGES 0.57 0.50-0.63 0.53 0.50-0.57 0.53 0.50-0.57
Bleeding risk models with scores as continuous variables.
Abbreviations: ROC = receiver operator characteristic; CR = clinically relevant; CI = confidence 
interval.
Table 4. net reclassification improvement analyses
Major bleeding CR bleeding Any bleeding
NRI SE P NRI SE P NRI SE P
HAS-BLED vs ATRIA -0.0632 0.071 0.894 -0.0564 0.036 0.119 -0.0851 0.033 0.009
HAS-BLED vs 
HEMORR2HAGES
-0.0360 0.078 0.460 -0.0561 0.043 0.194 -0.0372 0.038 0.334
HEMORR2HAGES vs 
ATRIA -0.0272 0.069 0.395 -0.0003 0.039 0.994 -0.0479 0.035 0.178
Bleeding risk models analyzed with dichotomized scores.16
Abbreviations: CR = clinically relevant; NRI = net reclassification improvement; SE = standard 
error; vs = versus.
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As for age, there was no association with major bleeding, neither studied as a 
continuous variable, nor as a dichotomous variable.
Estimated risk-benefit
In our VKA anticoagulated cohort rates for major bleeding and ischemic stroke or TIAs 
were 2.8 and 2.3 per 100 patient-years, respectively (Figure 2). Estimated event rates 
without VKA and associated NNT and NNH indicate that for every major bleeding 
caused by VKA treatment a total of four ischemic strokes or TIAs can be prevented, 
which is also true for patients categorized as high risk of bleeding according to cur-
rent guidelines (i.e. those with HAS-BLED≥3).
Figure 2: estimated benefit and harm of VKA therapy in the very elderly
Legend Figure 2: Observed rates for bleeding and ischemic events were calculated by dividing 
the number of patients with one or more events by the total years at risk. Event rates without 
VKA treatment were estimated with use of the reported relative risks for VKA versus placebo 
from the cumulative evidence of published trials2 (stroke: relative risk 0.36; major bleeding: 
relative risk 1.66). Based upon the estimated event rates without VKA treatment and the ob-
served rates in our cohort of VKA users, we calculated the number needed to harm (NNH) and 
treat (NNT).
Abbreviations: VKA = vitamin K antagonist; TIA = transient ischemic attack; NNH = number 
needed to harm; NNT = number needed to treat.
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disCussion
To our knowledge this is the first prospective registry of the very elderly with AF that 
addresses the performance of currently available bleeding risk models in this specific 
group of VKA users. Despite a significant association between the continuous scores 
of all models with major bleeding, we demonstrated that their discriminatory ability 
was poor, without clear superiority for either of the models. The reported statisti-
cally significant superior performance of ATRIA for any bleeding when compared to 
the HAS-BLED score (significant NRI) should be interpreted with caution given the 
aforementioned context of poor clinical performance. Despite poor discriminative 
ability, the bleeding risk models serve as an important tool in clinical practice to 
identify and follow-up patients who have modifiable risk factors. In that context, the 
identification of almost 60% of patients as low risk using the ATRIA model seems of 
practical concern.
Importantly, for all three of the respective bleeding risk models, we observed that 
the vast majority of the incorporated risk factors was not independently associated 
with major bleeding; this underscores the need for identification of elderly-specific 
risk factors .
Lack of performance of bleeding risk models
Not only in the elderly, but also in the general AF population, a search for a model 
with good performance for major bleeding remains a clinical and statistical chal-
lenge. As for the latter, the development of a model with an acceptable positive 
predictive value is hampered by the infrequent occurrence of major bleeding. From 
a clinical perspective, the respective derivation cohorts used to develop the cur-
rently available models may not be representative of the truly elderly population. 
In that context, the higher mean age in the derivation cohorts of HEMORR2HAGES 
and ATRIA (80 and 75 years, respectively) has been suggested as argument to prefer 
these models over HAS-BLED (65 years), but our data do not corroborate with these 
recommendations.7,10,11,23
Apart from the abovementioned aspects, other aspects such as non-uniformity in 
the definitions of risk variables are important factors that may complicate the identi-
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fication of bleeding risk factors. In the case of anemia, for example, two of the three 
risk models apply a similar definition, whereas in HAS-BLED a combination is made of 
anemia and previous bleeding.7,10,11 As such, the fact that bleeding predisposition in 
HAS-BLED is associated with major bleeding seems to imply that a history of previous 
bleeding may be of importance, whereas in fact -in our population- the association 
is driven by anemia only.
As for a history of bleeding, ATRIA and HEMORR2HAGES use the same definition, 
referring to any bleeding, whereas HAS-BLED scores admissions for major bleed-
ing.7,10,11 Irrespective of either definition for a history of bleeding, we did not observe 
an association with future major bleeding (exploratory analyses). Similar problems 
regarding uniformity of definitions are true for the use of drugs/antiplatelet agents 
and renal function (Online Supplementary Table 1).
Apart from these methodological issues, it should be appreciated that the very 
elderly patient will always be appointed the maximum score for age; hence, the dis-
criminative ability of the risk models will depend on the other variables in the model. 
As such, the suboptimal performance of all three models in our cohort is explained 
by the fact that we observed that most of the ‘classical’ bleeding risk factors that are 
incorporated in the risk models are not associated with major bleeding. This suggests 
that the risk factors for bleeding in the elderly may not be the same as observed in 
the general AF population.
Bleeding risk factors in the elderly
For all three respective models, we observed an independent association between 
anemia/bleeding predisposition and major bleeding during follow-up. In addition, 
for HAS-BLED the use of ‘high risk drugs’ (antiplatelet agents or NSAIDs; Online 
Supplementary Table 1) and for HEMORR2HAGES a ‘reduced platelet count/function’ 
(antiplatelet agents or thrombocytopenia; Online Supplementary Table 1) were also 
factors related to major bleeding.
Only a limited number of studies has focused on the identification of bleeding 
risk factors in the elderly AF patient specifically.24-31 As of to date, in only two other 
reports anemia was found to be a risk factor for bleeding.24,25 One study in patients 
≥75 years (n=208) identified the use of SSRIs as a risk factor.24 The other study is by 
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far the largest registry addressing risk factors for bleeding (over 26,000 patients), in 
which diabetes, female gender and the use of antiplatelet therapy were the other 
risk variables.25 Unfortunately, though intended as the first bleeding model for the 
elderly, its discriminative ability was modest, and the definition of ‘elderly’ was set at 
65 years, which can be considered rather young for AF patients.25
A third study, also in patients ≥75 years (n=199), reported that polypharmacy 
and variability in the INR were risk factors for major bleeding.26 Finally, in the largest 
cohort on patients ≥75 years (n=4130), renal impairment was the only risk factor for 
bleeding.27
Only two studies described bleeding risk factors in octogenarians.28,29 Neither 
identified anemia or antiplatelet therapy as predictors of bleeding. In contrast, active 
cancer, previous bleeding and a history of falls were found as independent predictors 
of major bleeding in the EPICA study (n=4093).28 Whereas age was not found to be 
related to bleeding, data from another cohort (n=798) identified age (>85 years) and 
diabetes mellitus as risk factors.29 In our study age was not associated with bleeding, 
neither as a continuous, nor as a dichotomous variable.
These contrasting data underscore the clinical challenge of bleeding prediction in 
general, but specifically in the elderly. Based on the available previous reports, we 
decided to study the impact of gender, diabetes, polypharmacy and the use of SSRIs 
as potential new risk factors for bleeding. As for the classical bleeding risk models, 
anemia and the use of drugs were the two variables of interest. Multivariable analy-
sis studying the impact of the abovementioned potential new risk variables did not 
result in a new contributing risk factor.
In summary, the majority of risk factors for bleeding represented in the current 
models, is found not to be associated with bleeding in the very elderly. This observa-
tion, in combination with reports that risk factors may differ between younger and 
older patients,27 underscores the need for additional studies with specific focus on 
bleeding in populations of elderly patients.
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Implications
Appreciating the consequences of undertreatment in the elderly AF patient, and the 
lack of performance of the current bleeding risk models, there are several implica-
tions for both future research and clinical practice.32
Future studies on risk factors for bleeding should ideally have a design that ac-
counts for the aforementioned issues. This includes a sufficiently sized, representa-
tive cohort of elderly patients with uniform definitions of both risk and outcome 
variables. This holds especially true for the definition of bleeding as an endpoint, but 
the definition of a history of bleeding as a baseline risk factor shows great variability 
as well. In our analysis, we opted for the ISTH definition of the endpoint bleeding, 
but use of the BARC definition would not have altered our findings.21,33 Importantly, 
to gain further insight into risk stratification of a rather infrequent event like major 
bleeding, we largely depend on quantitative and qualitative reviews, which are only 
possible if the abovementioned methodological issues have been accounted for.
Apart from more uniform study designs, future studies should anticipate that 
most risk factors derived from general AF populations do not apply to a very el-
derly population; therefore, it should be considered to study other, elderly-specific 
characteristics as potential risk factors, such as (the number/risk of) falls, cognitive 
function, polypharmacy and one might consider to pay more attention to other non-
cardiovascular comorbidities as represented in the Charlson comorbidity index.34 
Moreover, endpoints other than mortality, stroke and bleeding could be of value, 
such as the impact of bleeding on (instrumental) daily activities. Importantly, the fact 
that elderly patients experience major bleeding in case of a cutaneous localization 
(Online Supplementary Table 2), which is infrequently the case in younger popula-
tions, is yet another indication that the very elderly should be considered as a unique 
population by itself: not only risk factors for bleeding may vary, also the impact of a 
bleeding may vary from younger populations.
As of yet, it remains a clinical challenge to identify subjects at high risk of bleed-
ing, given the rather low frequency of major bleeding. Alternatively, identification of 
low risk patients seems feasible. Our data indicate that in the absence of other risk 
factors than age, a truly low risk group of about 25% of patients can be identified 
with 3-year rates of major bleeding of 4.1% (HAS-BLED=1), 3.7% (ATRIA=2) and 4.1% 
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(HEMORR2HAGES=1), respectively. According to stratification by the models, 60% 
of patients would be considered low risk according to ATRIA, as compared to 25% 
and 23% for HAS-BLED and HEMORR2HAGES respectively. This categorization is likely 
to result into less attention for lower risk individuals when using the ATRIA model. 
Especially in case of electronically based patient management systems, this could 
be a potential failing of the ATRIA model as this may result in a higher proportion of 
patients classified as ‘low risk’ and, as such, may cause less awareness for modifica-
tion of the reversible risk factors.
Although identification of a truly low-risk subgroup seems feasible (no other risk 
factors than age), the majority of patients will present with risk factors, and specific 
tools for guidance are lacking. This is further complicated by the fact that several 
variables incorporated in the current bleeding risk models are also known risk fac-
tors for stroke.8,9 In anticipation of future initiatives, and appreciating the rate of 
undertreatment and its adverse consequences, some form of guidance is warranted 
for the daily management of this growing population of the elderly.32
Based upon the observed event rates in the present cohort we estimate that, in 
general, the benefits of VKA therapy exceed the detrimental effects in an elderly AF 
population (Figure 2: NNH 91; NNT 22). To provide more objective guidance, new 
initiatives on bleeding risk factors in the very elderly are eagerly awaited, as well as 
additional safety data for the non-vitamin K oral anticoagulants.35,36
liMitations
A first limitation of our study refers to selection and generalizibility. About one-third 
of patients did not consent to participate and unfortunately, ethical considerations 
prohibited us from collecting other information than age and gender. Moreover, 
about a third of patients deceased before the end of follow-up. Their baseline profile 
was markedly different from survivors (history of falls, diabetes, anemia, throm-
bocytopenia). This, and the shorter time at risk of an event may have influenced 
our identification of risk factors for bleeding and/or the magnitude of the observed 
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associations. In addition, even though the rate of VKA discontinuation was low, this 
may have affected our findings.
Second, autopsy was not performed systematically and major bleeding in terms 
of deaths caused by (intracranial) bleeding could therefore have been missed. With 
regard to the net clinical benefit estimation, it should be considered that this calcula-
tion is based upon data from studies performed decades ago. Given the improved 
INR control (TTR) nowadays, associated with better efficacy and a lower bleeding 
risk of VKA treatment, the risk-benefit profile could even be more favorable than 
currently estimated.37,38
ConClusions
In this three year follow-up study of a large real-world cohort of very elderly AF 
patients, the currently available bleeding risk models did not provide clinically 
relevant discriminatory ability, despite statistically significant associations between 
the bleeding scores with major bleeding. Notably, apart from anemia and the use 
of antiplatelet agents none of the risk factors incorporated in the models derived in 
the general population was associated with major bleeding in this aged population.
Patients without other risk factors than age are at truly low risk of bleeding; 
for other patients, caution is warranted for the threshold to categorize patients as 
low-risk as this may inadvertently result in less attention for modifiable risk factors. 
Appreciating the issue of undertreatment, and the suggested favorable risk-benefit 
profile of oral anticoagulation in our cohort, tools that provide guidance in the po-
tential harm and benefit in this specific population are eagerly awaited in this era of 
increasing life expectancy.
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suMMary
In the general introduction of Chapter 1, background information is provided on the 
pathogenesis of an atherothrombotic event, the therapeutic options and its limita-
tions. The remaining part addresses the scope of the current thesis with the different 
study questions.
Chapter 2 describes the occurrence of gastrointestinal symptoms with different 
formulas of low-dose aspirin. In the 1980s, aspirin proved to be essential in the 
secondary prevention of cardiovascular disease and is now prescribed to over 1 
million patients in the Netherlands. Unfortunately, aspirin has gastrotoxic proper-
ties, both locally and systemically, which can manifest as gastric ulcer formation, 
gastric bleeding and is also associated with dyspepsia which affects compliance to 
aspirin. To reduce local gastric toxicity a buffered form of aspirin (effervescent cal-
cium carbasalate) has been developed. To compare the prevalence of self-reported 
gastrointestinal symptoms between plain and buffered aspirin, we used data of a 
large population based cohort study on gastrointestinal symptoms (n=18,317). In 
this cohort, 1544 participants used low-dose aspirin, which was used in plain form 
by 911 patients, whereas the buffered formulation was used by 633 subjects. We 
demonstrated that gastrointestinal symptoms were frequently reported (≈27%) with 
no difference between both groups. Also with regard to specific upper and lower 
gastrointestinal symptoms, no differences were observed between groups. Hence, 
our data indicate that as far as gastrointestinal symptoms are concerned, buffered 
aspirin has no additional value over plain aspirin. To optimize compliance to aspirin 
we feel that the addition of a proton pump inhibitor seems a better alternative, given 
that proton pump inhibitors have demonstrated to effectively reduce gastrointestinal 
symptoms.
Although proton pump inhibitors (PPIs) increase safety of aspirin, concerns have 
been raised that they might decrease the efficacy of clopidogrel. In Chapter 3, we 
performed a systematic review to study the impact of the addition of PPIs on platelet 
function and clinical cardiovascular outcome. At present, the European Society of 
Cardiology (ESC) guidelines recommend aspirin and clopidogrel as standard treat-
ment after a percutaneous coronary intervention for stable angina. Notably, although 
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a recent guideline update states that in patients with an acute coronary syndrome 
(ACS) more potent agents like ticagrelor and prasugrel are to be preferred, many ACS 
patients are still treated with clopidogrel as adjunctive to aspirin. In this context, the 
warnings issued by the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) in 2009 are still of interest. Co-therapy with a proton pump inhibi-
tor (PPI) was reported to potentially reduce the antiplatelet effect of clopidogrel as 
both these drugs act on the cytochrome P450 2C19 iso-enzyme, thereby reducing 
the transformation of clopidogrel to its active metabolite. These reports were ini-
tially based on laboratory and retrospective cohort studies. In follow-up of these 
first reports, several prospective studies have been conducted that challenged the 
retrospective data. With regard to the laboratory studies, 10 studies were identified 
that involved healthy volunteers and 18 included cardiovascular patients. In both 
settings the co-administration of a PPI resulted in a significant reduction of platelet 
inhibition of clopidogrel in the majority of the ex vivo studies (7/10 in healthy volun-
teers; 11/18 in patients). The impact of conjunctive use of PPIs on clinical outcome 
was investigated in 33 studies concerning over 200 thousand patients. Importantly, 
most of these studies were of retrospective design (21/33) with signs of prescription 
bias and imbalances in baseline characteristics. In addition, there was significant 
heterogeneity in observed outcomes, with risk ratios varying from 0.68 to 4.58. 
Notably, taken into consideration the established 20% relative benefit of the addi-
tion of clopidogrel to aspirin treatment, it should be acknowledged that the reports 
of a relative risk increase exceeding 50% cannot solely be attributed to the use of 
PPI co-treatment. More importantly, only 48% of the studies reported an increased 
risk for major adverse cardiovascular events (MACE) in case of concomitant PPI use. 
Moreover, of the two studies in which the PPI was randomly allocated, none showed 
signs of adverse outcome in case of PPI use. Hence, despite indications of reduced 
antiplatelet activity in laboratory studies, the available reports on clinical outcome 
do not uniformly support the statement that PPI co-treatment adversely affects the 
beneficial properties of clopidogrel.
Nonetheless, despite the use of dual antiplatelet therapy (aspirin plus clopido-
grel) following a myocardial infarction, recurrent events occur in about 10% of the 
patients within one year. In daily practice, this is a group that merits further attention 
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with regard to the antithrombotic regimen. In Chapter 4, we address the value of 
prolonged anticoagulation therapy in patients in whom dual antiplatelet therapy 
has been proven clinically ineffective. Vitamin K antagonists (VKAs) have proven 
efficacious in ACS as monotherapy, with outcomes similar to aspirin. As adjunct to 
aspirin, there is robust data indicating that long-term VKA therapy improves outcome 
after an ACS in patients with sinus rhythm. In a meta-analysis of 7,836 patients, the 
allocation of a VKA (INR 2.0-3.0) added to aspirin therapy reduced the risk of death, 
non-fatal myocardial infarction and/or stroke from 12.3% to 9.4%. Notably, this was 
at the cost of an increase in major bleeding from 1.1% towards 2.6%.
The development of the non-VKA oral anticoagulants (NOAC), without the need 
for monitoring, has renewed the interest for prolonged anticoagulation therapy. 
Importantly, these drugs have only been studied as adjunctive to dual antiplatelet 
therapy, which remains the cornerstone in the treatment of ACS. Of the NOACs, only 
rivaroxaban, used in very low doses, has demonstrated to improve clinical outcome. 
However, given the significant increase in bleeding risk, it should be used only in 
selected patients at very high risk of recurrent ischemic events.
The most challenging population concerns patients with a strict indication for oral 
anticoagulation therapy who develop an ACS. Given the scarcity of data of NOACs in 
the acute setting, we feel that NOACs should be discontinued during hospital admis-
sion in this specific group of patients. Following discharge, a NOAC used in a dose 
for atrial fibrillation should not be combined with dual antiplatelet therapy given 
the unacceptable high bleeding risk demonstrated in various phase II and III trials. 
Given these safety concerns, we recommend prolonged anticoagulation with VKAs 
in the first year following ACS. In case the indication for dual antiplatelet therapy has 
ended, physicians can reconsider switching the VKA to a NOAC.
The bleeding risk of NOACs is also the subject of Chapter 5. This chapter concerns 
a critical appraisal of a meta-analysis describing a 45% increased risk of gastrointes-
tinal bleeding associated with the use of NOACs prescribed for various indications. 
In this commentary, we call for a more cautious interpretation of the reported risk. 
First, the meta-analysis included studies in which the NOAC was used for second-
ary prevention of ACS in which placebo was the comparator. Importantly, in these 
studies the NOAC was used in doses used for stroke prevention in atrial fibrillation, 
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which have not been endorsed by current guidelines given the known high bleeding 
rates. Secondly, with regard to trials on AF, a substantial amount of data without an 
increased gastrointestinal bleeding risk was not incorporated in the meta-analysis. 
Finally, we call for a more careful evaluation of both the risks and benefits, such as 
the reduced risk of intracranial bleeding with NOAC therapy.
One of the NOACs that demonstrated to be safer and more effective than warfarin 
when used for stroke prevention in AF is apixaban. However, this drug was studied in 
a general AF population, and there are suggestions that patients with polypharmacy 
(i.e. ≥5 drugs) are older and more frail and could have a differential response to 
anticoagulation therapy. In this context, we performed a post-hoc analysis of the 
ARISTOTLE trial in which apixaban was compared to warfarin in 18,201 patients 
with AF (Chapter 6). We demonstrated that patients using more drugs constitute a 
population with greater comorbidity, increased risk of mortality and were at higher 
risk of ischemic and bleeding complications. With regard to efficacy, the superiority 
of apixaban when compared to warfarin for stroke (21% risk reduction) and mortal-
ity (11% risk reduction) observed in the complete population were irrespective of 
the number of concomitant drugs used. Notably, although apixaban demonstrated 
a 31% risk reduction on major bleeding in the main trial, we observed a statistically 
significant treatment interaction with relative risk reductions of apixaban varying 
from 50% (0-5 drugs) to 28% (6-8 drugs) and 16% (≥9 drugs). Interestingly, it did 
not appear that the use of warfarin or apixaban potentiating drugs explained this 
observed treatment effect. These findings indicate that observations on efficacy and 
safety in general populations can differ in high risk populations, such as the elderly 
with various comorbidities.
Despite evidence of beneficial effects of oral anticoagulation therapy in the very 
elderly, physicians remain concerned about the bleeding risk and undertreatment 
of these patients is common. Various bleeding risk models have been developed to 
assess the bleeding risk of which HAS-BLED, ATRIA and HEMORR2HAGES are mostly 
used. However, these models were developed in general populations and their per-
formance in the very elderly is unknown. In Chapter 7 we assessed and compared the 
discriminatory ability of three acknowledged bleeding risk models on major bleeding 
in the very elderly AF patients using a vitamin K antagonist. During a 3-year follow-up 
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period, major bleeding occurred in 6.7% of this specific population (rate: 2.8%/year). 
Despite a significant association of all three models with major bleeding, the dis-
criminatory abilities were rather poor (C-statistics < 0.60), without a clear superiority 
for any of the models. Notably, apart from anemia and the use of non-steroidal anti-
inflammatory drugs (NSAIDs) or antiplatelet agents none of the ‘classical’ risk factors 
incorporated in the models derived in the general population was associated with 
major bleeding in this aged population. To provide some guidance with regard to 
clinical decision making, we calculated an estimated risk-benefit and demonstrated 
that, in general, the benefits of VKA therapy exceed the detrimental effects in this 
growing population of the very elderly. To provide more objective guidance, new 
initiatives on bleeding risk factors in the very elderly are eagerly awaited, which 
should focus on elderly specific risk factors.
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ePiloGue
This thesis focused on the balance between safety and efficacy of oral antithrombotic 
therapy in the field of cardiology. This topic was studied in antiplatelet agents, such 
as aspirin and clopidogrel, as well as oral anticoagulants, which can be categorized as 
vitamin K antagonists (VKAs) and non-VKA oral antagonists (NOACs).
An optimal balance between safety and efficacy is essential. A reduced efficacy 
can cause thrombosis which can result in a more intensive antithrombotic treatment, 
thereby increasing the risk of bleeding complications. On the other hand, a perceived 
high bleeding risk can result in a reduced compliance and undertreatment, which 
demonstrates that the safety of an antithrombotic agent affects the effectiveness of 
a drug.
This thesis describes the abovementioned interaction between safety and effi-
cacy in the treatment and prevention of stable and unstable coronary artery disease 
as well as the treatment of atrial fibrillation.
aCute Coronary syndroMe
Efficacy
The prevention of an acute coronary syndrome (ACS) has changed extensively in the 
last decades. After aspirin became available, followed by clopidogrel, newer anti-
platelet agents have emerged which proved to be even more effective in the preven-
tion of ACS. In addition, more and more studies focused on the value of adding an 
(oral) anticoagulant as adjunct to the antiplatelet agents. These developments have 
improved the treatment of an ACS and significantly reduced the risk for recurrent 
events. Unfortunately, with the arrival of the antiplatelet agents, new problems have 
emerged.
Given the substantial number of patients with a recurrent thrombotic event 
despite dual antiplatelet therapy, the term ‘resistance’ to aspirin and clopidogrel has 
been introduced. It is uncertain to what extent this can be contributed to a subop-
timal efficacy of the antiplatelet agents. This topic has been given much attention 
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in the recent past in which the results of ex vivo platelet function tests were used 
as surrogate for efficacy in vivo. An important example is the supposed interaction 
between clopidogrel and proton pump inhibitors, resulting in a reduced production 
of the active metabolite of clopidogrel, which is discussed in this thesis. Notably, the 
initial warnings of the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) were based only on ex vivo studies and clinical studies with a retro-
spective design. On the one hand did the ex vivo results indicate a clear interaction 
given the higher platelet reactivity in case of PPI coadministration, albeit that this 
was most pronounced in healthy volunteers with no history of an ACS. On the other 
hand did the data of prospective (randomized) studies not suggest an effect on clini-
cal outcomes in case of clopidogrel and PPI coadministration.
This discrepancy between platelet function tests and clinical outcome has also 
been described in two large trials (GRAVITAS; ARCTIC) in which patients with an ex 
vivo increased platelet reactivity were randomized to more intensive antiplatelet 
therapy, or the continuation of the current treatment. These studies concluded that, 
although a more intensive approach significantly reduced platelet reactivity, it did 
not affect clinical outcome.
These findings in large randomized studies demonstrate the limitations of ret-
rospective studies, which is the result of prescription bias and reduced quality of 
the collected data. Although the warnings of the FDA and EMA can be advocated in 
terms of efficacy, these warnings could potentially result in changes in prescription 
patterns, such as discontinuation of the PPI or switching to another P2Y12 inhibitor 
such as ticlopidine, which affects safety issues such as gastrointestinal bleeding and 
bone marrow suppression.
Although a certain part of the recurrent events can be attributed to ‘resistance’ 
to antiplatelet therapy, it should be noted that inhibition of only the thrombocytes 
in the treatment and prevention of an ACS does not suffice. Several older studies 
clearly indicated that VKA monotherapy is effective in the setting of acute and 
chronic coronary disease. However, no studies were performed to further investigate 
the potential value of oral anticoagulation as adjunct to dual antiplatelet therapy, 
although VKAs also proved their potential when added to aspirin monotherapy. As of 
to date, no large randomized studies have investigated the potential of adding VKA to 
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dual antiplatelet therapy in patients with sinus rhythm and this combination is based 
upon expert opinion and applied only in selected cases. Interestingly, several phase II 
studies with NOACs in patients with dual antiplatelet therapy have been performed. 
The only completed phase III trial concerns the prescription of triple therapy with a 
very low dose of rivaroxaban, which significantly lowered the risk of ischemic events 
at the cost of a markedly increased bleeding risk. These data underscore the value 
of (adjunctive) anticoagulation therapy in reducing the risk of thrombotic events 
following an ACS.
Implications for future research. The large variety in possible devices to determine 
the platelet reactivity as well as the lack of definite normal values for the treatment 
of the individual patient are striking. Moreover, there is limited uniformity between 
studies with regard to the timing of the measurement in relation to the intake of 
the antithrombotic agent or the onset of symptoms. Finally, given the coefficient of 
variation of the various laboratory tests, a minimum of three measurements should 
be performed to provide a reliable result. Future research should incorporate these 
aspects in the design of the study.
Besides these methodological aspects impeding the detection of a possible rela-
tion, the hypothesis that recurrent events are the result of ‘resistance’ is subject to 
critique. First, the term ‘resistance’ does not take into account the normal course 
of an ACS, nor the possibility of a new plaque rupture with (sub)total thrombotic 
occlusion. Attributing this to a failure of the antithrombotic agent does not take into 
account the multifactorial character of a complex disease such as an ACS. Moreover, 
no large and well designed studies demonstrated that platelet reactivity measured 
with laboratory devices independently predicts clinical outcome. There appears to 
be a relation between an increased risk profile (diabetes, renal impairment, age) 
and platelet reactivity in ACS. These observations deserve more attention in future 
research to get a better understanding of the value of platelet function tests and 
to investigate its role in future patient tailored medicine based on platelet function 
tests.
As for future studies on the addition of anticoagulants, the challenge would be to 
define an optimal dose and duration for adjunctive therapy, as well as the possibility 
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to discontinue one of the antiplatelet agents. This concept should be placed in the 
context of the balance between the thrombotic risk and safety aspects.
In summary, although mechanistic studies can provide insight in the potential 
working mechanisms of antiplatelet agents, it should be appreciated that there is 
uncertainty with regard to the question whether laboratory findings translate into 
clinical practice. Given the fact that activation of platelets and the coagulation cas-
cade are intertwined and the proven efficacy of VKAs in patients with an ACS, we 
feel that renewed interest in the potential role for anticoagulation therapy in ACS is 
important, especially with the availability of the NOACs with their attractive safety 
profile.
Safety
With the improved efficacy of antithrombotic treatment, the risk of safety issues 
such as bleeding is also increased. Given the toxic effect of aspirin on the stomach, 
most research focused on the dose and formulation of this agent, and less attention 
was given to other antiplatelet agents.
As far as the dosing is concerned, randomized studies demonstrated an increased 
risk of gastro-intestinal complications in case of higher dosing. However, this con-
cerned doses higher than those recommended in the setting of ACS. Retrospective 
data of ACS patients treated with lower doses of aspirin (75-325 mg) indicated that 
also in ACS the dosing of aspirin is related to bleeding complications.
With regard to the formulation of aspirin, various studies have been conducted 
to investigate a potential role in the reduction of gastro-toxicity, of which enteric 
coated aspirin and effervescent calcium carbasalate are two examples. Effervescent 
calcium carbasalate better dissolves in the stomach and it does not transfer through 
the protective mucus layer as easily as compared to plain aspirin, which would 
theoretically lower the local gastro-toxicity of this agent. Although effervescent 
calcium carbasalate was associated with a reduced risk of gastrointestinal ulcers, this 
was studied in healthy volunteers using very high daily doses. In contrast, in a large 
retrospective study performed in patients using low doses of aspirin, no differences 
between formulations on gastric ulcers was observed. Another possible advantage 
of these aspirin formulations could be a reduced risk of dyspepsia, which could 
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potentially reduce compliance thereby indirectly reducing the efficacy. In this thesis, 
we demonstrate no advantage of effervescent calcium carbasalate when compared 
to plain aspirin with regard to the risk of dyspepsia. However, this latter is associated 
with higher costs, which even exceed those of the combination of plain aspirin with 
the addition of a PPI. Given the knowledge of previous studies demonstrating a sig-
nificant protective effect of PPIs on dyspepsia, we recommend to use a PPI in case a 
patient suffers from aspirin related dyspepsia. In addition, patients using aspirin who 
are at increased risk of gastrointestinal bleeding could also be prescribed a PPI. This 
risk can be assessed by the presence or absence of various clinical variables, such as 
a history of gastric ulcers or gastric bleeding, age, the use of two antiplatelet agents, 
or the concurrent use of an oral anticoagulant.
Implications for future research. The registration of the dose of aspirin has 
become standard in most of the large clinical trials. However, a systematic registra-
tion of gastrointestinal symptoms is lacking, despite its high occurrence and clinical 
importance. Notably, also the occurrence of gastrointestinal bleeding complications 
is not systematically reported. In an era in which consideration of the balance 
between risks and benefits is gaining importance, prospective registration of these 
safety aspects is essential. Moreover, with the introduction of new antithrombotic 
agents, the registration of the use of a PPI is important to provide insight in the 
gastrointestinal risk profile when comparing two antithrombotic regimens. In this 
context, the COMPASS trial is a major step forward. This study with a factorial design, 
not only compares the treatment of a NOAC with aspirin, but also studies the value 
of adding a PPI to these drugs.
Efficacy and safety: the balance
Now that the development of more potent antiplatelet agents has taken off, it is 
important to pay attention to the accurate balance between efficacy and safety. In 
addition to the risk of gastro-intestinal bleeding, the overall bleeding risk should 
also be assessed. For ACS the CRUSADE risk model has been developed, and ACS 
guidelines also refer to the HAS-BLED bleeding risk model. Notably, the HAS-BLED has 
been developed and validated in AF populations without ACS, in which the predictive 
ability already proved poor.
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The risk of future thrombotic events can be determined using the TIMI risk score 
or the GRACE model, the latter of which is used by most European physicians. Both 
the GRACE as well as the CRUSADE models have been extensively validated with 
acceptable predictive abilities in patients without AF.
Implications for future research. Although a first step towards risk-stratified treat-
ment has been made, data on the integration of information of both models and the 
potential treatment options is scarce. In this light, it is important that a consensus is 
formed about an acceptable number needed to harm (NNH) in relation to a provided 
number needed to treat (NNT). These questions could guide the trade-off between 
dual antiplatelet therapy with aspirin and clopidogrel versus one of the more potent 
antiplatelet agents (ticagrelor, prasugrel), but also for the adjunctive therapy with 
an anticoagulant as an intensified treatment option in the secondary prevention of 
an ACS. Especially for patients with sinus rhythm, the need exists for comparative 
research between the CRUSADE and the HAS-BLED score.
For AF patients, there often exists a life-long indication for oral anticoagulation, 
which is complicated by the fact that in case of an ACS these patients also require 
dual antiplatelet therapy. A recently published randomized controlled trial concern-
ing patients with an indication for a VKA who underwent a percutaneous coronary 
intervention were randomized to clopidogrel alone or in combination with aspirin 
both as adjunct to a VKA. This study indicated that the omission of aspirin resulted in 
less bleeding complications without signs of reduced efficacy. Studies with a similar 
design are also ongoing with NOAC therapy instead of a VKA, in which the combina-
tion of one antiplatelet agent and one anticoagulant seem to be the future standard. 
However, triple therapy with oral prolonged anticoagulation as well as the period of 
dual antiplatelet therapy are also being studied. Given the fact that dual antiplatelet 
therapy with a very low dose of rivaroxaban resulted in more bleeding in the ATLAS-
ACS-2 trial, but was also associated with significant increased efficacy, the trade-off 
in terms of NNT and NNH needs to be determined for these new regimens. It should 
be appreciated that this is more complex in AF patients, as they require a NOAC dose 
much higher than used for ACS.
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ATRIAL FIBRILLATIOn
Efficacy
As mentioned before, stroke prevention in AF consists of anticoagulation with a VKA 
or a NOAC, and there is no longer an indication for aspirin in this setting. Even treat-
ment with dual antiplatelet therapy is significantly inferior to the observed 60-70% 
risk reduction of anticoagulation therapy. Despite this impressive data on efficacy, 
oral anticoagulation is often withheld. One of the arguments concerns the question 
whether the trial data also apply to the ‘older’ and ‘fragile elderly’ patients. The 
data of the BAFTA trial, which studied a general population of patients aged 75 years 
or above, clearly demonstrated that VKA treatment is more effective than aspirin, 
without an increase in the risk of bleeding. Also with the NOACs, the available data 
indicate that the results with regard to efficacy also apply to the elderly patient.
In the current era of increasing life expectancy, but with an increasing extent of 
comorbidities, the question emerges about the trade-off between the NNT and NNH 
in this population. To provide more insight into this topic, we initiated a registry in 
collaboration with the INR Anticoagulation Clinic Arnhem-Nijmegen which focused 
on quality and patient satisfaction of VKA anticoagulated patients. In our cohort of 
patients aged 80 years or older, the balance between NNT and NNH seems te be in 
favor of VKA treatment. As for the NOACs, our data did not indicate a reduced effect 
in case of more comorbidity, which underscores the importance of treatment of the 
fragile elderly, also in the light of the reports on the risk of undertreatment.
Implication for future research. Although the populations studied in the recent 
AF trials are representative of the average outpatient clinic patient, they do not 
reflect all patients who are treated by the general physician. Especially patients 
with cognitive disorders, mobility dysfunction and for example patients with severe 
renal disorders are not represented in these trials and the subset of patients with 
extensive comorbidities would be rather low. For patients with these characteristics, 
future research is warranted, which should also include data on compliance, given its 
importance with regard to NOAC treatment.
Also patients with a recurrent stroke or TIA are a specific patient population 
that deserves more attention. For this group, measurements of the anticoagulation 
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activity could be incorporated in clinical practice to further enhance patient tailored 
medicine.
Safety
As described above, aspirin is not a safer alternative to oral anticoagulation therapy 
and the efficacy is significantly lower, findings which also hold true for the elderly. 
Another subset of patients whom are frequently prescribed aspirin are patients who 
are unwilling or have a contra-indication to take VKA. Also in this specific cohort, 
findings from a randomized study indicate that aspirin is not safer when compared to 
the oral anticoagulant apixaban, which is one of the NOACs.
In patients without a contra-indication for VKAs, NOACs are an at least as safe 
alternative with regard to major bleeding. Notably, for all NOACs an almost 50% 
risk reduction for intracranial bleeding was demonstrated, however, this advantage 
should be placed in the context of a higher risk of gastro-intestinal bleeding or other 
major bleeds for most of the NOACs.
Also with regard to safety the question emerges if the data from the NOAC trials 
apply for the ‘older’ and ‘fragile elderly’ patients. Patients with various comorbidities 
not only have an increased risk for the use of (potentially) interacting drugs, their 
general physical health is impaired as well as the adaptation mechanisms of the 
body. In this context, it is very well possible that the ‘fragile elderly’ are prone to 
a differential response to anticoagulation therapy when compared to younger pa-
tients. With regard to the elderly in general, safety outcomes of dabigatran 150 mg 
bid differ between the elderly and younger patients in which the elderly allocated to 
dabigatran are at higher risk of bleeding when compared to those receiving warfarin. 
For the other NOACs, no age-related differences with regard to safety were observed.
As for the safety of patients with various comorbidities, studies on both VKA as 
well as NOAC therapy are scarce. In our population of AF patients aged 80 years or 
above, we studied whether risk factors identified in general AF populations are asso-
ciated with bleeding in the elderly. Interestingly, only a minority of these classical risk 
factors were associated with bleeding in this elderly population. Nonetheless, the 
trade-off in terms of NNT versus NNH was clearly in favor of treatment with an oral 
anticoagulant, which implies that the assumption of the advantage of not treating a 
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patient with oral anticoagulation based upon a perceived high bleeding risk could not 
be substantiated in our cohort.
Studies conducted to investigate a potential differential response to NOACs in 
terms of safety in patients with a greater number of comorbidities used polyphar-
macy as a tool to categorize these patients. It was shown that polypharmacy was 
not only related to mortality and stroke, but was also associated with an increased 
bleeding risk. While the rates were consistently lower with apixaban, the magnitude 
of benefit with apixaban decreased with the number of concomitant drugs. Taken 
into account that the safety benefit of apixaban did not significantly differ between 
chronologically younger and older patients, it can be concluded that observations 
made in the ‘older’ patients cannot simply be inferred to the ‘fragile elderly’.
Implications for future research. The findings of the abovementioned retrospec-
tive analyses suggest that the safety of anticoagulation is related to the extent of 
comorbidity, the number of concomitant drugs, and the combination of these 
factors. Future large studies with emphasis placed on the biological age instead 
of chronological age are awaited, especially given the increasing life-expectancy 
and age dependent incidence of AF. The HAS-BLED model can be of some use in 
the risk stratification in general AF populations, however, the discriminative ability 
has proven to be very poor. As such, healthcare providers should be cautious with 
omitting anticoagulation therapy to a patient based only on a high HAS-BLED score. 
Alternatives for the HAS-BLED model have been proposed by several research groups 
in view of the improvements that can be made in the prediction of bleeding. Re-
cently, the ABC-model has been proposed which combines clinical factors with age 
and biomarkers. Although this model seemed a better alternative when compared 
to other models, the accuracy is still not optimal and deserves further optimization.
The fact that the risk factors incorporated in the HAS-BLED model are not as-
sociated with bleeding in the elderly gives the impression that there is a need for 
‘elderly-specific’ risk models. Examples of risk factors could be polypharmacy, cogni-
tive function, but perhaps also easy to perform geriatric tests that could help in the 
assessment of a patient’s biological age.
Finally, the question emerges if risk factors for bleeding differ between patients 
using a VKA or a NOAC. Although both concern oral anticoagulants, there are distinc-
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tive differences with regard to the working mechanism, elimination and interacting 
drugs which calls for a renewed inventory of risk factors. Moreover, it could be of 
potential value to adjust the dose of NOACs based upon the anticoagulation activity 
measured with laboratory tests. Improved insight in factors associated with bleeding 
could give guidance to physicians, thereby reducing undertreatment and optimize 
the balance between safety and efficacy.
Efficacy and safety: the balance
With the addition of the NOACs as a treatment option, the landscape of antithrom-
botic therapy in AF has evolved and new questions have emerged. Although in 
general the NOACs improved safety, there is a need for the calculation of the risks 
versus the benefits, especially in view of the increased risk of gastrointestinal bleed-
ing. Although the CHA2DS2-VASc model has been associated with ischemic events in 
both VKA and NOACs, research on the value of the HAS-BLED model in patients using 
a NOAC limited.
Implications for future research. In view of the above, it is important that a 
consensus is formed about an acceptable number needed to harm in relation to a 
provided number needed to treat. This consensus can be applied to the comparison 
between VKA versus a NOAC, but future research is likely to focus more on ‘patient 
tailored’ medicine. This could include risk-benefit models for all of the NOACs when 
compared to a VKA. However, the need will be especially high for the development 
of a bleeding risk model with good predicitive ability which could guide healthcare 
providers with decision making in daily clinical practice.
All in all, the field of anticoagulation is moving forward and given the wide 
selection of options of drugs, further refinement of the treatment of atrial fibrilla-
tion seems possible with the currently available options, especially if the balance 
between safety and efficacy is given special notice.
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In de algemene introductie in Hoofdstuk 1 wordt basale achtergrond informatie ge-
geven met betrekking tot de pathogenese van een atherotrombotische gebeurtenis, 
de therapeutische mogelijkheden en tekortkomingen. In het overige deel wordt de 
uiteenzetting van het proefschrift weergegeven met de verschillende studievragen.
Hoofdstuk 2 beschrijft het voorkomen van gastro-intestinale symptomen bij 
verschillende formules van aspirine. In de jaren 80 van de vorige eeuw is aangetoond 
dat aspirine essentieel is bij de secundaire preventie van cardiovasculaire ziekten 
en momenteel wordt het door meer dan 1 miljoen Nederlanders gebruikt. Helaas is 
aspirine geassocieerd met gastro-toxische bijwerkingen, zowel lokaal als systemisch, 
wat zich kan manifesteren als maagulcera, maagbloedingen, alsook dyspepsie het-
geen de therapietrouw van aspirine negatief kan beïnvloeden. Om lokale effecten van 
aspirine op de maag te reduceren is er een gebufferde vorm van aspirine ontwikkeld 
(calcium carbasalaat). Om de prevalentie van zelf gerapporteerde gastro-intestinale 
symptomen te vergelijken tussen ‘gewone’ aspirine en de gebufferde variant, hebben 
we gebruik gemaakt van een grote cohort studie naar gastro-intestinale symptomen 
(n=18.317). In dit cohort gebruikten 1544 deelnemers een lage dosering aspirine, 
waarvan 911 ‘gewone’ aspirine gebruikten en 633 deelnemers de gebufferde vari-
ant. Onze studie toonde aan dat gastro-intestinale symptomen frequent voorkomen 
(~27%) zonder een verschil tussen de twee groepen. Ook met betrekking tot symp-
tomen die de bovenste dan wel het onderste deel van het maag-darm systeem be-
treft zien we geen voordeel van de gebufferde aspirine in vergelijking met ‘gewone’ 
aspirine. Om de therapietrouw te optimaliseren is toevoeging van een protonpom-
premmer ons inziens een beter alternatief, aangezien het gebruik hiervan wel heeft 
aangetoond gastro-intestinale symptomen te verminderen.
Alhoewel protonpompremmers de veiligheid van aspirine verbeteren, zijn er aan-
wijzingen dat het gebruik hiervan de effectiviteit van clopidogrel kan verminderen. 
In hoofdstuk 3 hebben wij een systematisch review uitgevoerd om de impact van het 
toevoegen van een protonpompremmer op plaatjesfunctie en klinische cardiovas-
culaire uitkomsten te onderzoeken. De huidige European Society of Cardiology (ESC) 
richtlijn adviseert om aspirine en clopidogrel als standaard therapie te gebruiken na 
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een dotterprocedure bij stabiele angina pectoris. Alhoewel een recente update van 
de richtlijnen aangeeft dat bij patiënten met een acuut coronair syndroom (ACS) de 
voorkeur wordt gegeven aan potentere medicamenten als ticagrelor en prasugrel, 
worden veel patiënten nog steeds met clopidogrel als aanvulling op aspirine behan-
deld. In deze context zijn de waarschuwingen van de Food and Drug Administration 
(FDA) en European Medicines Agency (EMA) uit 2009 nog steeds actueel. Gelijktijdig 
gebruik van een protonpompremmer zou mogelijk het effect van clopidogrel op de 
trombocytenaggregatieremming verminderen doordat deze beide medicamenten 
van invloed zijn op het iso-enzym 2C19 van cytochroom P450. Hierdoor zou de 
transformatie van clopidogrel naar zijn actieve metaboliet worden verminderd. Deze 
waarschuwingen waren initieel gebaseerd op laboratorium studies en retrospectieve 
klinische studies. In navolging van deze studies zijn er verscheidene prospectieve 
onderzoeken verricht die niet in overeenstemming waren met de retrospectieve 
studies. Met betrekking tot de laboratorium studies zijn er 10 studies geïdenti-
ficeerd die gezonde vrijwilligers includeerden en 18 studies waarbij cardiovasculaire 
patiënten werden onderzocht. In het merendeel van beide van deze studieopzetten 
bleek dat het gebruik van een protonpompremmer resulteerde in een significante 
reductie van de plaatjesremming van clopidogrel (7/10 bij gezonde vrijwilligers; 
11/18 bij patiënten). Het effect van gelijktijdig gebruik van een protonpompremmer 
met betrekking tot klinische uitkomsten is onderzocht in 33 studies hetgeen in totaal 
meer dan 200.000 patiënten betrof. Van belang is dat de meeste van deze studies 
(21/33) een retrospectieve opzet hadden met aanwijzingen voor voorschrijfbias 
en verschillen in baseline karakteristieken tussen patiënten met en zonder een 
protonpompremmer. Bovendien was er sprake van een significante heterogeniteit 
in de geobserveerde uitkomsten, met relatieve risico’s variërend van 0.68 tot 4.58. 
Beseffende dat clopidogrel geassocieerd is met een 20% relatieve risicoreductie op 
ischemische complicaties na toevoeging aan aspirine, kan een verhoogd risico van 
meer dan 50% niet alleen toegeschreven worden aan een verminderd effect van 
clopidogrel door gelijktijdig gebruik van een protonpompremmer. Tevens was er 
slechts in 48% van de studies sprake van een verhoogd risico op majeure cardiovas-
culaire events bij patiënten die een protonpompremmer gebruikten en werd er in 
geen van de gerandomiseerde studies een nadelig effect geobserveerd bij patiënten 
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waarbij een protonpompremmer werd toegewezen. Samenvattend kan worden 
gesteld dat alhoewel er aanwijzingen zijn voor een verminderd effect van clopidogrel 
in laboratorium studies wordt dit effect niet uniform bevestigd in klinische studies.
Ongeveer 10% van de patiënten met een myocardinfarct zal binnen een jaar 
opnieuw een infarct doormaken ondanks het gebruik van duale antiplaatjestherapie. 
Dit betreft een populatie die meer aandacht verdient met betrekking tot antitrom-
botische behandeling. In Hoofdstuk 4 beschrijven we de waarde van behandeling met 
langdurige antistolling bij patiënten waarbij duale antiplaatjestherapie ineffectief is 
gebleken. Behandeling met vitamine-K antagonisten (VKA) is bewezen effectief bij 
ACS als monotherapie, met vergelijkbare uitkomsten als aspirine. Ook als toevoeg-
ing aan aspirine is duidelijk vastgesteld dat langdurige behandeling met een VKA de 
klinische uitkomsten verbeterd na een ACS bij patiënten in sinusritme. In een meta-
analyse van 7.836 patiënten resulteerde randomisatie naar een VKA als toevoeging 
aan aspirine in een reductie van dood, niet fataal myocard infarct en/of een beroerte 
van 12,3% naar 9,4%. Hierbij was wel sprake van een toename in majeure bloedingen 
van 1.1% naar 2.6%.
De ontwikkeling van de non-VKA orale anticoagulantia (NOAC) waarbij er geen 
monitoring benodigd is, heeft de rol van verlengde antistolling nieuw leven ingebla-
zen. Hierbij is het van belang om te realiseren dat deze groep medicijnen alleen is 
onderzocht als toevoeging aan duale antiplaatjestherapie, hetgeen tot op heden de 
hoeksteen blijft in de behandeling van ACS. Van de NOACs is alleen bij een zeer lage 
dosering van rivaroxaban aangetoond dat het klinische uitkomsten verbetert. Echter, 
gezien de significante toename van het bloedingsrisico dient deze therapie alleen 
in uitzonderlijke gevallen bij patiënten met een hoog risico op recidief ischemische 
events te worden toegepast.
De meest uitdagende patiëntengroep betreft diegene met een strikte indicatie 
voor orale antistolling die tevens een ACS ontwikkelt. Gezien het gebrek aan studies 
van NOACs in de acute setting van een ACS, adviseren wij om de NOAC te stoppen 
tijdens de opname in het ziekenhuis bij deze specifieke patiëntenpopulatie. Na ont-
slag uit het ziekenhuis dient er geen NOAC gebruikt te worden in een AF dosering 
in combinatie met duale antiplaatjestherapie gezien het onacceptabel hoge bloe-
dingsrisico hetgeen is aangetoond in meerdere fase II en III trials. In het kader van 
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deze veiligheidsaspecten raden wij aan om in het eerste jaar na een ACS een VKA 
te gebruiken. Indien de indicatie van duale antiplaatjestherapie is vervallen kan het 
gebruik van een NOAC heroverwogen worden.
Het verhoogde bloedingrisico van NOACs is tevens het onderwerp van Hoofdstuk 
5. Dit hoofdstuk betreft een kritische kanttekening op een meta-analyse waarin 
een 45% verhoogd risico op gastro-intestinale bloedingen wordt beschreven bij het 
gebruik van een NOAC voor verschillende indicaties. In dit commentaar vragen wij 
om een meer voorzichtige interpretatie van het gerapporteerde risico. Ten eerste 
zijn in deze meta-analyse ook studies geïncludeerd waarbij NOACs zijn gebruikt als 
secundaire preventie na een ACS waarbij placebo werd gebruikt als controle. Van 
belang bij deze studies is dat de NOACs hierbij ook in AF doseringen zijn gebruikt, 
hetgeen niet door de huidige richtlijnen wordt aanbevolen gezien het bekende hoge 
bloedingsrisico. Ten tweede is er een substantieel deel van de data waarbij NOACs 
niet geassocieerd waren met een verhoogd risico op gastro-intestinale bloedingen 
buiten beschouwing gelaten in deze meta-analyse. Ten slotte roepen wij op tot een 
voorzichtigere interpretatie van data waarbij zowel de risico’s alsook de voordelen 
worden afgewogen, zoals bijvoorbeeld het verlaagde risico op intracraniële bloedin-
gen bij behandeling met NOACs.
Eén van de NOACs waarbij is aangetoond dat het zowel veiliger als meer effectief 
is als warfarine ter preventie van trombo-embolische events bij AF, is apixaban. Ech-
ter is dit medicijn alleen onderzocht in een algemene AF populatie en er zijn aanwijz-
ingen dat patiënten met polyfarmacie (i.e. ≥5 medicijnen) ouder en zieker zijn en dat 
er sprake kan zijn van een andere respons op antistolling bij deze populatie. Met deze 
kennis hebben wij een post-hoc analyse uitgevoerd van de ARISTOTLE trial waarin 
apixaban is vergeleken met warfarine bij 18.201 patiënten met AF (Hoofdstuk 6). Wij 
toonden aan dat patiënten die meer medicijnen gebruikten een groep vormen waar-
bij comorbiditeit frequenter voorkomt, dat ze een hoger risico op overlijden hebben 
en dat er een hoger risico bestaat op ischemische en bloedingscomplicaties. Met 
betrekking tot de effectiviteit bleek dat de superioriteit van apixaban vergeleken met 
warfarine met betrekking tot beroertes (21% risico reductie) en overlijden (11% risico 
reductie) geobserveerd in de algehele trial populatie, niet significant verschilde tus-
sen patiënten met veel of weinig medicijnen. Echter, alhoewel apixaban geassocieerd 
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is met een risico reductie van 31% voor majeure bloedingen in de gehele populatie, 
observeerden we een statistisch significante verschil in behandelingseffect tussen de 
twee anticoagulantia met relatieve risico’s voor apixaban, variërende van 50% (0-5 
medicijnen) naar 28% (6-8 medicijnen) en 16% (≥9 medicijnen). De interactie leek 
niet verklaard te kunnen worden door het gebruik van interacterende medicijnen. 
Onze bevindingen suggereren dat observaties met betrekking tot effectiviteit en 
veiligheid van antistolling in algemene populaties kunnen verschillen van hoog risico 
groepen zoals de ouderen met veel co morbiditeit.
Ondanks het bewijs dat antistolling ook in het voordeel is bij de ouderen, blijven 
artsen bezorgd om het bloedingsrisico bij deze groep en is onderbehandeling een 
frequent voorkomend probleem. Verschillende modellen zijn ontworpen om het 
bloedingsrisico van patiënten in te kunnen schatten. Hiervan worden de HAS-BLED, 
ATRIA en HEMORR2HAGES momenteel het meest toegepast. Echter zijn deze model-
len ontwikkeld in algemene AF populaties en is het onbekend of deze modellen ook 
goed kunnen discrimineren binnen de oudere patiënten. In Hoofdstuk 7 hebben wij 
het discriminerend vermogen van de drie modellen onderzocht en tevens met elkaar 
vergeleken in een zeer oude populatie van patiënten met AF die een VKA gebruikten. 
Gedurende een 3-jarige vervolgperiode kwam een majeure bloeding voor bij 6,7% 
van de populatie (rate 2,8%/jaar). Ondanks een significante associatie met majeure 
bloedingen voor alle drie de modellen bleek het discriminerende vermogen in alle 
modellen zeer matig (C-statistic < 0,60) zonder superioriteit voor één van de model-
len. Een belangrijke bevinding was dat behoudens anemie en het gebruik van trom-
bocytenaggregatieremmers, geen van de ‘klassieke’ risicofactoren behorende bij de 
modellen geassocieerd was met majeure bloedingen in deze oudere patiëntengroep. 
Om enige richting te geven aan de klinische beslisvorming hebben wij een geschatte 
risk-benefit berekend waaruit bleek dat de voordelen van VKA behandeling in het 
algemeen groter waren dan het nadeel bij deze groeiende groep van ouderen. Om 
meer objectieve adviezen te kunnen geven zijn nieuwe initiatieven nodig om risico-
factoren voor bloeden bij de ouderen te identificeren, waarbij de nadruk dient te 
liggen op ouder-specifieke risicofactoren.
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Dit proefschrift heeft zich gericht op de balans tussen veiligheid en effectiviteit met 
betrekking tot orale antitrombotica in de cardiologie. Hierbij is aandacht besteed aan 
trombocytenaggregatieremmers, zoals aspirine en clopidogrel, alsook orale antico-
agulantia, namelijk vitamine K antagonisten (VKA) en non-VKA orale anticoagulantia 
(NOAC).
Een goede balans tussen veiligheid en effectiviteit is van essentieel belang. Een 
verminderde effectiviteit kan resulteren in trombose met als gevolg een intensiver-
ing van de antitrombotische therapie waarbij het risico op bijvoorbeeld bloedingen 
wordt verhoogd. Anderszins kan de perceptie van een verhoogd bloedingrisico leiden 
tot angst en hierdoor een verminderde compliantie of een terughoudendheid in het 
voorschrijfgedrag. Hieruit blijkt dat de veiligheid van een antitromboticum ook weer 
invloed kan hebben op de gerealiseerde effectiviteit.
In dit proefschrift zijn bovengenoemde wisselwerkingen aan bod gekomen bij de 
behandeling en preventie van stabiel en acuut coronair lijden, als ook bij de behan-
deling van atriumfibrilleren (AF).
aCuut Coronair syndrooM
Effectiviteit
De preventie van een acuut coronair syndroom (ACS) heeft in de laatste decennia 
een vogelvlucht genomen. Na de komst van aspirine, gevolgd door clopidogrel, zijn 
er sinds enige tijd nieuwere trombocytenaggregatieremmers beschikbaar gekomen 
waarbij er is aangetoond dat deze middelen een nog betere bescherming tegen acute 
coronaire syndromen bieden. Bovendien zijn er steeds meer onderzoeken gaande 
naar de waarde van (orale) antistolling als toevoeging aan deze trombocytenaggrega-
tieremmers. Door deze ontwikkelingen is de behandeling na een ACSverbeterd en is 
het risico op een recidief in het algemeen sterk verlaagd. Helaas zijn er met de komst 
van de trombocytenaggregatieremmers ook nieuwe problemen ontstaan.
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Met betrekking tot de effectiviteit van aspirine en clopidogrel is het begrip 
‘resistentie’ geïntroduceerd, gebaseerd op het feit dat ondanks duale antiplaatjes-
therapie er in een substantieel deel van de patiënten terugkerende events worden 
waargenomen. De vraag is in hoeverre dit gerelateerd is aan suboptimale werking van 
trombocytenaggregatieremmers. Hier is de laatste jaren veel aandacht aan besteed, 
waarbij de uitslagen van ex vivo plaatjesfunctietesten veelal werden toegepast als 
surrogaat voor een in vivo verminderd effect. Een belangrijk voorbeeld hiervan is 
de in dit proefschrift bediscussieerde mogelijke interactie tussen clopidogrel en pro-
tonpomp remmers (PPIs) met als gevolg een verminderde productie van het actieve 
substraat van clopidogrel. De initiële waarschuwingen van de FDA en EMA waren 
louter gebaseerd op ex vivo studies en retrospectieve klinische studies. Enerzijds 
bleken er ex vivo duidelijke aanwijzingen te bestaan voor een interactie gezien de 
verhoogde reactiviteit van de trombocyten bij PPI gebruik, weliswaar voornamelijk 
geconstateerd in populaties van gezonden, en patiënten zonder ACS. Anderzijds 
bleek er in de prospectieve (gerandomiseerde) studies geen duidelijke verminderde 
effectiviteit op klinische eindpunten bij de combinatie clopidogrel met een PPI te 
bestaan.
Deze discrepantie tussen plaatjesfunctietesten en klinische gevolgen is ook 
eerder geobjectiveerd bij twee grote studies (GRAVITAS; ARCTIC) waarbij patiënten 
met een verhoogde plaatjesreactiviteit werden gerandomiseerd naar wel of geen 
intensievere behandeling met trombocytenaggregatieremmers. Uit deze studies 
bleek dat intensivering van de trombocytenaggregatietherapie wél de ex vivo 
plaatjesreactiviteit verminderde, maar niet resulteerde in een klinische verbetering 
in vergelijking met patiënten die geen intensievere therapie ondergingen.
Deze bevindingen in grote gerandomiseerde studies demonstreren de beperking 
van observaties uit retrospectieve studies, o.a. als gevolg van bias in het voorschri-
jfgedrag en minder optimale datacollectie. Hoewel deels begrijpelijk vanuit het 
oogpunt van effectiviteit, heeft de waarschuwing van de FDA en EMA ook geleid tot 
veranderingen in medicatie, zoals het stoppen van PPIs, of switchen naar bijvoor-
beeld ticlopidine met daarmee verhoogde kans op gastro-intestinale en beenmerg 
problemen.
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Hoewel door sommigen terugkerende events worden toegeschreven aan ‘resis-
tentie’ voor antiplaatjestherapie, is de gedachte dat alleen bloedplaatjesremming 
afdoende is voor de behandeling en preventie van een ACS mogelijk te eenzijdig. 
Ondanks dat meerdere oudere studies overtuigend hebben aangetoond dat vitamine 
K antagonisten als monotherapie effectief zijn bij acuut en chronisch coronairlijden, 
heeft het onderzoek naar het nut van orale anticoagulantia bij ACS lange tijd stil 
gestaan. Dit ondanks een meta-analyse die een gunstig effect liet zien van de to-
evoeging van VKAs aan aspirine. Voor patiënten in sinusritme bestaan er geen grote 
gerandomiseerde studies waarbij het effect van VKAs is onderzocht als toevoeging 
aan dubbele antiplaatjestherapie en wordt dit slechts op theoretische gronden in ge-
selecteerde gevallen toegepast. Wel bestaan er sinds enkele jaren verschillende fase 
II studies voor de NOACs. De enige afgeronde fase III studie betreft triple therapie met 
een zeer lage dosering rivaroxaban, waarbij de effectiviteit significant verbetert ten 
koste van een sterk verhoogd bloedingrisico. Deze data onderschrijven dat ook in het 
huidige tijdperk (adjuvante) antistollingstherapie invloed heeft op de trombotische 
uitkomstmaten na een ACS.
Implicaties voor toekomstig onderzoek. Opvallend is dat er een grote vers-
cheidenheid van mogelijke devices bestaat om de plaatjesactiviteit te bepalen en dat 
er geen duidelijke naar het individu te vertalen normaalwaarden te formuleren zijn. 
Ook bestaat er geringe uniformiteit in het protocol met betrekking tot het tijdstip van 
de bepalingen na medicatie inname, dan wel ten opzichte van het tijdstip van start 
klachten. Tenslotte is de variatie coëfficiënt van verschillende methodes dusdanig 
dat minimaal 3 bepalingen nodig zouden zijn voor een betrouwbare meting. Voor 
eventueel toekomstig onderzoek dienen deze aspecten meegenomen te worden in 
het studie design.
Los van methodologische aspecten die het scherp krijgen van een mogelijke 
relatie bemoeilijken, is de primaire hypothese dat het krijgen van een nieuw event 
voor een groot deel samenhangt met ‘resistentie’ aan kritiek onderhevig. Ten eerste 
wordt hiermee voorbij gegaan aan het natuurlijk beloop na een acuut coronair 
syndroom, en het feit van altijd mogelijke hernieuwde plaque ruptuur met eventuele 
(sub)totale trombotische occlusie. De gedachte dat het optreden hiervan falen van 
een antitromboticum weergeeft doet geen recht aan het multifactoriële karakter van 
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een complex ziektebeeld als een acuut coronair syndroom. Bovendien is de mate van 
plaatjesactiviteit gemeten met een device nog nooit als onafhankelijke voorspeller 
van uitkomst naar voren gekomen in grote, goed ontworpen studies. Er lijkt een 
samenhang te bestaan tussen een verhoogd klinisch risicoprofiel (diabetes, ver-
minderde nierfunctie, leeftijd) en de mate van plaatjesreativiteit tijdens een acuut 
coronair syndroom. Bovengenoemde overwegingen verdienen nader onderzoek, 
om tot een beter inzicht te komen, en de mogelijkheid te onderzoeken of er een 
toekomstige rol weggelegd is voor een individueel getrieërde behandeling middels 
een plaatjesactiviteit device.
Met betrekking tot toekomstige studies naar het effect van anticoagulantia, zal 
de uitdaging liggen in het bepalen van de juiste dosering en duur van de adjuvante 
antistolling, en het al dan niet vroegtijdig stoppen van één van beide antiplaatjesmid-
delen. Dit alles in de context van een individueel bepaalde afweging op basis van het 
geschatte trombotisch risico en de kans op bloedingen.
Samengevat kunnen we stellen dat mechanistische studies inzicht kunnen geven 
in potentiële werkingsmechanismes, maar dat er in de toekomst terughoudend moet 
worden omgegaan met het gebruik van ex vivo maten zoals plaatjesreactiviteit als 
surrogaat voor in vivo werking van deze middelen. In het kader van genoemde verw-
evenheid van bloedplaatjes en stollingsfactoren bij het ontstaan van een ACS, en de 
reeds jarenlange bekende effectiviteit van VKAs bij coronairlijden, lijkt hernieuwde 
aandacht voor de rol van anticoagulantia gerechtvaardigd, zeker na de introductie 
van de veiliger imponerende NOACs.
Veiligheid
Met de verbeterde effectiviteit van de huidige behandeling met antitrombotica is 
ook de aandacht voor een verhoogd bloedingrisico toegenomen. Gezien de etsende 
werking van aspirine op de maagwand, heeft het meeste onderzoek zich in eerste 
instantie gericht op de dosis en vorm van dit medicament, en niet zozeer op de 
andere antiplaatjes middelen.
Met betrekking tot de dosis is uit gerandomiseerd onderzoek gebleken dat hogere 
doseringen gepaard gaan met meer gastro-intestinale complicaties. Echter, het be-
trof hier doseringen hoger dan gebruikelijk bij een ACS. Retrospectief onderzoek bij 
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ACS patiënten behandeld in lagere doseringen (75-325 mg) dan deze studies liet zien 
dat ook bij ACS de dosis aspirine gerelateerd kan worden aan de kans op bloedingen.
Met betrekking tot de vorm waarin aspirine wordt ingenomen is ook het 
nodige onderzoek verricht. Voorbeelden hiervan zijn enteric coated aspirine en 
carbasalaatcalcium. De laatste zou door betere oplosbaarheid en verminderde 
toelaatbaarheid door de beschermende mucuslaag van de maag, geassocieerd zijn 
met minder directe schadelijke werking op de maag. Alhoewel er aanwijzingen zijn 
dat deze vorm van aspirine geassocieerd is met minder gastro-intestinale ulcera, is 
dit onderzocht in gezonde proefpersonen waarbij er zeer hoge doseringen werden 
gebruikt. Bovendien is er in een groot retrospectieve cohort studie geen voordeel 
aangetoond indien het in de lage dosering bij patiënten werd toegepast. Een ander 
mogelijk voordeel van dergelijke aspirine-preparaten zou een verbetering zijn van 
andere veiligheidsaspecten zoals dyspepsie, hetgeen een negatief effect kan hebben 
op de compliantie, wat indirect de effectiviteit beïnvloedt. In het huidige proefschrift 
blijkt er geen voordeel van deze vorm van aspirine op het optreden van dyspepsie. 
Echter, deze gebufferde vorm van aspirine gaat wel gepaard met verhoogde kosten, 
hetgeen zelfs de kosten van een combinatie van aspirine met een PPI overschrijdt. 
Gezien deze bevindingen en de kennis van voorgaande studies waarin is aangetoond 
dat PPIs wel een positief effect hebben op het reduceren van dyspeptische klachten 
zien wij geen meerwaarde in carbasalaatcalcium en dient er in geval van klachten 
overwogen te worden om te starten met een PPI. Tevens dient volgens de huidige 
richtlijnen een PPI gestart te worden bij patiënten met een verhoogd risico op gastro-
intestinale bloedingen die een trombocytenaggregatieremmer gebruiken. Dit risico 
kan worden ingeschat door het nagaan van verscheidene klinische factoren zoals een 
voorgeschiedenis van een maagulcus of -bloeding, de leeftijd, het gebruik van twee 
trombocytenaggregatieremmers en het gelijktijdig gebruik van anticoagulantia.
Implicaties voor toekomstig onderzoek. Over de jaren is het inmiddels bijna stan-
daard gebruik geworden om de gebruikte dosis van aspirine tijdens de grote trials te 
registreren. Met betrekking tot gastro-intestinale klachten blijkt er in een groot aan-
tal studies nog geen systematische rapportage plaats te vinden van deze toch vaak 
optredende relevante bijwerkingen. Zelfs het rapporteren van een gastro-intestinale 
bloeding is in recente studies met nieuwe antitrombotica niet altijd vanzelfsprekend. 
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In een tijdperk waarin afweging van risico’s en voordelen steeds belangrijker wordt, 
is prospectieve registratie van deze cruciale events onontbeerlijk. Bovendien is het bij 
de introductie van nieuwe antitrombotische medicatie van belang het concomitante 
gebruik van PPIs in de studies nauwgezet bij te houden, om een correcte inschatting 
van het gerapporteerde gastro-intestinale risico te kunnen bepalen wanneer twee 
antitrombotica worden vergeleken. In deze context is het initiatief van de COMPASS 
studie een belangrijke stap voorwaarts, waarbij in een factorial design, naast het 
effect van een NOAC ten opzichte van aspirine ook de vraag wordt beantwoord of 
additionele behandeling met een PPI van waarde is.
Effectiviteit en veiligheid: de balans
Nu de ontwikkeling van nog sterkere trombocytenaggregatieremmers een enorme 
vlucht heeft genomen, is het zaak nog meer attent te zijn op de juiste balans tussen 
effectiviteit en veiligheid. Naast gastro-intestinale bloedingcomplicaties is het ook 
van belang om het algehele risico op bloedingen in te schatten. Bij ACS is hiervoor het 
CRUSADE risico model ontwikkeld, en wordt in de guidelines nogal eens gerefereerd 
naar het HAS-BLED risicomodel. Het is belangrijk te vermelden dat dit laatste model 
primair gevalideerd is op patiënten met atriumfibrilleren, zonder ACS, en dat de 
predictieve waarde in die setting reeds beperkt is.
Het risico op toekomstige trombotische events kan worden ingeschat met behulp 
van de TIMI risk score, of het in Europa veelal gebruikte GRACE risicomodel. Zowel 
het GRACE model als de CRUSADE zijn uitgebreid gevalideerd, met acceptabele pre-
dictieve waardes, waarbij het patiënten betrof zonder atriumfibrilleren.
Implicaties voor toekomstig onderzoek. Hoewel de eerste stap richting risk-strat-
ified treatment is gemaakt, is er nog weinig data waar het gaat om de integratie van 
informatie uit beide modellen, en potentiële behandelingskeuzes. Belangrijk hierbij 
is tot een vorm van consensus te komen over het te accepteren number needed to 
harm, gegeven een bepaald number needed to treat. Deze vragen kunnen gelden 
voor de juiste trade off tussen duale antiplaatjestherapie met aspirine en clopido-
grel versus een sterker antiplaatjesmiddel (ticagrelor, prasugrel), maar kunnen ook 
de toevoeging betreffen van orale anticoagulantia aan duale antiplaatjestherapie 
als intensievere vorm van secundaire coronaire preventie. Juist voor patiënten in 
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sinusritme bestaat er behoefte aan vergelijkend onderzoek tussen de waarde van de 
CRUSADE score ten opzichte van de regelmatig geadviseerde HAS-BLED score.
Voor patiënten met atriumfibrilleren geldt dat er vaak een indicatie voor lev-
enslange orale antistolling bestaat, en wordt bij een ACS de situatie precair gezien 
de huidige consensus dat er ook duale antiplaatjestherapie dient te worden voorge-
schreven. Bij patiënten met een indicatie voor een VKA die een dotter procedure 
ondergingen, heeft een recente gerandomiseerde studie aangetoond dat gebruik van 
clopidogrel met weglaten van de aspirine resulteerde in minder bloedingen, zonder 
dat er aanwijzingen waren voor een verminderde effectiviteit. Ook voor NOACs zijn 
er verschillende studies gestart bij patiënten met een ACS, waarbij de combinatie van 
1 trombocytenaggregatieremmer en 1 anticoagulans de toekomst lijken te hebben. 
Echter, triple therapie met langdurige orale antistolling en wisselende periodes van 
adjuvante duale antiplaatjestherapie worden ook bestudeerd. Gegeven het feit dat 
in de ATLAS-ACS-2 studie duale antiplaatjes therapie met een zeer lage dosis rivar-
oxaban evident meer bloedingen gaf, maar ook significant effect op de effectiviteit 
liet zien, valt te bezien hoe de NNT en NNH er voor de te testen nieuwe regimes uit 
komen te zien. Wetende dat bij atriumfibrilleren de dosis van een NOAC vele malen 
hoger ligt dan in de huidige studie bij sinusritme, maakt dit de situatie in deze laatste 
categorie patiënten extra complex.
ATRIuMFIBRILLeRen
Effectiviteit
Zoals beschreven bestaat de behandeling van patiënten met atriumfibrilleren uit 
antistolling in de vorm van een VKA of een NOAC, en is er geen plaats meer voor 
aspirine. Zelfs duale antiplaatjes therapie komt qua reductie van trombo-embolieën 
niet in de buurt van de 60-70% reductie behaald met orale antistolling.
Ondanks deze indrukwekkende effectiviteitsdata wordt orale antistolling nogal 
eens niet gegeven. Eén van de argumenten is dat getwijfeld wordt in hoeverre data 
uit studies ook naar ‘de oudere’, en de ‘fragiele oudere’ te vertalen is. In de BAFTA 
studie is overtuigend aangetoond in een huisartsen populatie van 75 jaar en ouder 
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dat een VKA evident effectiever is dan aspirine, en niet tot meer bloedingen leidt. 
Ook met NOACs is uit de beschikbare data naar voren gekomen dat de gevonden 
resultaten qua effectiviteit kunnen worden doorvertaald naar de oudere patiënt.
In het huidige tijdperk van vergrijzing, waarin patiënten gemiddeld langer leven, 
maar wel met meer comorbiditeit, rijst de vraag in hoeverre hier de verhouding 
NNT en NNH gunstig ligt. Hiertoe maakten wij een eerste aanzet door een kwaliteit 
en patienttevredenheids project met de Trombosedienst Arnhem-Nijmegen op te 
starten. In het door ons beschreven cohort van 80 ‘plussers lijkt de verhouding NNT 
en NNH voordelig te liggen. Voor NOACs konden wij bij toenemende comorbiditeit 
geen vermindering van de effectiviteit waarnemen, wat het belang onderstreept van 
behandeling van de fragiele oudere, en de rapportages over de nadelen van onder-
behandeling onderschrijft.
Implicaties voor toekomstig onderzoek. Hoewel de recente studies met atriumfi-
brilleren een behoorlijk goede weerspiegeling zijn van de ‘gemiddelde patiënt’ op de 
polikliniek, is dit mogelijk niet het geval voor alle patiënten die de huisartsenpraktijk 
bezoeken. Met name patiënten met cognitieve stoornissen, mobiliteitsproblemen en 
bijvoorbeeld ernstige nierfunctiestoornissen zijn niet vertegenwoordigd in de grote 
gerandomiseerde studies, en het percentage patiënten met uitgebreide comorbidit-
eit zal ook relatief laag liggen. Voor patiënten met deze kenmerken is aanvullend 
onderzoek gewenst, waarbij ook compliance data bij het gebruik van NOACs van 
belang zijn.
Daarnaast vormen patiënten met een recidief CVA/TIAs onder NOAC gebruik een 
groep van aandacht, bij wie mogelijk zelfs metingen van de antistollingsactiviteit geïn-
corporeerd zouden kunnen worden om tot nog betere, op het individu toegespitste 
behandelingen te komen.
Veiligheid
Zoals beschreven, vormt aspirine geen veiliger alternatief voor orale antistolling, ook 
niet bij ouderen, en is de effectiviteit duidelijk minder. Een andere groep patiënten 
met atriumfibrilleren die nogal eens met aspirine werd behandeld bestaat uit mensen 
die geen VKA willen, danwel een contra-indicatie hebben voor een VKA. Ook in deze 
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specifieke setting blijkt uit gerandomiseerd onderzoek dat aspirine niet veiliger is dan 
orale antistolling, dit maal in de vorm van de NOAC apixaban.
Bij patiënten zonder contra-indicaties voor een VKA, vormen de NOACs een alter-
natief dat minstens net zo veilig is, als het de majeure bloedingen betreft. Voor alle 
NOACs geldt een bijna 50% reductie in de kans op intracraniële bloedingen, echter 
bij een aantal van de NOACs gaat deze winst teniet door een grotere kans op gastro-
intestinale bloedingen en/of andere grote bloedingen.
Ook qua veiligheid rijst de vraag of de resultaten behaald met NOACs vertaald 
kunnen worden naar ‘de oudere’, dan wel ‘de fragiele oudere’. Zeker voor de patiënt 
met multipele comorbiditeiten geldt dat er niet alleen sprake is van het gebruik van 
verschillende (potentieel) interacterende medicijnen, maar dat ook de algehele 
fysieke conditie minder is, en regelmechanismen minder (snelle) adaptie vertonen. 
In deze context is het heel wel mogelijk dat ‘fragiele ouderen’ een andere respons op 
antistolling medicatie vertonen dan vitale ouderen, of jongeren.
Met betrekking tot de oudere in het algemeen, is het zo dat qua veiligheid de 
resultaten beschreven in de gehele studiepopulatie niet zonder meer vertaald 
kunnen worden naar ‘de oudere’, als het om dabigatran 150 mg gaat. Patiënten 
ouder dan 75 jaar hebben duidelijk nadeel bij gebruik van dabigatran, als het om 
het veiligheidsaspecten gaat. Bij de overige NOACs zijn de veiligheidsconclusies van 
ouderen en jongeren ten opzichte van VKA niet verschillend.
Als het gaat om de veiligheid bij patiënten met multipele bijkomende aandoenin-
gen, is zowel het onderzoek naar VKAs als naar NOACs nog schaars. In onze 80-plus 
populatie analyseerden wij in hoeverre risicofactoren voor bloeden op VKAs zoals 
die zijn gevonden in de algemene populatie met atriumfibrilleren ook golden bij de 
80-plusser. Het bleek dat slechts weinig van de klassieke risicofactoren ook bij oud-
eren een associatie vertoonden met bloeden. Desalniettemin kwam de NNT vs NNH 
verhouding dusdanig te liggen, dat het niet behandelen op basis van een verwacht 
hoog bloedingrisico in dit cohort niet onderbouwd kon worden.
De studies naar NOACs die een mogelijk verschil in veiligheid bestudeerden bij 
patiënten met uitgebreidere comorbiditeit deden dit via het al dan niet bekend zijn 
met polyfarmacie. Polyfarmacie is niet alleen gekoppeld aan mortaliteit en de kans 
op een ischemische beroerte, maar gaat ook gepaard met een verhoogd bloedin-
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grisico. Hieruit bleek dat de mate van het voordeel qua bloedingreductie behaald 
met apixaban afnam in relatie tot een toenemend aantal medicamenten. Dit dient 
afgezet te worden tegen het feit dat bij de oudere in het algemeen de reductie in 
bloedingen ten opzichte van VKAs vergelijkbaar was ten opzichte van de reductie 
bij jongeren. Deze observaties laten zien dat resultaten voor ‘de oudere’ niet zonder 
meer te vertalen zijn naar ‘de fragiele oudere’.
Implicaties voor toekomstig onderzoek. De indicaties uit bovenstaande retrospec-
tieve analyses doen vermoeden dat de veiligheid van antistolling gerelateerd is aan 
de mate van comorbiditeit, het aantal concomitante medicijnen en de combinatie 
van deze invloeden. Grootschaliger onderzoek met meer nadruk op de ‘biologische 
oudere’ dan op de ‘chronologisch oudere’ is gewenst, zeker in het licht van de 
toegenomen levensverwachting, en de leeftijdsafhankelijke incidentie van atrium-
fibrilleren.
Het HAS-BLED model in de algehele populatie met atriumfibrilleren is mogelijk 
een nog geaccepteerde vorm van risicostratificatie; echter, het discriminerend ver-
mogen van dit model is in de meerderheid van de literatuur zeer matig gebleken. 
Voorschrijvers dienen voorzichtig te zijn met het onthouden van antistolling enkel 
en alleen op basis van een hoge HAS-BLED score. Verschillende research groepen 
hebben alternatieven voor de HAS-BLED geponeerd, omdat juist qua predictie van 
bloedingen nog de nodige winst te behalen valt. Een recent gepubliceerd model, het 
ABC-model genaamd, combineert klinische factoren met leeftijd en biomarkers, en 
heeft een betere, doch nog steeds niet optimale diagnostische accuratesse.
Het feit dat bij ouderen bijna geen van de variabelen in het HAS-BLED model 
gerelateerd is aan de kans op een bloeding doet vermoeden dat er behoefte is aan 
meer ‘op de oudere toegespitste’ risicomodellen. Hierbij valt te denken aan een 
rol voor polyfarmacie, cognitieve functie, maar wellicht ook makkelijk uit te voeren 
geriatrische onderzoeken die de biologische leeftijd van de patiënt proberen in te 
schatten.
Tot slot rijst de vraag of risicofactoren voor een bloeding bij het gebruik van een 
VKA wel overeenkomen met de factoren bij NOAC gebruik. Hoewel het in beide 
gevallen orale antistolling betreft, zijn er duidelijke verschillen qua werkingsmecha-
nisme, eliminatie en interacterende medicijnen waardoor een nieuwe inventarisatie 
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gerechtvaardigd lijkt. Ook is de vraag actueel in hoeverre in geselecteerde gevallen 
dosisaanpassing zou kunnen plaatsvinden op basis van metingen van de antistolling-
sactiviteit. Beter inzicht in de factoren die gepaard gaan met een bloeding, kan door 
het bieden van meer houvast voor voorschrijvers onderbehandeling reduceren en 
zorgen voor een betere balans tussen effectiviteit en veiligheid.
Effectiviteit en veiligheid: de balans
Nu de ontwikkeling van NOACs heeft geleid tot een zich langzaam aan veranderend 
landschap qua antitrombotische behandeling van atriumfibrilleren, worden nieuwe 
vragen relevant. Hoewel door de bank genomen de behandeling met NOACs veiliger 
is geworden, bestaat er behoefte aan een risk-benefit bepaling, zeker gezien de bij 
een aantal NOACs gekende verhoging van het risico op gastro-intestinale bloedingen. 
Daar waar de CHA2DS 2-VASc score zowel op VKA als op NOACs gerelateerd is met 
ischemische events, is dit voor de HAS-BLED score nog niet goed onderzocht als het 
gaat om de predictie van bloedingen op NOACs.
Implicaties voor toekomstig onderzoek. Belangrijk hierbij is tot een vorm van 
consensus te komen over het te accepteren number needed to harm, gegeven een 
bepaald number needed to treat. Deze beslissingen kunnen gaan over de vraag VKA 
versus NOAC, maar toekomstig onderzoek zal mogelijk ook meer gericht zijn op ‘pa-
tient tailored’ medicine. Hierbij valt te denken aan risk-benefit modellen voor ieder 
van de verschillende NOACs, in vergelijking tot VKAs. De meeste vraag blijft bestaan 
naar een risico model voor bloedingen dat tot een betere klinische inschatting leidt.
Samengevat is er op het gebied van antistolling een duidelijke stap voorwaarts 
gemaakt, en is er een dusdanig breed palet aan keuzes dat verdere verfijning van de 
behandeling van atriumfibrilleren mogelijk lijkt met de reeds beschikbare medica-
menten, wanneer deze met meer kennis over effectiviteit en veiligheid in specifieke 
doelgroepen kunnen worden voorgeschreven.
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dankwoord
Een proefschrift is een team-effort waar veel mensen bij betrokken zijn. Ik wil mijn 
dank uitspreken voor iedereen die heeft bijgedragen aan de totstandkoming van 
deze thesis, zowel op wetenschappelijk als emotioneel en persoonlijk vlak. Zonder 
jullie zou dit proefschrift niet zijn geworden tot wat het nu is.
Allereerst wil ik mijn dank uitspreken naar mijn promotieteam.
Prof. dr. Freek W.A. Verheugt, beste Freek, alhoewel mijn komst in het Radboudumc 
snel werd opgevolgd door uw vertrek naar het OLVG was u altijd bereikbaar voor 
overleg en werden de manuscripten binnen korte tijd van kritiek voorzien. Speciale 
dank ook voor uw hulp bij het opzetten van samenwerkingsverbanden waaronder 
het project DCRI. Ik heb genoten van de traditionele diners tijdens de congressen. 
Het is een eer om nog onder u te mogen promoveren.
Prof. dr. Menko-Jan de Boer, beste Menko-Jan, ik wil u bedanken voor uw steun 
en vertrouwen en de gelegenheid die mij is geboden om te promoveren. Ik heb grote 
bewondering en respect voor de wijze waarop u met uw visie onze afdeling cardiolo-
gie de afgelopen jaren heeft geleid. Ook uw inzet voor de adequate behandeling van 
de ‘oudere patiënt’ is een pluspunt voor onze afdeling.
Dr. Marc A. Brouwer, allerbeste Marc. Tijdens mijn wetenschappelijke stage 
kwam ik je voor het eerst tegen en viel me jouw enthousiasme voor het onderzoek 
direct op. Al snel raakten we in gesprek over vervolgonderzoek. Jouw bevlogenheid, 
originaliteit en inspiratie heeft mij enthousiast gemaakt en het vertrouwen gegeven 
dat een promotietraject onder jouw hoede in het Radboudumc de beste volgende 
stap voor mij zou zijn. Dit vertrouwen heb je ook nooit beschaamd. Hoe druk jij ook 
was, zeker gezien de enorme groei van de onderzoeksafdeling, je probeerde altijd 
tijd vrij te maken ook al ging dit vaak ten koste van je vrije tijd. Ik heb erg genoten 
van de onderzoeksavonden waarbij een wijntje nooit ontbrak. Misschien nog wel 
belangrijker is jouw aandacht voor mij als persoon. Jouw luisterend oor heeft enorm 
geholpen, zeker in de laatste periode van het onderzoek. Bedankt voor alles en 
bovenal voor de vriendschap die we in al die jaren hebben opgebouwd. Zonder jou 
was dit nooit gelukt.
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Prof. dr. Niels P. Riksen, Prof. dr. Wim J. Morshuis en dr. Robert G. Tieleman, ik ben 
jullie allen zeer erkentelijk voor de kritische beoordeling van het manuscript.
Dit proefschrift is tot stand gekomen door samenwerking met verschillende afdelin-
gen en ziekenhuizen. 
Dr. Martijn van Oijen, beste Martijn, net als Marc ben jij een zeer bevlogen onder-
zoeker en heb jij me geënthousiasmeerd voor het onderzoek. Alhoewel onze paden 
gedurende het traject gescheiden zijn ben ik je zeer dankbaar voor al je steun en 
hulp. Dr. Merel Tielemans, beste Merel, ik heb het ontzettend fijn gevonden om met 
je samen te werken. Het samen sparren en zoeken naar oplossingen heeft ontzettend 
geholpen. 
Ik wil alle medewerkers van de INR Trombosedienst bedanken voor de nauwkeu-
rige complicatieregistratie waarin jullie een voorbeeld zijn voor vele instellingen. In 
het speciaal wil ik Marjo Albers-Akkers, Lucie Bloem-de Vries en Petra Groos-Eekhof 
bedanken voor de samenwerking en bijdrage aan dit proefschrift. 
Ook Susanne Buvelot en dr. Evert Lamfers van het Canisius Wilhelmina zieken-
huis, Elli Verhaaff en dr. Frank Willems van het Rijnstate ziekenhuis en Ralf Vromans 
van het Pantein ziekenhuis ben ik dankbaar voor de hulp om de NAR registratie tot 
een succes te maken.
Prof. dr. Chris Granger, Prof. dr. John Alexander and dr. Renato Lopes, I would 
like to express my appreciation for the collaboration between the Radboudumc and 
DCRI. It has been a great experience and I hope to continue working together in the 
future. I would also like to thank Daniel Wojdyla and Liz Cook for their help with the 
ARISTOTLE manuscript. Finally Catherine Dalsing, thank you for the help and warm 
welcome.
Tenslotte wil ik alle andere co-auteurs bedanken voor hun essentiële bijdrage aan 
dit proefschrift.
Alle patiënten die hebben deelgenomen aan de in deze thesis beschreven studies 
verdienen ook een speciale vermelding. Jullie medewerking en vertrouwen in onze 
onderzoeksafdeling heeft mijn verwachting overtroffen en zonder jullie zouden deze 
onderzoeken nooit mogelijk zijn geweest.
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Ik wil mijn waardering uitspreken voor alle steun en interesse van de collega’s van de 
afdeling cardiologie in het Radboudumc. Prof. Dr. Harry Suryapranata, beste Harry, 
met uw komst heeft de research afdeling een professioneel karakter gekregen. Be-
dankt voor al uw hulp en vertrouwen.Beste Lonneke, ik waardeer de ondersteuning 
die mij is gegeven om mijn promotietraject en samenwerking met de VS goed af te 
kunnen ronden. Beste Arie, beste Peter, ik wil mijn waardering uitspreken voor de 
opleidingsplaats die mij is gegeven en de flexibiliteit die jullie hebben getoond. Ik kijk 
ernaar uit om over 3 jaar weer terug te keren naar het Radboudumc. Sjoerd, dank 
voor je hulp met de studies, maar vooral voor de persoonlijke gesprekken. Cyril, dank 
voor al je tomeloze inzet voor de studies en de gezelligheid tijdens borrels en con-
gressen. Gheorghe, alhoewel de inclusie nogal ‘unhappy’ verloopt wil ik u bedanken 
voor de samenwerking tijdens mijn promotie-traject. Ook wil ik alle andere stafleden 
en fellows bedanken voor jullie inzet, niet alleen met betrekking tot deze thesis, maar 
ook voor de hulp bij het opbouwen van een onderzoeksafdeling en het includeren 
bij de studies. Natuurlijk geldt dit ook voor alle (oud)assistenten. Tenslotte wil ik het 
secretariaat en alle medewerkers van de polikliniek, de afdelingen, cath-kamer en 
functieafdeling bedanken voor alle ondersteuning.
Mijn paranimfen Judith Bonnes en Stijn van Vugt.
Judith, mede dankzij jou (en de gezellige tripjes die we hebben gemaakt) heb 
ik zo’n fantastische tijd gehad tijdens mijn promotie-traject. Ik vind het dan ook 
ontzettend leuk dat wij nu weer samen werken (en carpoolen) in het Rijnstate. Je 
bent een fantastische (en getalenteerde) collega en ik hoop dat we nog lang samen 
blijven werken in de toekomst.
Stijn, ik ben ontzettend blij dat jij mijn project hebt overgenomen. Jouw ontspan-
nen houding, je ontzettend strakke planning (jaloers!) en de manier waarop jij de 
zaken regelt zijn een voorbeeld voor velen. Ik weet zeker dat jij nog ver gaat komen 
en ik kijk uit naar jouw promotie.
Ook alle andere (arts-)onderzoekers van de afdeling wil ik bedanken, ondanks alle 
bekertjes water. Nog iedere dag mis ik de experimentele, en dat komt vooral door de 
gezellige en collegiale sfeer die wij samen hebben gecreëerd.  
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Etienne, jouw creativiteit is verbluffend en ik hoop dan ook dat jouw prachtige 
TRAMICI project snel de (hoge) bladen zal bereiken. Ik heb altijd genoten van onze 
samenwerking en kijk ernaar uit om over drie jaar weer met je samen te mogen 
werken. Ik hoop je binnenkort de ‘wisselmok’ te kunnen overhandigen, maar ik weet 
zeker dat jij deze snel weer door zal geven. Frank, toen ik begon was jij al als student 
aan het werk bij onze afdeling. Ik vond het ontzettend leuk om met je samen te 
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